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The Role of the CXCR3 Signaling Axes in Pancreatic
Ductal Adenocarcinoma
Abstract
Andrew C. Cannon, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: Surinder K. Batra, Ph.D.
Numerous cytokines promote pancreatic ductal adenocarcinoma (PDAC) progression and
suppress anti-tumor immune response leading to poor prognosis in PDAC patients. Despite
this, many cytokines have not been investigated in PDAC. Bioinformatic analyses of
PDAC microarray and RNA-Seq datasets were used to identify cytokines overexpressed in
PDAC, confirm the expression of cognate receptors, determine the association of cytokines
with patient survival, and define key underlying molecular associations. Bioinformatic
findings were validated using immunohistochemical (IHC) staining, comparative cytokine
qPCR-array in KrasLSL-G12D:TP53LSL-R172H:Pdx1-Cre (KPC) and KrasLSL-G12D:Pdx1-Cre
(KC) PDAC models and multicolor immunofluorescence staining. Tail-vein injections of
PDAC cells with/without CXCR3 inhibition were used to study altered metastatic potential
in vivo, and functional assays were conducted to demonstrate causal relationships between
CXCR3 activation and metastatic properties of PDAC cells. CXCR3 ligands CXCL9 and
CXCL10 were consistently overexpressed in PDAC datasets. CXCR3 was expressed in the
majority of PDAC samples according to RNA-Seq, microarray, and IHC analysis. CXCR3
ligands CXCL4, 9, and 10 were associated with poor patient survival and were
overexpressed in the aggressive KPC murine model compared to KC mice. CXCR3 was
associated with increased overall survival in humans. Pathway analysis showed that
CXCR3 is associated with T-cell-related genes, while CXCL9 and CXCL10 were
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associated with T-cell and immunosuppressive genes. CIBERSORT, gene set enrichment,
and immunofluorescence analysis supported these findings. With respect to metastasis,
inhibition of CXCR3 suppressed the number of cancer cells in the lungs following tail vein
injection. Cancer cells treated with activated platelets and/or CXCL4 demonstrated
increased ability to survive low attachment conditions and fluid shear stress and to adhere
to endothelium, suggesting pleiotropic roles in the metastatic process. Overall, CXCR3
ligands are overexpressed in PDAC and are associated with poor survival likely related to
alterations in immune cell infiltrate/activity and augmented metastatic potential.
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Chapter 1: Introduction

Portions of the content covered in this chapter are the subject of a published
article in Genes and Cancer by Cannon, A. et al. [1]
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Chapter 1A: Pancreatic Ductal Adenocarcinoma
PDAC represents a significant challenge in the United States (U.S.) healthcare
system in terms of both the difficulty associated with effectively diagnosing and treating
this disease and the burden of this malignancy on the healthcare system and society. While
the underlying causes of these issues are complex, a fundamental understanding of the
pancreas, the origins of PDAC, and the epidemiological, pathological, and clinical features
of PDAC as a disease yield critical insights as to why PDAC is the challenge that it is. For
instance, the anatomy of the pancreas accounts, in part, for the presentation of PDAC as
well as challenges associated with the surgical management of the disease while the
development of the pancreas shows trends that are mirrored in PDAC progression and give
critical insights into the metastatic and desmoplastic nature of PDAC. Similarly, study of
the origin of PDAC demonstrates a central role of inflammation in PDAC development,
which is an important feature clinically and a concept that is, in many ways, fundamental
to the work presented in this dissertation. Moreover, the epidemiology of PDAC defines
key risk factors for the development of PDAC and objectively outlines the burden of this
disease in terms of its impact on human lives, and again highlights the metastatic nature of
PDAC. The pathology of PDAC delves into critical histologic features of the disease,
which define it largely in terms of desmoplasia and aggressive invasion, and the clinical
management of PDAC demonstrates both the lethality of this disease and how the interplay
of the aforementioned features of PDAC give rise to this lethality. While the content
presented in this section is not critical to understanding the original scientific work
presented within this dissertation, it is critical to placing that work within the broader
context of PDAC, the disease, and the clinical and societal burden it imposes. Thus, the
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information presented here is a key justification for the original work presented in this
dissertation.
1A.1 An Overview of the Development and Anatomy of the Pancreas
A cursory understanding of the underlying developmental processes and final
anatomy of the pancreas is requisite for understanding the overarching themes and clinical
management of PDAC. The molecules which guide the embryonic development of the
pancreas are also frequently conspicuous threads that run through the natural history of
PDAC progression. Similarly, the anatomy of the pancreas dictates the presentation of the
disease, the course of metastatic progression, and much of the clinical management of the
disease.
Following the formation of the gut tube, the pancreas develops from the dorsal and
ventral pancreatic buds derived from the endoderm of the foregut between the layers of the
mesentery [2, 3]. The notochord and the cardiogenic mesenchyme guide this process for
the dorsal and ventral pancreatic fields respectively through fibroblast growth factor
(FGF)- and activin-mediated suppression of sonic hedgehog (SHH) signaling in the
pancreatic fields, which is required for the expression of pancreatic duodenal homeobox1
(PDX1), a master regulator of pancreatogenesis [3, 4]. PDX1 is expressed shortly after the
fusion of the paired dorsal aortas, and while it is not required for the formation of the early
dorsal bud of the pancreas, without PDX1, the ventral pancreatic bud, the exocrine
pancreas, and all but glucagon-secreting endocrine cells of the dorsal bud fail to develop.
Shortly after the expression of PDX1 in the developing pancreatic fields, PTF1a expression
appears in the pancreatic fields likely under the influence of the fused dorsal aorta, further
indicating the specification of the pancreatic progenitor cells. PTF1a is critical for diverting

4

PDX1 positive cells toward forming the pancreas [5, 6]. Importantly PTF1a-positive cells
give rise to essentially all acinar cells, and 95% of ductal cells and 75% of alpha-cells and
all non-alpha endocrine cells indicating a clear role of PTF1a in exocrine pancreas
formation with less clear roles in the development of the endocrine pancreas[3]. From this
point, interactions with pancreatic mesenchyme seem to guide the differentiation of PTF1apositive cells between the exocrine and endocrine compartments with the interplay of FGF,
NOTCH, and Neurogenin 3 activities [3]. During the sixth to seventh week of
development, rotation of the duodenum brings the ventral bud into proximity with the
dorsal bud forming the precursor to the full pancreas in which the ventral bud makes up
the uncinate process, and the larger dorsal bud forms the remainder of the head, the body,
and tail of the pancreas. Furthermore, rotation of the duodenum brings the dorsal buds to
the posterior of the abdomen and into the retroperitoneal space.
It is important to note that PDX1 and PTF1a, respectively, are expressed in all and
most pancreatic progenitor cells. The promoters of these genes are frequently used for the
conditional expression of Cre recombinase used in genetically engineered mouse models
for the study of PDAC. The expression patterns of these two molecules have critical
bearings for the expression of mutations in genetically engineered models and thus the
validity of the models. Furthermore, SHH is a critical factor for both the regeneration of
the pancreas following insult and the development of dense desmoplastic reaction that
occurs in the setting of PDAC. Similarly, retinoids, FGF, NOTCH, TGFs, and epidermal
growth factor receptor ligands (EGFs) all have roles in the development of the pancreas,
as well as the development and pathological features of PDAC.
While the development of the pancreas lends insight into the molecular processes
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governing the development of PDAC, the anatomy of the pancreas is key to understanding
the presentation, management, and progression of PDAC. As previously mentioned, the
pancreas is positioned posteriorly in the abdomen in the retroperitoneal space at the level
of the L1 and L2 vertebrae. The head and uncinate process of the pancreas sit right of the
midline and are nestled in the C-shaped curve of the duodenum. The body and tail of the
pancreas extend superiorly and to the left in the abdominal cavity with the tail of the
pancreas ending in very close proximity to the splenic hilum at approximately the T10
vertebral level.
The arterial supply of the pancreas is derived from several major sources within the
abdominal cavity. Just superior to the head of the pancreas, the common hepatic artery (the
right projecting branch of the celiac artery) trifurcates to give rise to the right gastroomental
artery, and the anterior and posterior superior pancreaticoduodenal arteries. Importantly
the anterior and posterior superior pancreaticoduodenal arteries anastomose with the
anterior and posterior inferior pancreaticoduodenal arteries, which are branches of the
superior mesenteric artery; this anastomosis is responsible for supplying the majority of
arterial blood to the head and uncinate process of the pancreas [7]. The body and tail of the
pancreas receive arterial blood from the dorsal and greater pancreatic arteries, which are
branches of the splenic artery (the left projecting branch of the celiac artery) [7]. Notably,
these vessels have anastomotic connections with both each other and the arteries supplying
the head of the pancreas. Venous drainage of the pancreas occurs through the veins
corresponding to the arterial supply of the pancreas. Importantly, these veins coalesce just
posterior to the head of the pancreas into the hepatic portal vein, and thus, venous blood
from the pancreas passes through capillary beds of the liver prior to being returned to the
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heart [7]. Lymph drainage of the pancreas can end in several distinct chains of lymph
nodes, including the pancreaticosplenic lymph nodes which run along the splenic artery,
the pyloric lymph nodes near the confluence of the head of the pancreas, the duodenum
and the gastric pylorus, superior mesenteric lymph nodes located at the root of the superior
mesenteric artery in the abdominal aorta, and the hepatic and celiac lymph nodes [7].
Innervation of the pancreas is almost entirely autonomic being derived from the Vagus
Nerve, and splanchnic nerves by way of the celiac and mesenteric plexi. It is worth noting
that visceral afferent innervation (sensory) is carried along the splanchnic nerves. In the
pancreas, this innervation is relatively sparse and is sensitive mainly to the stretching of
hollow viscera.
The presentation of pancreatic cancer is largely the product of its anatomical
features. The retroperitoneal positioning in the middle of the abdomen makes the pancreas
relatively inaccessible for manual and endoscopic examination of the organ for masses.
This combined with a lack of clear external output (i.e., urine or feces) and the relatively
scarce sensory innervation of the organ dictates that diagnosis of PDAC must stem from
clinical workup initiated by either the vague symptomology of PDAC resulting from mass
effects after substantial tumor growth or from incidental findings on imaging studies. These
factors may contribute substantially to the overwhelmingly large fraction of patients with
PDAC that are diagnosed with late-stage disease. This hypothesis is supported, in part, by
comparison of patients with ampullary adenocarcinoma (a disease with similar biology to
PDAC but located near common bile duct) to those with PDAC. Patients with ampullary
carcinoma typically present due to pain from the occlusion of the common bile duct or the
main pancreatic duct. As a result, these patients are typically diagnosed at earlier stages
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—particularly with respect to nodal and distant metastasis, are amenable to surgical
resection and ultimately have greatly improved survival over PDAC patients in which
severe pain is typically not appreciated until much later in the disease course [8, 9].
Similarly, the pancreas lacks adequate, safe, and effective screening strategies in part due
to its positioning within the body, and, though not as analogous, PDAC is typically
diagnosed much later than cancers, which are easily accessible for examination and cancer
screening. Pertinent examples of this include breast cancer via mammography and manual
examination, prostate cancer via digital rectal exam, colon via colonoscopy, and cervical
cancer via Papanicolaou smear.
Furthermore, the proximity of the pancreas to several key structures within the
abdomen has important consequences for the treatment of PDAC. The most important and
notable case of pancreatic anatomy dictating the clinical management of PDAC is the cases
of borderline resectable and locally advanced unresectable PDAC. Borderline resectable
PDAC is defined by meeting one of three criteria as defined by the American
Hepatopancreaticobiliary Association, the Society for Surgery of Alimentary Tract, the
Society of Surgical Oncology, and the National Comprehensive Cancer Network. The first
criterion is involvement of the superior mesenteric vein/portal vein by abutment,
encasement, or short segment venous occlusion with suitable segments of uninvolved vein
distal and proximal to the site of involvement to allow safe reconstruction following
resection. The second case is gastroduodenal artery encasement up to the common hepatic
artery with short segment encasement or abutment of the common hepatic artery without
involvement of the celiac axis. Finally, the third case is tumor involvement of the superior
mesenteric artery of fewer than 180 degrees [10]. In these cases, the extent to which the
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tumor will be able to be safely resected in its entirety due to the involvement of critical
regional vasculature is unclear. Failure to achieve a complete resection has an adverse
relationship with patient outcomes; patients with residual tumor on histologic examination
have decreased survival relative to those without residual disease, and patients with gross
residual disease do not differ from patients who did not receive operative treatment [10].
Thus, neoadjuvant therapy is currently recommended for those patients who can tolerate it
in order to maximize the likelihood of complete resection. It is worth noting that vascular
involvement exceeding that outlined by the definition of borderline resectable PDAC
would be classified as locally advanced unresectable PDAC. These specific case types of
PDAC aptly demonstrate the critical nature of anatomy in dictating the treatment of PDAC.
The central location of the pancreas places it near the origin of critical vascular structures.
Involvement of these structures by the tumor limits the usage of the most effective and only
curative treatment option for PDAC.
1A.2 The Origin of Pancreatic Ductal Adenocarcinoma
As with all cancers, PDAC arises because of mutations that occur in the cell(s) of
origin, resulting in malignant transformation of these cell(s). PDAC arises from the
malignant transformation of the exocrine pancreas, which is composed of both ductal and
acinar cell compartments. In PDAC, there is a relatively restricted set of mutations that
occur. Activating mutations of KRAS through mutation of the 12th and/or 61st codons of
the KRAS gene were initially estimated to be present in over 95% of PDAC tumors [11]
and has since been confirmed to be present in 93% of patients in a cohort of 150 patients
[12]. In this same study, mutations in tumor suppressors TP53, CDKN2A, and SMAD4
were also extremely common, occurring in 72, 30, and 32% of patients, respectively.
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Additional studies regarding the progression of PDAC from precursor PanIN lesions
suggested that mutations in KRAS are the first to occur as the majority of PanIN 1 lesions
(low-grade dysplasia) have this mutation. CDKN2A, while not found in PanIN 1 lesions,
was present in substantially more PanIN 2 lesions, followed by the growing presence of
TP53 and SMAD4 in PanIN3 lesion (high-grade dysplasia) [13]. Finally, GNAS mutation
or amplification occurs in a small number of patients (6-8%); however, it is the only
recurrently identified driver mutation in KRAS-mutation negative samples, suggesting that
it may have a very important function in the absence of activated KRAS [12, 14].
PDAC is currently known to arise from three distinct precursor lesions. In mouse
models, PanIN lesions appear to be the most frequent precursors to the development of
PDAC. Supporting the idea that PanINs give rise to PDAC in humans is the observation
that PanIN and PDAC lesions isolated from the same pancreas harbor the same driver
mutations, with the majority of shared mutations being the activating KRAS and TP53
mutations [15]. However, in humans, the association between PanINs and the development
of PDAC is weak, with 16% of normal pancreata and 60% of patients with chronic
pancreatitis harboring PanIN lesions compared to 59-82% of pancreata with PDAC
harboring PanIN lesions [16, 17]. Furthermore, because of the lack of ability to follow
PanIN lesions non-invasively, it has not been possible thus far to directly demonstrate the
progression of a PanIN lesion into PDAC; thus, there is significant doubt surrounding the
extent to which PDAC arises from PanIN lesions in humans. Mucinous cystic neoplasms
(MCN) make up only 2-5% of exocrine pancreatic tumors, and while the majority of MCNs
are benign, MCNs have been shown to harbor mucinous adenocarcinoma in 6-36% of cases
[18].

In another study, the prevalence of malignancy-harboring MCNs increased
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substantially with age, suggesting the progression to malignancy. In addition to age,
radiographic findings can also be indicative of a malignancy harboring MCN [19].
Multilocular appearance, papillary projections, mural nodules, as well as location within
the head of the pancreas are all associated with increased risk of malignancy. As in PanINs,
MCNs have a very high rate of mutations that are also frequently observed in PDAC.
KRAS mutations are observed in about 80% of MCNs, and with increasing dysplasia
CDKN2A, Tp53, and SMAD4 alterations increase in prevalence [20]. Finally, intraductal
papillary mucinous neoplasms (IPMN) can give rise to PDAC. IPMNs are somewhat less
common in humans than are MCNs and PanIN lesions representing 1-3% of the tumors of
the exocrine pancreas. The risk of an IPMN harboring malignancy increases with time
from diagnosis, indicating the potential for the progression to malignancy, as is the case
for MCN lesions. Similarly, IPMNs can be stratified by radiographic appearance into high
and low-risk groups. Here size, specifically greater than 5 mm dilation of the main
pancreatic duct, and presence of a mural nodule are indicative of high-risk lesions.
Furthermore, the location of the lesion relative to the main pancreatic duct is also indicative
of the risk of developing malignancy. Main duct and mixed duct IPMNs carry a relatively
high risk of developing PDAC in comparison to branch duct type IPMNs [18].
Additionally, the type of epithelium lining the IPMN is also associated with the likelihood
of harboring or developing a malignancy [18]. In this case, the pancreaticobiliary and
oncocytic type epithelia are associated with the greatest likelihood of harboring
malignancy, but these are the two rarest types of IMPN linings, and most of the IPMNs
that harbor malignancy have intestinal-type epithelium [18]. Like PanINs and MCNs,
IPMNs have mutational features that overlap with those of PDAC, including KRAS

11

alterations in 80% of patients, and the presence of TP53, CDKN2A and SMAD4 alteration
occurring with increasing prevalence with increasing dysplasia [20]. However, a subset of
IPMNs also harbors activating GNAS mutations (40-60% of patient samples) [21].
Importantly, 25-66% of IPMNs harbored both KRAS and GNAS mutations [14, 21]. Later,
these activating GNAS mutations were shown to induce pancreatic cancer through IPMNs
in cooperation with KRAS mutations [22]. Overall, the presence of GNAS mutation in
IPMNs and PDAC suggests that GNAS mutated PDACs are likely derived from IPMN
lesions.
The precise cell of origin of PDAC remains a topic of debate in the field, which
may reflect the possibility that PDAC as a disease category is heterogeneous with respect
to the cells of origin. Despite this, it is likely that ductal and/or acinar cells are the cells of
PDAC origin. PDAC was originally thought to arise from transformed ductal cells due in
large part to the overall ductal histology of PDAC as well as the expression of cytokeratin
19 (CK19) in ducts and PDAC lesions. A ductal origin of PDAC is supported by the fact
that Hnf1b-CreERT2KrasG12D, Brg1fl/fl develop PDAC from intraductal mucinous papillary
neoplasms (IPMN) due to expression of KrasG12D specifically in adult ductal cells [23].
These ductal cells were later shown in vitro to undergo a dedifferentiation event and
ultimately to form IPMNs that can progress to PDAC [24]. In contrast, to these findings
expression of KrasG12D under Sox9 promoter, another duct specific marker, or under the
Hnf1b promoter with heterozygous loss of the Brg1 did not produce altered pancreatic
histology suggesting that the IPMN related PDAC phenomenon might be specific to the
Brg1 null phenotype [23, 25].
With respect to an acinar origin of PDAC, expression of the KrasG12D mutation
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under the acinar-cell-specific elastase and Mist1 promoters both result in the formation of
PanINs [26, 27]. They further showed that cooperation between activated Kras and Notch
signaling reprograms acinar cells to ductal cells with expression of the prototypical ductal
marker CK19 [26, 27]. Further support of acinar cells being the PDAC cell of origin comes
from a study by Guerra et al. demonstrating that pancreatitis is required for the
development of PanINs and, ultimately, PDAC resulting from KrasG12V expression under
the same elastase promoter [28]. This is of particular importance as pancreatitis promotes
the metaplastic conversion of acinar cells to cells bearing a ductal phenotype, which
includes CK19 expression [29]. Additionally, when activating KRAS mutations are
expressed under the more general Ptf1a promoter, pancreatitis, while not strictly required
for the formation of PanIN lesions, greatly accelerated the formation of PanINs, further
suggesting prerequisite transition of acinar cells to a ductal morphology prior to transition
into PanIN lesions [25, 29]. Moreover, pancreatitis was not able to augment PanIN
formation when activated KRAS was expressed under the ductal specific Sox9 promoter,
but Sox9 itself was required for both ADM and the formation of PanINs in Ptf1a promoterdriven models further demonstrating the capability and requirement of acinar to ductal
metaplasia prior to the formation of PanIN lesions and potential progression to PDAC [25].
Finally, it may be worth noting that Brg1 was found to inhibit the development of IPMNs
and subsequent conversion to PDAC when activated KRAS is expressed in the ductal
compartment. However, when the activated KRAS is expressed in the acinar compartment,
Brg1 is required for the expression of Sox9 and the development of PanIN lesions. Further,
Brg1 is silenced in about 10% of PDAC cases suggesting the possibility that these cases
may be derived from IPMNs rather than PanIN or MCN lesions [30].
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1A.3 Epidemiologic, Pathologic and Clinical Features of PDAC
Epidemiology
In 2019, there were an estimated 56,770 new cases of pancreatic cancer diagnosed
with PDAC constituting slightly over 95% of these, making pancreatic cancer as a whole
the eleventh most common cancer (Figure 1.1A). Overall, there is a roughly 1.6% lifetime
risk of developing pancreatic cancer [31, 32], and as with most cancers of non-sex organs,
there is a slight preponderance of PDAC for males over females (53 vs. 47% of cases). In
direct contrast to the relatively low incidence of pancreatic cancer is its mortality.
Pancreatic cancer is the fourth leading cause of cancer-related mortality in males and
females, accounting for an estimated 45,750 thousand deaths (Figure 1.1B), again with a
slight preference for males over females (52 vs. 48%). The fact that the estimated deaths
are nearly equal to estimated new cases is strongly suggestive of poor overall survival of
patients with pancreatic cancer. Surveillance Epidemiology and End Results (SEER) data
estimate the five-year overall survival of pancreatic cancer as 9.5% between the years 2009
and 2015, though this figure is for pancreatic cancer, including neuroendocrine tumors, as
a whole rather than PDAC specifically [33]. This poor survival is likely related, at least in
part, to the relative distribution of patients across stages at diagnosis. For pancreatic
cancer, over half of patients present with distant metastases and over a quarter present with
regional lymph node metastases (Figure 1.2A) [33]. The impact of the frequency of latestage diagnosis on survival can be appreciated through a comparison of 5-year overall
survival by stage at diagnosis. In comparison to localized disease at diagnosis (37%),
patients that present with regional metastases and distant metastases have 11.5 and 2.9%
survival at five years, respectively (Figure 1.2B) [33].
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Figure 1.1
A.

B.

Figure 1. 1: SEER-Estimated New Cases and Deaths by Cancer in 2019.
A) Estimated new cases for common cancers reported on in SEER for 2019; pancreatic cancer
(PC) represents the second most common gastrointestinal cancer and 11 most common cancer
overall. B) Estimated deaths for each cancer reported on in SEER for 2019; pancreatic cancer is
the fourth leading cause of cancer-related death.
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Figure 1.2
A.

B.

Figure 1. 2: Distribution of Pancreatic Cancer Stage and Impact on 5-Year Survival.
A) Distribution of pancreatic cancer stage at diagnosis as reported by SEER in 2019; 81% of
pancreatic cancer patients are diagnosed with metastatic disease, with 52% being diagnosed with
distant metastases. B) The five-year overall survival rate of pancreatic cancer by stage at diagnosis.
34.3, 11.5, and 2.7 % of patients with local disease regional metastasis, and distant metastasis
respectively survive to 5 years.
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Perhaps more importantly than the static facts regarding pancreatic cancer are the
recent epidemiologic trends regarding PDAC. Starting in 2002, the incidence of pancreatic
cancer has increased steadily from 11 to 12.9 per 100,000 people per year in 2016 (Figure
1.3A). This increase in incidence was accompanied by a minimal increase in the 5-year
overall survival rate (Figure 1.3B), resulting in a rise in mortality from 10.5 to 11 per
100,000 people per year (Figure 1.3C) and an appreciable increase in the number of lifeyears lost from 436 to 644 thousand years (Figure 1.3D). Furthermore, because of the
increased incidence and corresponding increases in mortality, pancreatic cancer is
projected to be the second leading cause of cancer-related mortality in the U.S. by 2030
[34]. These data demonstrate that pancreatic cancer represents a substantial public health
problem in the United States, and the current trends indicate that the impact of PDAC will
continue to grow in the coming years.
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Figure 1.3
A.

B.

C.

D

Figure 1. 3: Trend in PC Incidence, Survival, Mortality, and Life-Years Lost.
A) Line graph demonstrating increasing incidence of PC form 2002-2016 (11.1 to 12.9) in SEER
data. B) Line graph representing an increasing 5-year survival rate as reported by SEER from 20022016 for all PC patients (4.5 to 9.3). C) Line graph showing the trend of increasing mortality (from
10.5 to 11) between 2002 and 2016 in SEER data. D) The trend in life years lost as a result of PC;
from 2002 to 2016, the number of life-years lost to PC increased from 436.5K years to 644K years.
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There are several recognized genetic and behavioral factors that predispose an
individual to the development of PDAC. In terms of the genetic risk factors, there are
several syndromes associated with an increased risk of PDAC. Germline mutations in
BRCA1/2 and PALB2 are associated with a 2-3.5-fold increase in PDAC risk [35].
Familial adenomatous polyposis syndrome, caused by germline mutations of tumor
suppressor APC, and cystic fibrosis, caused by a mutation in CFTR, are associated with a
similarly increased risk of 4.5-6-fold and 3.5-fold respectively.

Lynch syndrome,

characterized mutations in the DNA mismatch repair pathway, is associated with an 8.6fold increase in risk. Familial pancreatic cancer syndrome has a varying degree of
increased risk with a 9-fold increase for people with one first degree relative to a 32-fold
increase for people with three first degree relatives [35]. The most striking increases in the
risk of pancreatic cancer are those associated with Familial atypical multiple mole
melanoma pancreatic carcinoma syndrome (P16INK4A/CDKN2A), hereditary pancreatitis
(PRSS1, SPINK1), and Peutz-Jeghers syndrome (STK11/LKB1) with 47-fold, 69-fold and
between 96 and 132-fold increase in PDAC risk [36]. Despite this relatively long list of
possible hereditary or germline causes of PDAC and the striking elevation in the risk of
PDAC that is associated with each condition, the incidence of these predisposing
conditions is very low; as a result, germline/genetic causes of PDAC cumulatively account
for only about 10% of PDAC cases.
In addition to genetic risk factors for PDAC, there are several behavioral/
environmental/medical predisposing factors. Among these, chronic pancreatitis is
associated with the greatest increase in PDAC risk of 13.3-fold increase; tobacco use
carries a substantially increased risk of PDAC ranging from 1.5-2.2-fold. BMI greater than
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40 is associated with 2.8-fold and 1.5-fold increased risk in females and males,
respectively. In addition to obesity, diabetes mellitus is associated with 2.0-fold and 1.8fold increases for type1 and type2 diabetes, respectively. Consumption of more than three
alcoholic drinks per day, cholecystectomy, gastrectomy, and H. pylori infection are all
associated with moderately increased risk of 1.2-1.5-fold [35].

These risk factors

demonstrate a pattern in which conditions associated with inflammation of the pancreas,
including pancreatitis, obesity, diabetes, H. pylori infection, and, to a lesser extent, tobacco
use, all have roles in predisposing individuals to the development of PDAC. These
associations draw important connections to the processes of acinar to ductal metaplasia,
which is required for the formation of PanIN lesions upon mutation of KRAS in pancreatic
acinar cells.
Pathology
There are several defining pathological features of PDAC at the gross and
microscopic levels. Grossly, carcinomas of the exocrine pancreas are hard, poorly defined,
greyish-white masses that typically arise in the head of the pancreas. Frequently, there is
gross evidence of local tumor invasion into the peripancreatic tissues. Histologically, most
pancreatic carcinomas, to some extent, resemble the ductal epithelium of the normal
pancreas through the formation of glands and the secretion of mucins. Despite the
resemblance of PDAC glands to those in the normal pancreas, the glands formed in PDAC
are distinguished from normal glands by several features. For instance, the ductal structure
of malignant glands is typically aborted in blind ends (they don’t connect to a large duct
system) and demonstrate substantial diversity in their size, cellular lining, and architectural
complexity [37]. Moreover, the cells that make up the malignant ducts are also atypical.
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These cells are cuboidal to columnar in shape and demonstrate significant cellular atypia,
nuclear pleomorphism, and disorganization in cellular positioning, further differentiating
these ducts as being neoplastic. Importantly these epithelial structures demonstrate
histologic evidence of a highly invasive nature, mainly in the form of microscopic
infiltration of the surrounding extra-pancreatic tissues, neural sheaths, lymphatic vessels,
and large blood vessels of the pancreas. This evidence of aggressive dissemination of
neoplastic cells is a histologic hallmark of PDAC. A second histologic hallmark of PDAC
is the dense non-malignant reaction of fibroblastic proliferation, deposition of the
extracellular matrix, and lymphocyte infiltration known as desmoplasia or desmoplastic
response which occurs as a host response to the presence and progression of the tumor [37].
It is this desmoplasia that gives rise to the characteristic hardness of PDAC tumors upon
gross examination and has been shown in recent years to play important roles in PDAC
progression that will be discussed in detail in Chapter 1B. As a final note, there are several
much less common histologic patterns of carcinoma of the exocrine pancreas including
adenosquamous, colloid, signet ring cell, and undifferentiated among others; in this work,
we have made no effort to distinguish between these rarer carcinomas of the exocrine
pancreas and PDAC [37].
Clinical
The clinical presentation of PDAC frequently occurs late in the disease course.
This late presentation of PDAC is a function of several disease-related factors. As
discussed in chapter 1A.1, the anatomy of the pancreas plays a significant role in the
delayed clinical presentation of PDAC. Briefly, the positioning of the pancreas in the
retroperitoneum of the central abdominal cavity makes the pancreas inaccessible for safe
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examination, while the sparse sensory innervation and lack of clear external output from
the organ limit the development of specific symptoms that would trigger an early diagnostic
workup. Consistent with this, pain resulting from mass effect of the tumor on surrounding
structures (frequently the main pancreatic duct) is the most frequent presenting symptom
followed by changes in stools [37, 38]. Obstructive jaundice is also associated with tumors
in the head of the pancreas but, as with pain, only presents after substantial tumor growth
[37, 38]. PDAC is also frequently accompanied by weight loss, anorexia, fatigue,
weakness, and general malaise, but these symptoms typically arise in the setting of
advanced or metastatic disease. Finally, about 10% of patients with PDAC have migratory
thrombophlebitis or Trousseau syndrome (when accompanied by an underlying
malignancy). In addition to the late occurrence of these signs/symptoms relative to the
disease course of PDAC, it is important to note that these symptoms are not specific to
PDAC; the differentials for pain, obstructive jaundice, and general malaise are incredibly
broad. In contrast, migratory thrombophlebitis is a rare condition, and a fair percentage of
the patients presenting with it have an underlying gastrointestinal malignancy; however, it
is in no way specific to PDAC and as a diagnostic tool suffers from a lack of
generalizability in the sense that only about 10% of patients with PDAC have this
sign/symptom.
In addition to the role that pancreatic anatomy plays in the delayed presentation of
PDAC, the intrinsic biology of the disease itself also contributes substantially to its late
presentation. Evidence of an invasive nature at both the gross and histologic levels is a
pathologic hallmark of PDAC, meaning that this feature is present in all or nearly all PDAC
tumors and is thus characteristic even of comparatively young tumors. This fact indicates
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that from its outset, PDAC displays a strong tendency towards the dissemination of
malignant cells into surrounding structures and throughout the body as a whole. Recent
work in murine models of PDAC has further supported this concept of early, aggressive
dissemination of PDAC. Using pancreatic lineage tracing studies through Pdx1-mediated
activation of YFP expression, Rhim et al. demonstrated micrometastatic seeding of the
liver in 8 to 10-week-old mice (based on the KPC model) bearing frank PDAC. Moreover,
they demonstrated the presence of neoplastic cells with an EMT phenotype in the pancreas
and YFP positive cells in the livers and bloodstream of KPC mice prior to the development
of frank pancreatic carcinoma [39]. Importantly, the specific EMT phenotypes associated
with these early disseminating cells were noted to include the expression of cancer stem
cell/pancreatic progenitor cell markers and was induced by inflammation in the pancreas
[39]. These findings were confirmed by a second group demonstrating the same presence
of YFP positive cells very early in PDAC progression in a KPC-based model [40]. This
second report went on to show the presence of the disseminated PDAC cells in human
samples in tumors with TP53 loss-of-heterozygosity, which allowed for tracking of tumor
cells throughout the body using staining for mutant P53 [40, 41]. Though this study has
substantial issues, mainly the presence of overt PDAC and metastases in the human
subjects, it does provide circumstantial evidence for occult dissemination of cancer cells
and that this process begins very early in the course of PDAC in humans as well as in mice.
Overall, the anatomy of the pancreas and the biology of pancreatic cancer give rise to
disease that metastasizes well before the presentation of symptoms leading to the strong
majority of diagnoses being made after the establishment of metastatic disease. This
presentation has tremendous ramifications for the treatment of PDAC and the clinical
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course of patients with PDAC.
Following the presentation of a patient with the risk factors for pancreatic cancer
and symptomology, indicating the possibility of pancreatic disease, a diagnostic workup is
initiated. Here the differential diagnosis must include any condition which can present as
a solid pancreatic mass, including acute pancreatitis, exacerbations of chronic pancreatitis,
intra-pancreatic cholangiocarcinoma, MCN, and IPMN. Imaging plays a critical role in
the diagnosis of PDAC. In this setting, thin-cut CT scan with dynamic contrast is the
imaging modality of choice as it provides information regarding the stage of this disease,
vascular invasion, and the potential for resection [42]. MRI of cystic lesions identified by
CT is also recommended based on its ability to aid in the identification of concerning
features. Finally, as with the vast majority of cancers, pathologic confirmation of PDAC
is required for a proper diagnosis. In this case, endoscopic ultrasound with fine needle
aspirate is the recommended means of obtaining biopsy material from the pancreas.
Biopsies should be obtained for suspected PDAC as well as cysts found on CT with
concerning features on MRI to allow for cytologic and cystic fluid analysis.
Several treatment options exist for patients with pathologically confirmed PDAC.
Currently, surgery is the only curative treatment option for PDAC. However, because
many patients present with distant or loco-regional metastasis, or locally advanced PDAC,
only about 20% of patients are eligible for curative resection at the time of diagnosis.
Additionally, curative resection for patients with PDAC is considerably less successful
than it is for many other malignancies. In one large trial regarding the effectiveness of
adjuvant gemcitabine vs. surgical resection alone in R0 or R1 resected patients, 92% of
patients who underwent resection alone experienced recurrence [43]. The median disease-
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free and overall survival (DFS and OS respectively) for this group of patients were 6.9 and
20 months, respectively [43]. As expected, these results clearly demonstrate improved
outcomes of surgical resection patients relative to patients with more advanced disease, yet
the fact that more than 90% of patients experience recurrence demonstrates the overall
ineffectiveness of surgical resection of PDAC in comparison to other cancers. In this
cohort, more than half of the patients that recurred had distant metastasis as the sole form
of recurrence, and 40% of patients experienced local or local and distant recurrence.
Overall, these findings further point to the metastatic nature of PDAC being a critical
barrier to the effective treatment of PDAC and highlight the need for adjuvant and
neoadjuvant therapies for PDAC. One of the major functions of neoadjuvant therapy is to
increase the percentage of patients ultimately able to undergo curative resection of their
tumor. In patients initially diagnosed with borderline resectable or unresectable disease,
15-60% of patients are ultimately deemed appropriate to undergo surgery following the
administration of neoadjuvant therapy [44, 45]. However, neoadjuvant therapy is not
without risks —15-35% of patients demonstrate chemotherapy-resistant disease during the
pre-operative period and are thus unable to undergo surgery [44]. Furthermore, surgery is
the sole curative treatment modality for PDAC, and neoadjuvant therapy necessitates an
extension of the preoperative period, which has potential implications for successful
outcomes following resection that require further investigation. For these reasons, the
current use of neoadjuvant therapy is restricted to cases of borderline resectable or
unresectable tumors.
In contrast to neoadjuvant therapy that is given to make surgical resection of the
tumor an available treatment option, adjuvant therapy is given to prolong survival, more

25

specifically disease-free survival, following PDAC resection with curative intent. There is
currently strong evidence for the use of adjuvant therapy in the setting of PDAC. The first
notable trial demonstrated that six months of gemcitabine post-resection increased the
median disease-free survival from 6.9 to 13.4 months and overall survival from 20.2 to
22.8 months. Since this initial trial, several other regimens have demonstrated additional
benefit over gemcitabine monotherapy. Gemcitabine plus capecitabine showed increased
overall survival relative to gemcitabine monotherapy (28 vs. 25.5 months) [46] while a
modification of FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, and
oxaliplatin) continuous infusion of 5-FU and reduced irinotecan from 180 mg/m2 to 150
mg/m2) showed the greatest promise with median DFS over 21 months compared to 12.8
months for gemcitabine monotherapy and a median OS of 54.4 vs. 35.0 months [47].
However, the incidence and severity of adverse events were greatly increased in patients
who received FOLFIRINOX, and thus, toxicity may limit the applicability of this regimen
to the aged population of PDAC patients. Furthermore, adjuvant therapy as a whole has
several caveats, including the fact that, due to disease factors as well as surgical
complications, a substantial proportion of patients are ultimately unable to receive postsurgical chemotherapy. Finally, it is critical to note that in each arm of these three studies,
which included highly selected, early-stage patients, more than half of the patients still
experienced recurrence, and of these, distant recurrence was the most frequent site. Again,
these data demonstrate the role that metastasis plays in the lethality of PDAC (Figure 1.4).
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Figure 1.4

Figure 1. 4: Rates of Local and Distant PDAC Recurrence in Patients Receiving Adjuvant
Chemotherapy.
Patients receiving the indicated chemotherapy regimen following resection with curative intent
have high rates of distant recurrence. Most arms have roughly 50% of patients that recur with
disease at a distant site only. Note that local recurrence is reported as the percent of patients that
had local recurrence with or without recurrence at a distant site.
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For the majority of patients, surgical resection is strictly not an option due to the
presence of metastatic disease. For these patients, there are three therapeutic regimens that
are currently considered first-line therapy for metastatic PDAC depending upon patient
characteristics. The oldest of these regimens is gemcitabine monotherapy, which was
established by Burris and colleagues in a 1997 report [48]. In this randomized, phase III
trial of gemcitabine vs. 5-FU in advanced PDAC patients, gemcitabine was shown to
improve the median overall survival from 4.41 months to 5.65 months and increase the
percentage of patients that survived 12 months or longer from 2% to 18%. Furthermore,
23.8% of patients in the gemcitabine group experienced clinical benefit, defined as a
measure of pain performance status and weight, from the regimen compared to only 4.8%
in the 5-FU treated group. Finally, 5.4% and 39% of patients in the gemcitabine arm
experienced a partial response or stable disease compared to 0% and 19% in the 5-FU arm
[48]. These results demonstrated the superiority of gemcitabine over 5-FU and have, for
now, confirmed the status of gemcitabine as a standard PDAC treatment. Since this study,
there have been two additional drug regimens approved, both of which were shown to have
benefit over gemcitabine. In 2011, a study of FOLFIRINOX vs. gemcitabine in metastatic
PDAC patients reported FOLFIRINOX produced longer median OS, progression-free
survival (PFS), and increased the objective response rate (ORR) relative to gemcitabine
monotherapy (OS: 11.1 vs. 6.8 months, PFS: 6.4 vs. 3.3 months, and ORR: 31.6 vs. 9.4%)
[49]. These results make FOLFIRINOX the most effective drug regimen, in terms of
prolonging patient life, for the treatment of PDAC identified to date; however, it is
associated with a high frequency of high-grade toxicity, causing its utilization to be limited
to patients with unresectable PDAC with EOCG performance score less than or equal to
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one [50]. For patients unable to tolerate the toxicity associated with FOLFIRINOX, nabpaclitaxel with gemcitabine is a promising alternative regimen. In the phase III,
randomized trial of nab-Paclitaxel and gemcitabine vs. gemcitabine monotherapy, the
median overall survival for the gemcitabine plus nab-Paclitaxel was 8.3 months compared
to 6.7 months in the gemcitabine arm. Similarly, the progression-free survival in the combo
arm was significantly longer at 5.5 vs. 3.7 months for gemcitabine alone, and the response
rate for the combination compared to monotherapy was 23 vs. 7% [51]. Importantly, a
follow-up study of the long-term survival of the patients enrolled in this trial showed that
a total of 4% of patients who received nab-paclitaxel plus gemcitabine survived longer than
three years compared to 0% of the gemcitabine monotherapy arm [52]. As with
FOLFIRINOX, combination treatment in this trial was associated with increases in the
frequency of high-grade toxicities; however, the severity and frequency of these toxicities
did not rise to the level of those observed with FOLFIRINOX treatment, and as a result,
nab-paclitaxel and gemcitabine can be administered to patients with EOCG performance
scores less than or equal to two. Finally, for patients with poor performance scores (greater
than 2), gemcitabine continues to be the gold standard of treatment [48].
Overall understanding of the basic development and anatomy of the pancreas, the
origin of PDAC, and the epidemiologic, pathologic and clinical features of PDAC highlight
important themes that are central to clinical and biological aspects of PDAC. Most
importantly, the epidemiology, pathology, clinical presentation, and failure of surgical
resection with curative intent in the vast majority cases of PDAC all suggest the highly
metastatic nature of PDAC. This metastatic nature, combined with the anatomy of the
pancreas, which is a major contributor to the lack of specific PDAC symptomology, leads
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to the diagnosis of the majority of patients with late-stage disease. Diagnosis late in disease
progression limits the usage of surgical resection as a treatment modality (which despite
being relatively poor in terms of patient outcomes is still the most effective treatment in
terms of prolonging life and the only treatment option with curative potential).
Furthermore, late-stage diagnosis causes a reliance on chemotherapies, which are both
highly toxic and prolong survival by only short periods. The corollary to this argument is
that metastasis, especially early in disease progression, represents a major burden to the
effective diagnosis and treatment of PDAC; thus, further study of the processes that
promote or permit the aggressive systemic dissemination of PDAC cells is tantamount to
understanding PDAC metastasis and ultimately finding means of therapeutically targeting
either metastatic lesions or the processes that facilitate their development.
Chapter 1B: The PDAC Tumor Microenvironment (TME)
In the year 2000, Drs. Douglas Hanahan and Robert Weinberg published a seminal
review article in which they enumerated what they considered at the time to be the
underlying hallmarks of cancer. The six listed hallmarks can be summarized by the
following: 1) evasion of apoptosis, 2) cell-autonomous sufficiency of growth signaling, 3)
insensitivity to anti-proliferative signaling, 4) invasion and metastasis, 5) limitless potential
for replication, and 6) sustained angiogenesis [53]. Of these six listed hallmarks, five
hallmarks pertain to the characteristics of the malignant cells themselves while only one
hallmark, sustained angiogenesis, focused on the interaction of the cancer cells with host
tissue or the larger environment within a tumor. By 2011, these same authors added four
additional hallmarks of cancer, including 7) avoidance of immune surveillance, 8)
inflammation-mediated tumor promotion, 9) genomic instability, and 10) dysregulation of
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cellular energy metabolism [54]. These additions paralleled the growing recognition that
cancer cell interactions with the host, and specifically the host immune systems, ultimately
play a critical role in the development of a tumor. Moreover, within the text, the authors
delineate the contribution of several other stromal features, including endothelial cells,
immune cells, cancer-associated fibroblasts, and the extracellular matrix (ECM), to several
hallmarks of cancer. Overall, we have begun to view tumors as complex entities rather
than simply masses of malignant cells, and thus, understanding the interactions of
malignant cells with those of the host is critical to understanding cancer biology as a whole.
In PDAC, malignant cells have interactions with numerous cell types, including
endothelial cells and pericytes, cancer-associated fibroblasts and/or pancreatic stellate cells
(PSCs), and cells of the innate and adaptive immune system. Additionally, acellular
components, such as the ECM, and the overall biochemical environment, including
hypoxia, have been shown to have an impact on PDAC biology. Despite this tremendous
diversity in the interactions of cancer cells with the host cells, desmoplasia is a key
determinant of the PDAC TME, and as such, contributes substantially to each of these
aspects. Thus, discussion of the PDAC TME here focuses on the role of desmoplasia in
terms of its contribution to heterologous cellular interactions in the tumor —including
those with endothelial and infiltrating immune cells— and the effect of desmoplasia on
disease progression.
1B.1 Desmoplasia in PDAC: An Introduction
As previously discussed in the section regarding PDAC pathology, desmoplasia,
composed of ECM, activated fibroblasts, and lymphocytes, is a histologic hallmark of the
PDAC TME. While its contribution to PDAC progression was initially overlooked,
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desmoplasia has recently been recognized as an important contributor to the pathobiology
of this disease. Initial studies showed that in the course of PDAC development, cancer
cells recruit and activate fibroblasts causing them to proliferate, deposit extracellular
matrix, and secrete numerous factors, which, in turn, profoundly affect malignant cell
behavior. The confluence of data from these early studies demonstrated the tumorpromoting role of desmoplasia through driving tumor cell proliferation, promoting invasive
and stem cell-like properties, and suppressing the anti-tumor immune response.
Furthermore, pharmacologic inhibition of desmoplasia slowed PDAC progression in
animal models, thereby highlighting desmoplasia as a potential therapeutic target in PDAC
[55-59]. Although numerous studies form in vitro and in vivo models showing the
desmoplasia promotes PDAC progression, spontaneous PDAC animal models lacking
important drivers of the desmoplastic reaction showed accelerated disease progression,
indicating that the role of desmoplasia in PDAC is more complex than initially imagined.
Moreover, these contrasting results raise fundamental questions regarding the function of
desmoplasia in PDAC and the theoretical basis of desmoplasia-targeted therapies.
Regardless, desmoplasia is a key feature of PDAC biology for numerous reasons, including
its contribution to the CXCR3 signaling axis.
1B.2 Origins of Desmoplasia in PDAC
Much of the information regarding the origins of the desmoplastic reaction in
PDAC is derived from the study of pancreatic fibrosis in other settings, such as chronic
pancreatitis, as well as in PDAC. For instance, in the course of studying cell populations
within the pancreas, a pancreas-resident, quiescent fibroblast population present in the
interacinar and interlobular spaces was discovered. These cells stored cytoplasmic lipid

32

droplets containing retinoids and expressed desmin similar to hepatic stellate cells (HSC),
and thus, these cells were dubbed pancreatic stellate cells (PSC) [60, 61]. Upon culture,
the PSCs lost their cytoplasmic lipids and retinol and began expressing α-smooth muscle
actin (SMA), along with various ECM proteins including Collagens I and III, fibronectin
and laminin which mirror the features of HSC activation, a critical step in hepatic fibrosis
[60-62]. Because of their relation to hepatic stellate cells and the known contribution of
HSCs to cirrhosis, it was hypothesized that PSCs might also play an important role in the
pancreatic fibrosis observed in PDAC. Consistent with this hypothesis, SMA-positive cells
expressing pro-collagen genes show marked proliferation in fibrotic regions of inflamed
pancreas, surrounding PanIN lesion, and adjacent to PDAC glands in humans and mouse
models of PDAC suggesting that PSC-like cells are responsible for a large proportion of
the ECM deposition and cellular fraction of the desmoplasia observed in PDAC and
chronic pancreatitis [63-65]. While it is still widely believed that PSCs are a major
contributor to the desmoplastic reaction observed in PDAC, there is some debate regarding
the origin of the fibroblasts observed within PDAC desmoplasia; several recent studies
have demonstrated the recruitment of bone marrow-derived stem cells to chronically
inflamed pancreas [66, 67] and PDAC tumors [68], which differentiate to fibroblasts and
express markers of activated PSCs. Because the origin of the fibroblasts that comprise the
desmoplastic reaction is uncertain, this dissertation refers to PSCs and bone marrowderived fibroblasts in the setting of PDAC as cancer-associated fibroblasts (CAFs), as
pancreatic fibroblasts in the setting of non-malignant pathologies or when referring to
features common to both malignant and non-malignant fibrosing conditions of the
pancreas, and as PSCs only in the setting of quiescent cells in, or isolated from normal
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pancreas —the setting in which these cells can be described, with certainty, as being
resident to the pancreas as opposed to being recruited to the pancreas by an underlying,
ongoing, pathological process.
At the outset of a pancreas fibrosing pathology, activation of pancreatic fibroblasts
is an essential part of the fibrotic process as quiescent pancreatic fibroblasts are neither
proliferative nor secretory. The molecular processes underlying the activation of pancreatic
fibroblasts/PSCs are diverse and proceed through several mechanisms. Broadly, these
mechanisms include those mediated by receptor-ligand interactions and cellular
environment-mediated mechanisms. In terms of receptor-ligand-mediated mechanisms,
these can be sub-classified by the type of ligands involved with the major types being
peptide and small-molecule ligands. Numerous peptide ligands and their receptors have
been implicated in the activation of pancreatic fibroblasts; critical roles for platelet-derived
growth factor (PDGF), transforming growth factor-β1 (TGF-β1), FGF2, and SHH have
been characterized. In PSCs and pancreatic fibroblasts isolated from chronic pancreatitis
patients, PDGF treatment caused notable increases in cell proliferation [62, 69].
Consistently, the conditioned media of PDAC cell lines MiaPaCa-2, PANC-1, and SW850
stimulated the proliferation and synthesis of collagen I and fibronectin in cultured human
pancreatic fibroblast isolated from PDAC and chronic pancreatitis patients [70].
Subsequent studies showed that inhibition of PDGF-mediated signaling by neutralizing
antibodies against the A and B isoforms of PDGF resulted in a loss of the conditioned
media-induced proliferation of pancreatic fibroblasts [70]. Notably, PDGF neutralization
resulted in variable inhibition of fibronectin synthesis across cell line models and was
insignificant in two out of three models [70].
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Similarly, TGF-β1 has important roles in the generation of the activated pancreatic
fibroblast phenotype. However, TGF-β1 did not affect the proliferation of pancreatic
fibroblasts but instead increased the expression of activated pancreatic fibroblast marker
SMA and the expression of ECM proteins, including procollagens I and III, laminin and
fibronectin [62, 69, 71]. Interestingly, in vitro treatment of PSCs with TGF-β1 resulted in
the upregulation of PDGF receptors on PSCs. Moreover, the phenotype of transgenic mice
expressing TGF-β1 under the rat insulin II promoter supports this fibrogenic role of TGFβ1 in the pancreas in that fibrosis occurs spontaneously in the pancreata of these mice along
with increased expression of additional pro-fibrotic cytokines, such as CTGF and FGF1
and 2 [71]. Notably, PDGF A and B did not increase with time in these mice. In the setting
of PDAC, neutralization of TGF-β1 abrogated the production of fibronectin induced by
PDAC cell line-conditioned media [70]. Similarly, neutralization of FGF2 also suppressed
the production of fibronectin in pancreatic fibroblasts stimulated with PDAC cellconditioned media. Importantly, in the TGF-β1 and FGF2 neutralization studies, inhibition
of either molecule resulted in nearly complete abrogation of fibronectin production except
for the PANC1-based model in which the effect of FGF2 was more prominent. This
observation may indicate that both TGF-β1 and FGF2 may be required for stimulation of
ECM synthesis in CAFs depending upon the secretome of the cancer cells driving the
desmoplastic reaction. These results were later supported by an independent study, which
showed that PANC-1 cells lack substantial expression of TGF-β1 thereby explaining the
more pronounced effect of FGF2 neutralization in the PANC-1 model of the previously
published report [70, 72]. Furthermore, when TGF-β1 was ectopically overexpressed in
PANC-1 cells, there was an increase in the desmoplasia observed in orthotopic tumors

35

compared to tumors derived from mock-transfected PANC-1 cells [72]. Cumulatively,
these findings suggest that TGF-β1 may be a master regulator of pancreatic fibrosis in
general, and specifically the desmoplastic reaction of PDAC, by directly and indirectly
driving pancreatic fibroblast ECM synthesis and indirectly promoting fibroblast
proliferation through increasing the ability of fibroblasts to respond to PDGF.
SHH, a molecule essential to the embryonic development of the pancreas, is yet
another critical factor in the promotion of desmoplasia. Using a cell line-based orthotopic
PDAC model, Bailey et al. demonstrated that neutralizing antibody against SHH
profoundly suppressed the appearance of desmoplasia in Capan-2-derived tumors, as
measured by Hematoxylin and Eosin (H&E), as well as SMA, collagen I and fibronectin
staining [73]. Further, in T-HPNE derived tumors, which do not naturally express SHH,
the ectopic overexpression of SHH profoundly augmented the desmoplasia induced by
orthotopic injection of T-HPNE.SHH compared to injection of T-HPNE as assessed by the
same criteria as the Capan-2 based model. The authors went on to show in these models
that the CAFs were negative for SHH and positive for GLI-1 whereas the human-derived
tumor cells were positive for SHH and negative for GLI-1 indicating that the effect of the
SHH on the desmoplastic reaction was not likely the result of an autocrine signaling
mechanism [73]. Ultimately, SHH was shown to augment the proliferation of CAFs,
promote their activation as measured by expression of SMA, and drive the migration of the
CAFs toward SHH-secreting cancer cells [73].
Several additional pathways can contribute to the development of pancreatic
fibrosis and desmoplasia. Local angiotensin signaling in the pancreas has been shown to
play a role in the development of desmoplasia through studies using inhibitors of both
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angiotensin-converting enzymes as well as angiotensin receptors. The initial involvement
of the pancreatic renin-angiotensin systems was discovered in Wistar rats in which the
administration of lisinopril or candesartan suppressed the formation of the pancreatic
fibrosis and overexpression of TGF-β1 resulting from spontaneously occurring chronic
pancreatitis [74, 75]. Subsequently, rat PSCs were shown to express type I and II
angiotensin receptors (AT2R1 and AT2R2 respectively), and treatment of PSCs with
angiotensin II resulted in transactivation of receptor tyrosine kinases through a G-proteincoupled receptor (GPCR)-mediated mechanism [76]. Moreover, treatment of orthotopic
PDAC tumors with angiotensin-II receptor 1 (AT2R1) inhibitors losartan or olmesartan,
and to a lesser extent lisinopril, reduced the number of SMA-positive CAFs and the
expression of TGF-β1, collagen and fibronectin [58, 64]. Furthermore, whole-body
knockout (KO) of AT2R1 in mice followed by orthotopic implantation of cancer cells had
a similar effect on tumor composition, indicating that angiotensin acts predominantly to
activate the fibroblasts in the tumor microenvironment [64]. Despite these convincing
findings, it remains unclear what the underlying defect in the angiotensin pathway in
PDAC is, and how this pathway allows the expansion of desmoplasia.
Galectin-3 was recently implicated in the formation of the desmoplastic reaction.
Here, Zhao and colleagues showed that exposure of CAFs to Galectin-3 resulted in an
augmented state of CAF activation, which included increased proliferation, migration, and
invasion in cultured CAFs as well as increased expression of SMA, collagens, laminins,
and fibronectin. Additionally, treatment of CAFs with Galectin-3 increased the production
of inflammatory cytokines by CAFs, including interleukin-8 (IL8, CXCL8), through an
integrin/ nuclear factor kappa-light-chain-enhancer of activated B-cells (NFκB)-dependent
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mechanism. In the setting of PDAC, the invasion and proliferation of CAFs in response to
co-culture with PDAC cells correlated with the extent to which those cancer cells produced
galectin-3 [77]. Moreover, inhibition of Galectin-3 in orthotopic PANC-1 derived tumors
suppressed the expression of SMA in vivo. These results partially support the role of NFκB
signaling as a promoter of desmoplasia reported in a previous study [78] as well as the
observation that various proinflammatory cytokines, including tumor necrosis factor-α
(TNF-α) and interleukin-10 (IL-10) activate PSCs [79].
The final peptide ligand that merits substantial discussion, connective tissue growth
factor (CTGF), plays a role in the development of desmoplasia and pancreatic fibrosis in
general. Notably, CTGF is regulated in large part by TGF-β1 and PDGF signaling [80],
and in chronic pancreatitis specimens, CTGF and TGF-β1pathway members were
concomitantly upregulated by greater than 20-fold [81]. Furthermore, in vitro studies
revealed that CTGF is an interaction partner for integrin α5β1. Acting through this
integrin, CTGF stimulates proliferation, migration, matrix adhesion, and collagen I
synthesis of rat PSCs [80]. The profibrogenic role of CTGF has also been implicated in the
pancreatic fibrosis observed in PDAC; CTGF was shown to be highly upregulated in CAFs
in PDAC tissues. Moreover, the murine homologue of CTGF, Fisp12, was induced upon
orthotopic implantation of human PDAC cell lines into the murine pancreas [82]. While
suggestive of a role in the promotion of a desmoplastic response, additional studies
regarding the neutralization or genetic ablation of CTGF expression in the settings of
chronic pancreatitis and PDAC would be useful to better understand differential
contributions of this axis to pancreatic fibrosis/desmoplasia and epithelial cells.
In addition to the various pathways involving peptide ligands and their receptors,
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there are several small molecule-mediated pathways that have profound effects on the
activity of pancreatic fibroblasts. Among these, notable molecules include prostaglandin,
retinoids, and vitamin D. The role of prostaglandins in pancreatic fibroblast activation was
initially suspected from studies showing that exposure to PANC-1-conditioned media
upregulated the expression of the rate-limiting enzyme in the synthesis of prostaglandins,
Cyclooxygenase-2 (COX-2), in PSCs [83]. Moreover, the inhibition of COX2 suppressed
the proliferation of PSCs stimulated by PANC-1-conditioned media [83]. Subsequent
investigation supported these results by demonstrating that prostaglandin E2, a product
downstream of COX-2 in the eicosanoid pathway, stimulated the proliferation and
migration of PSCs, as well as the expression of ECM proteins and matrix
metalloproteinases in a prostaglandin EP4 receptor-dependent manner [84]. Though it
should be noted that these effects may be dependent on the specific prostaglandin receptor
involved; another study focusing on the EP2 receptor showed inhibitory effects of PGE2
on pancreatic fibroblast activation [85]. In PDAC animal models with KrasG12D expressed
from a tamoxifen-sensitive Cre under control of the elastase promoter, KO of Cox2 from
the exocrine pancreas resulted in delayed progression to PDAC as well as complete loss of
the associated desmoplasia, thereby further supporting the role of COX2 in the
development of desmoplasia [86]. Similarly, ectopic expression of COX2 in the acinar
compartment of mice resulted spontaneously in a phenotype resembling chronic
pancreatitis, including the presence of inflammatory cells, acinar-to-ductal metaplasia, and
progressive deposition of ECM [87]. It must be noted, however, that the effects of COX2 KO and overexpression in these models, respectively, on desmoplasia may be indirect
effects mediated by the loss of neoplastic insult or modulation of immune infiltrate given
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the classical role of prostaglandins in the innate immune response and the established
contribution of inflammatory cytokines to pancreatic fibroblast activation.
In contrast to the desmoplasia-promoting role of COX-2 and the prostaglandins
resulting from its activity, all-trans retinoic acid (ATRA) and vitamin D have prominent
anti-fibrotic/desmoplastic roles. Retinoids are one of the best-characterized modulators of
PSC activity. With the initial identification and characterization of PSCs, it was found that
like HSCs, PSCs store retinoids in cytoplasmic lipid droplets, which are lost upon
activation [60, 61]. Despite the correlation between the loss of cytoplasmic retinoids and
the process of PSC activation, the causal relationship between these two remained weak
until more detailed reports were published. Retinol, vitamin A, is acquired through the diet
and enters cells through physical interaction with retinol-binding protein [88]. Once inside
the cell, retinol is either metabolized to the biologically active retinoic acid by two enzymes
retinol Dehydrogenase (RolDH) and retinaldehyde dehydrogenase (RALDH) or converted
to retinol esters for storage [89]. Retinoic acid has two major forms in the body, 9-Cis RA
and ATRA, which serve as ligands for two families of nuclear receptors, retinoic acid
receptors (RARs) and retinoid X receptors (RXRs) [90]. Interestingly, the two forms of
retinoic acid show differential affinities for the two families of receptors; ATRA is a highaffinity ligand of RARs while 9-Cis RA can bind and activate both types of receptors [91].
Importantly, PSCs express RolDHII as well as members of both retinoic acid receptor
families suggesting that PSCs contain all the necessary components for an active retinoic
acid signaling pathway [92]. Moreover, treatment of cultured rat PSCs with exogenous
ATRA suppressed their proliferation, collagen synthesis, and MMP2 expression [93].
However, SMA, as well as PDGF-induced phosphorylated ERK 1 and 2 —key molecules
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in the activation of pancreatic fibroblasts— were not reduced, and MMP9 expression was
increased relative to untreated controls [93]. Ultimately, it was shown that ATRA acts as
a transrepressor of the AP-1 complex without affecting upstream activating signals, such
as ERK phosphorylation, or the binding of the AP-1 complex to its DNA binding sites [93].
A second study exploring the differential effects of retinol and both of its derivatives
extended these findings. Consistent with the previous study, Apte et al. demonstrated that
retinol, 9-Cis RA, and ATRA suppressed the proliferation as well as collagen and
fibronectin expression of PSCs. Additionally, they were able to show that SMA expression,
phospho-ERK1/2,

phospho-p38, and phospho-JNK-2 [92] is abrogated by all three

retinoids; however, the extent of these changes was minor compared to the effect on
proliferation and occurred at time points much later than were investigated in the original
report. Thus, the delay in the observed changes may reflect indirect effects of retinoid
signaling. Further, this group was able to show that all retinoids inhibited the activation of
PSCs in response to ethanol, implicating the pathway in the pathogenesis of alcoholinduced pancreatitis [92]. Finally, in the setting of PDAC, treatment of PSC with ATRA
was shown to inhibit the activation of stellate cells mediated specifically by the stiffness
of the growth substrate. Here, the authors showed that ATRA suppresses the ability of
PSCs to both sense strain in, and apply force to their attachment surface, which results in
a loss of ability to contract polyacrylamide gels of different stiffnesses and is accompanied
by loss of SMA and vimentin expression indicating the link between sensing of matrix
stiffness and pancreatic fibroblast activation[94].
Like ATRA, vitamin D and its analogues suppress the activity of pancreatic
fibroblasts. Sherman et al. identified vitamin D receptor VDR expression in mouse
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pancreatic fibroblasts and human CAFs. Subsequently, they found that activation of VDR
through treating isolated pancreatic fibroblasts with calcipotriol, a vitamin D derivative,
suppressed the activation-associated gene signature and phenotype of the fibroblasts,
including downregulation of collagen I, MMP2 and IL6, as well as increased accumulation
of cytoplasmic lipid droplets, a hallmark of quiescent PSCs [55]. Transient knockdown of
VDR abrogated this calcipotriol-induced quiescence indicating that VDR was required for
the inactivation of fibroblasts and that the mechanism likely includes the competition of
VDR for SMAD3 binding at the promoters of profibrotic genes. Moreover, in mice,
calcipotriol abrogated pancreatic fibrosis in response to cerulein-induced pancreatitis and
vdr-/- mice showed spontaneous fibrosis of the pancreas [55]. While these studies clearly
demonstrate the ability of VDR to reprogram already activated pancreatic fibroblasts and
suggests that loss of VDR activity, in the form of receptor knockdown, leads to pancreatic
fibrosis, it remains unclear if and how this fibrosis-suppressing pathway is altered in the
setting of pancreatic pathologies and how these underlying alterations lead to pancreatic
fibrosis.
In addition to receptor-ligand mediated mechanisms of PSC activation, the
biochemical environment itself can also activate pancreatic fibroblasts. In this setting,
significant evidence has been found for hypoxia and ECM stiffness. In cultured pancreatic
fibroblasts, hypoxia induced a migratory phenotype and increased expression of collagen
I [95, 96]. Importantly this hypoxia promoted VEGF expression that stimulated the
proliferation of endothelial cells as well as the migratory phenotype of pancreatic
fibroblasts [95, 96].

These changes were further associated with decreases in the

microvessel density in PDAC as well as chronic pancreatitis[96]. Interestingly one study
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found that hypoxia not only changed the amount of collagen produced but also the
orientation of the collagen that is deposited, which has implications for the migration and
invasion of cancer cells [97]. Interactions of PSCs with a rigid growth substrate is another
classic means of fibroblast activation. It is this mechanism by which isolated PSCs become
activated in culture on plastic.

To further support these findings from the initial

characterization of PSCs/pancreatic fibroblasts, pancreatic fibroblasts from chronic
pancreatitis patients that were grown on Matrigel showed early morphological changes
indicative of quiescence and, over time, showed increased cytoplasmic lipid accumulation
as assessed by oil red O staining over cells cultured in plastic alone [98]. While culture of
pancreatic fibroblasts in Matrigel resulted in decreased expression of SMA, Collagen I,
TGF-β1, and CTGF, it did not reduce the proliferation of the pancreatic fibroblast nor the
expression of fibronectin and increased the expression of glial fibrillary acidic protein
(GFAP) [98]. It should be noted, however, that these results from studies in Matrigel may
be the result of interactions of surface receptors with the biologically active components
present in Matrigel. Despite this, similar results were obtained from a second study that
used polyacrylamide gels to modulate the rigidity of the growth surface of pancreatic
fibroblasts, thereby limiting much of the confounding influences of the biological activity
of Matrigel [94, 99].
There are two promising potential mechanisms by which the rigidity of the
attachment substrate might regulate PSC activation in vivo. The first is that when it is
secreted, TGF-β is bound to the latent TGF-β binding protein (LTBP). To produce active
TGF-β a cell must apply tension to fibronectin fibrils allowing the release of TGF-β from
LTBP-1 [100]. In this process, both cellular contractility and the ECM are critical for the
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release of TGF-β [101, 102]. In pancreatic fibroblasts, Sarper and colleagues showed that
inhibition of PSC activation, using ATRA, as well as inhibition of activated fibroblast
contraction, using blebbistatin, impaired the release of TGF-β1 from LTBP-1 thereby
demonstrating that this mechanism of TGF-β1 release can play an important role in
pancreatic fibroblast activation, specifically in situations in which the rigid attachment
substrate is ECM-based [103]. While the second potential mechanism has not been
explicitly investigated in pancreatic fibroblasts associated with chronic pancreatitis or
PDAC, Calvo and colleagues showed the blockage of matrix remodeling by CAFs, isolated
from breast and squamous cell carcinomas, blocked the activation of YAP1, which was, in
turn, required for the function/activation of CAFs in terms of vimentin expression, collagen
production, and collagen disc contraction [104]. These results are partially supported in
the setting of PDAC by several independent observations. Notably, in different mouse
models of PDAC, the level of Yap activation parallels the degree of matricellular tension
present within the TME [105], which is consistent with a mechanical mechanism of YAP
activation [106]. Furthermore, YAP expression is induced by PDAC and chronic
pancreatitis in pancreatic fibroblasts, and knockdown or inhibition of YAP in pancreatic
fibroblasts suppresses the activated phenotype [107, 108]

Based on these studies, it is

likely that, in PSCs, Yap plays a critical role in activation and function in the setting of
pancreas fibrosis, and that this Yap activation is, at least in part mediated by attachment
substrate rigidity.
As a final note, it is important to consider two features of the environment-mediated
mechanisms of pancreatic fibroblast activation. The first is the fact that both hypoxia and
extracellular matrix rigidity are features of advanced fibrotic disease. Because of this,
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neither of these features can account for the initiation of a fibrotic reaction in the pancreas.
The second point is a corollary to the first. Neither of these mechanisms of activation can
initiate pancreatic fibrosis. Because they are products of the fibrotic reaction, they may
contribute substantially to the ongoing fibrotic process and thus may represent targets for
breaking the vicious cycle that otherwise would result in worsening fibrosis.
Despite the diversity of the extracellular elements that regulate the activation of
PSCs/pancreatic fibroblasts, the list of intracellular signaling mechanisms leading to
PSC/pancreatic fibroblast activation is surprisingly succinct. Here, important roles of
ERK-, Rho kinase-, YAP1-, and SMAD-mediated signaling mechanisms have been
described. The initial observation implicating ERK signaling in PSC activation was the
spontaneous increase in ERK activation with progressive days in culture and increasing
SMA expression [109]. This study further demonstrated that PDGF treatment induced ERK
phosphorylation in PSCs downstream of RAS and RAF and that inhibition of ERK
signaling with trapidil or PD98059 suppressed PDGF-stimulated proliferation of the PSCs
[109] as well as the unstimulated growth of pancreatic fibroblasts in culture [110].
Furthermore, ERK signaling was shown to mediate some of the effects of TGF-β1 on
PSCs. In this setting, inhibition of ERK with TGF-β1 treatment suppressed the ability of
TGF-β1 to upregulate its own mRNA [111]. Similarly, inhibition of ERK signaling in
pancreatic fibroblasts treated with PANC1-conditioned media abrogated the expression
TIMP-1 in response to PANC1-conditioned media, thereby supporting the role of the ERK
signaling in both the proliferative and fibrotic activities of pancreatic fibroblasts [112].
Interestingly, using lovastatin, a hydroxymethylglutaryl coenzyme A reductase (HMGCoA
reductase) inhibitor, Jaster and colleagues inhibited ERK activation in PSCs, resulting in
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loss of proliferation and PSC apoptosis [113].

Ultimately, inhibition of HMGCoA

reductase was shown to interfere with isoprenylation of Rho and Ras family members,
causing reduced membrane localization and suppression of ERK signaling [113]. Finally,
ERK signaling is also implicated in the angiotensin-II mediated activation of PSCs. Here
Angiotensin II treatment activates EGFR through non-canonical heterotrimeric G-proteinmediated transactivation resulting in ERK activation [76]. Importantly inhibition of EGFR
and ERK signaling in this setting abrogated the proliferation of pancreatic fibroblasts in
response to angiotensin II [76].
Along similar lines as ERK signaling, Rho kinases have also been implicated in
pancreatic fibroblast activation. Pancreatic fibroblasts isolated from male Wistar rats
demonstrated expression of RhoA as well as ROCK-1 and 2 [114]. Furthermore, the
inhibition of ROCK using Y-27632 and HA-1077 suppressed stress fiber formation
(characteristic of PSC activation), SMA expression, pancreatic fibroblast proliferation and
migration in response to serum or PDGF, and collagen synthesis [114]. Importantly, these
changes in pancreatic fibroblast activation occurred independently of changes in ERK
activation, suggesting an additional requirement for RhoA and ROCK in PSC activation
[114]. Furthermore, inhibition of ROCK kinases in PDAC mouse models resulted in
decreased collagen density within tumors providing further evidence that this pathway of
activation may be important in vivo and specifically in the setting of PDAC [115].
The parallel changes in stress fiber formation and the activation state of pancreatic
fibroblasts are indicative that mechanical factors may be important for pancreatic fibroblast
activation. As previously discussed, YAP1 signaling can be stimulated by mechanically
transduced signals.

In cultured mouse and human pancreatic fibroblasts, transient
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knockdown of YAP1 inhibited the activation of pancreatic fibroblasts induced by both
PDGF and TGF-β1 treatment. Notably, these changes were not affected by
phosphorylation of YAP1 at serine127, a known negative regulatory mark. Interestingly,
mechanical activation of YAP1 is independent of phosphorylation of serine127 [106].
These results indicate the possibility that specifically mechanotransduction dependent on
RhoA/ROCK signaling results in the non-canonical activation of YAP, which in turn
cooperates with PDGF and TGF-β1 signaling to promote PSC activation.
Given the prominent role of TGF-β1 in PSC activation, it is not surprising that
SMADs also play a prominent role in the intracellular signaling leading to PSC activation.
Using a dominant-negative form of Smad3, which inhibits both Smad2 and three signaling,
along with co-expression of either Smad2 or Smad3, Ohnishi and colleagues studied the
differential effects of these Smads in response to TGF-β1 treatment in PSCs [111]. Upon
TGF-β1 treatment, both Smad2 and 3 translocated to the nucleus of PSCs. Further,
expression of the dominant-negative form of Smad3 suppressed the expression of SMA
and augmented cell proliferation in fibroblasts in culture [111]. Co-expression of Smad2
with the dominant-negative form did not suppress the increased proliferation of fibroblasts
that was stimulated by the dominant-negative Smad. In contrast, co-expression of Smad3
suppressed the increased proliferation indicating that Smad3 signaling may be responsible
for the decreased proliferation observed with TGF-β1 treatment. Later, this same
dominant-negative Smad2/3 was used to show that Smad3 also promoted the expression
of IL-1B and IL-6 [116, 117]. To extend the role of Smad to the setting of pancreasfibrosing disease, He et al. used cerulein to induce chronic pancreatitis in mice with
pancreas-specific, transgenic Smad7 expression, an inhibitor of receptor/co-Smad
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signaling. In this model, the expression of Smad7 reduced cerulein-induced pancreatic
fibrosis along with the number of SMA-positive stromal cells [118]. Though, it must be
noted that the expression of Smad7 in this model is under control of the elastase promoter,
and thus, the expression of Smad7 in PSCs/pancreatic fibroblasts and subsequent
modulation of TGF-β1 signaling in this population by Smad7 is questionable [118, 119].
A second cerulein-induced model of chronic pancreatitis comparing wild type and
haploinsufficient BMP2 mice showed that loss of BMP2 exacerbated the fibrosis in
response to recurrent cerulein injection. Interestingly, the mechanism was shown to occur
through a loss of Smad1/5/8 signaling, which in turn increased Smad2/3 signaling and
worsened pancreatic fibrosis [120].
Cumulatively, these studies demonstrate that the secreted molecules derived from
cancer cells, as well as stromal cells within the microenvironment, play an important role
in the activation of fibroblasts/CAFs in the setting of PDAC. Further, these activated
fibroblasts secrete a large proportion of the ECM present in the desmoplastic reaction.
However, the underlying role that the desmoplastic reaction plays in the progression of
PDAC remains more controversial.
1B.3 Role of Desmoplasia in PDAC Progression
Numerous studies have supported myriad pro-tumorigenic roles of desmoplasia in
PDAC. These effects are derived from biochemical interactions with the CAFs that produce
ECM, the ECM itself, and the environment created by the desmoplasia. Moreover, several
cell types partake in these interactions, including cancer cells, leukocytes, and endothelial
cells. An understanding of these interactions and the consequences of them, at the
biochemical, cellular and ultimately the patient level, is critical to understanding PDAC as
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a complex tumor organ, the natural course of PDAC progression, and, specific to this
dissertation, the context from which CXCR3 ligands arise (Figure 1.5). However, because
of the diversity in the molecules mediating these interactions, and the cells that participate
in them, there is an incredible amount of literature focusing specifically on the
desmoplastic reaction in PDAC. This section of the dissertation will focus only on the
seminal studies that have helped to shape the overall understanding of the contribution of
desmoplasia to PDAC progression.

49

Figure 1.5

Figure 1. 5: The Origins and Pathobiological Functions of Desmoplasia in PDAC.
A schematic overview of the driving factors that promote the formation of desmoplastic reaction
in PDAC and, in turn, the classically reported functions of desmoplasia with respect to PDAC
progression. Cancer cells secrete multiple factors, including SHH, FGF2, TGFβ1, and PDGF, that
result in CAF proliferation, recruitment of CAF precursors, and activation of CAFs. Activated
CAFs, in turn, secrete factors that promote the proliferation, invasion, migration, and metastatic
features of PDAC cells. In addition, activated CAFs secrete immunosuppressive cytokines and
components of extracellular matrix (ECM), obstructing tumor perfusion and promoting a hypoxic
environment. The dense ECM further contributes to PDAC progression through contact-mediated
lymphocyte trapping and stimulation of integrin/FAK signaling in PDAC cells.
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Classically, CAFs were thought to promote tumor progression through their
interactions with PDAC cells. This concept arose from numerous studies demonstrating
diverse mechanisms through which CAFs augmented the malignant features of PDAC. For
instance, subcutaneous injection of MiaPaCa-2, Panc-1, or SW850 PDAC lines with
primary CAFs resulted in greater tumor volumes compared to tumors derived from cancer
cells alone [70]. Similarly, mice orthotopically injected with primary CAFs and MiaPaCa2 had larger tumors with dense fibrotic bands and increased α-SMA staining compared to
mice injected with MiaPaCa-2 or CAFs alone [121]. Furthermore, tumors derived from coimplantation of cancer cells and fibroblasts had increased numbers of PCNA-positive
cancer cells, suggesting that increased tumor volume was, at least partially, due to
increased proliferation of malignant cells. Finally, mice with co-injected tumors had
increased loco-regional and distant metastasis. In vitro, CAF-conditioned media increased
PDAC cell proliferation, migration, invasion, and decreased apoptosis. Additionally, CAFs
increased expression of cancer stem cell and epithelial-mesenchymal transition markers in
PDAC cells, supporting a role of CAFs in metastasis and therapy resistance [122, 123].
CAFs have also been shown to promote immunosuppression in PDAC. CAFderived thymic stromal lymphopoietin (TSLP) modulated dendritic cell (DC) cytokine
profiles to favor Th2 polarization in vitro. Further analysis demonstrated that TSLP is
derived from fibroblast activation protein (FAP)-positive CAFs; correspondingly, TSLPRpositive DCs are found only in the tumor and tumor-draining lymph nodes [124]. Depletion
of FAP-positive CAFs in an autochthonous mouse model decreased the growth of tumors
and increased T-effector cell infiltration in a CXCL12/CXCR4-dependent manner [125].
Additional subsets of CAFs have been shown to promote differentiation of PBMCs to
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MDSCs ex vivo through STAT3 [126].
ECM is a prominent feature of desmoplasia and is thought to promote PDAC
progression. For instance, collagen I potentiates proliferation and migration of PDAC cells
and limits T-cell infiltration into the TME [127, 128]. Further, ECM constituents increase
intra-tumor interstitial fluid pressure (IFP) and matricellular tension (MCT) [105, 129].
Increased MCT in KrasLSL-G12D; TGFBR2fl/fl; Ptf1a-Cre (KTC) mice enhanced STAT3mediated signaling in PDAC cells and accelerated disease progression compared to KPC
mice [105]. Increased IFP also contributed to vascular dysfunction in KPC mice, thereby
limiting the accumulation of chemotherapeutics within the tumor [129] and increasing
tumor hypoxia [130]. Hypoxia further modulates tumor-stroma crosstalk [131, 132], and
selects for more aggressive clones [133]. Cumulatively, these studies demonstrate that
desmoplasia significantly contributes to rapid PDAC progression and provide a rationale
for the development of desmoplasia-targeted therapies in PDAC. However, studies
utilizing genetically engineered mouse models suggest a more nuanced role of desmoplasia
in PDAC.
SHH overexpression in PDAC cells promotes desmoplasia through paracrine
signaling [73, 134, 135]. On this basis, two studies used SHH-KO murine models to study
the effects of desmoplasia depletion on PDAC progression. Rhim et al. generated SKPC
(Pdx1-Cre;SHHfl/fl;KrasLSL-G12D/+;P53fl/+;Rosa26LSL-YFP/+) mice to deplete SHH expression
in pancreatic epithelium. While SKPC pancreata lacked SHH, Indian Hedgehog (IHH)
expression was increased. Despite this compensation, expression of Gli-1 in F4/80-positive
cells and pancreatic tumors decreased more than ten-fold, indicating decreased HH
signaling [136]. SKPC tumors showed decreased α-SMA staining and increased vascular
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density (CD31-positive area) compared to KPC mice. Furthermore, SKPC mice developed
undifferentiated tumors with increased expression of EMT markers [136]. Unexpectedly,
SKPC mice had decreased survival and increased metastasis. Long-term inhibition of
Smoothened with IPI-926 recapitulated SHH KO, and concomitant administration of
gemcitabine did not rescue decreased survival, suggesting that increased gemcitabine
delivery does not overcome the aggressive behavior of SKPC tumors. Interestingly, loss of
SHH signaling sensitized tumors to VEGFR2 blockade, which suggests that the aggressive
behavior of SKPC tumors is mediated by increased vascular density [136].
Similarly, Lee et al. generated SKC (SHHfl/fl; Ptf1a-Cre; KrasLSL-G12D) and SKPC
(SHHfl/fl; Ptf1a-CRE; KrasLSL-G12D; P53fl/+) murine PDAC models [137]. SKC mice
showed robust, early development of PanIN lesions and an increased propensity for
development of PDAC by 55 weeks of age. Further, SKC mice demonstrated persistence
of PanIN lesions following cerulein-induced injury to pancreatic parenchyma. Consistent
with Rhim et al. [136], SKPC mice showed reduced survival and increased vascular density
compared to KPC mice. Pharmacological modulation of SHH signaling with ceruleinaccelerated carcinogenesis demonstrated an inverse relationship between hedgehog
signaling and the presence of PDX-1-positive EPCAM-positive progenitor cells. These
results suggest that SHH signaling may constrain the expansion of pancreatic progenitor
cells following inflammation [137].
Collectively, these data suggest several mechanisms through which SHH deletion
may contribute to PDAC progression. First, changes in differentiation status, expression of
EMT markers, and the persistence of PanIN lesions are plausibly due to disruption of SHH
signaling that impairs the production of CAF-derived factors required for suppression of

53

observed neoplastic cell phenotypes. Second, the lack of SHH-driven ECM deposition may
allow increased dissemination of cancer cells from the primary site to distant sites. As in
the setting of enzymatic depletion of ECM [129, 130], both Rhim and Lee observed
increased vascular density with the loss of SHH. While increased vascular density and
tumor perfusion increase the delivery of therapeutics to the tumor [130, 136, 138], they
may also increase the opportunity for cancer cells to metastasize and alleviate the stress
associated with hypoxia or nutrient deprivation. Thus, the aggressive disease observed in
these models is plausibly attributable to the overall loss of SHH-driven desmoplasia.
However, it remains difficult to discern the actual contribution of loss of
desmoplasia to the aggressive phenotype observed in SKPC mice. Despite studies
demonstrating SHH’s function in pancreatic mesenchyme [73, 135, 139], Lee et al.
suggested that SHH may be critical for the regeneration of the exocrine pancreas and
resolution of inflammation [137]. This is consistent with observations of prolonged
pancreatic inflammation and persistence of PanIN lesions in response to cerulein treatment
and induction of iKrasG12D in Gli1fl/+ animals [140]. Additional studies showed changes in
gene expression in metaplastic pancreatic epithelium consistent with HH pathway
activation [141, 142]. Most convincingly, Fendrich et al. showed that smoothenedfl/fl PdxCre and Ela-Cre mice had persistent acinar-to-ductal metaplasia seven days after cerulein
treatment suggesting that loss of HH signaling in pancreatic epithelium impairs resolution
of pancreatic inflammatory changes [143]. Overall, the aggressive phenotype resulting
from SHH deletion may be the result of the loss of autocrine, not paracrine, SHH signaling.
Similarly, SHH deletion increased intratumoral vascular density, which was not the
result of the loss of SHH signaling in endothelium [136]. These findings were confirmed
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by a subcutaneous PDAC model in which PDAC lines were co-injected with WT
fibroblasts or fibroblasts with homozygous deletion of SHH co-receptors (GAS1-/- and
BOC-/- or GAS1-/-, BOC-/- and CDON-/-) [144]. Here, suppression of SHH signaling in
fibroblasts (GAS1-/-, BOC-/-) increased angiogenesis through upregulation of fibroblastderived angiopoietin-1 and -2 and augmented tumor growth. However, complete loss of
SHH signaling in fibroblasts (GAS1-/-, BOC-/- and CDON-/-) abrogated angiogenesis and
tumor growth. Interestingly, suppression of SHH signaling in fibroblasts did not decrease
desmoplasia or change PDAC cell phenotype, which is consistent with findings from
biopsies of patients treated with the smoothened inhibitor GDC-0449 [144, 145]. These
observations suggest that upregulation of IHH in SKPC mice may contribute to increased
vascular density and the aggressive disease observed in SKPC mice. Thus, increased
vascular density rather than depletion of stroma per se may mediate aggressive disease
course in SKPC mice [144]. It is, however, difficult to understand the impact of SHH coreceptor deletion on the course of the disease, given that tumors in SKPC mice were
smaller, whereas GAS1-/-, BOC-/- tumors were larger compared to respective controls.
Regardless, these findings are, to some extent, mirrored in an Ela-myc model of PDAC, in
which deletion of Galectin-1, a promoter of SHH signaling in PDAC, resulted in decreased
angiogenesis, desmoplasia, and prolonged survival of mice [146].
Finally, Rhim et al. reported significant weight loss, reminiscent of cachexia, in
SKPC mice prior to euthanasia. While the mechanism of the observed weight loss is
unknown, it represents another aspect of the SKPC phenotype that confounds interpretation
of the role of stromal depletion in PDAC progression [136].
Importantly, both SHH-/- PDAC models replicate the findings from clinical trials of
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smoothened inhibitors in PDAC. Phase I trials of IPI-926 showed potential, but a phase II
trial was halted due to decreased survival in patients receiving IPI-926 [147]. Similarly,
another smoothened inhibitor, GDC-0449, in phase I and II clinical trials with gemcitabine
failed to demonstrate benefit over gemcitabine, as well as compared to historical and
placebo controls [145, 148]. These trials demonstrated that SHH blockade reduced
desmoplasia and increased tumor perfusion in a subset of patients, but these changes did
not correlate with patient survival. Rhim and Lee et al. suggest that this lack of efficacy
may result from the emergence of more aggressive disease with the loss of SHH. Overall,
SHH-/- models are capable of elucidating changes in the TME due to loss of SHH signaling
and potentially highlighting mechanisms by which SHH inhibitors failed in clinical trials,
but the pleiotropic effects of SHH deletion limit extrapolation of data to the role of
desmoplasia in PDAC.
The α-SMA-positive CAFs (PSCs / myofibroblasts alternatively) are an abundant
population of CAFs in PDAC. To determine the contribution of α-SMA-positive CAFs to
PDAC progression, Ozdemir et al. cloned human herpes virus thymidine kinase under the
α-SMA promoter into Ptf1a-Cre;KrasLSL-G12D;Tgfbr2fl/fl mice thereby sensitizing α-SMApositive cells to ganciclovir and allowing temporal control of myofibroblast depletion
[149]. Mice treated with ganciclovir demonstrated a modest reduction in desmoplasia with
a marked decrease in α-SMA-positive cells. As in previous studies, myofibroblast-depleted
tumors demonstrate less differentiated histology with increased expression of EMT and
CD133-positive cells (PDAC stem cell marker), and reduced survival for early and late
depletion groups, which was not rescued by administration of gemcitabine. Ganciclovirtreated mice experienced marked weight loss, as in Rhim et al., and showed an increased
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incidence of pulmonary embolism. Despite this similarity, myofibroblast-depleted tumors
showed decreased tumor vasculature, implying that increased vascularity in SHH-KO
studies may be specific to the suppression of SHH signaling. Interestingly, gene expression
analysis suggested that myofibroblast depletion caused significant alterations in the tumor
immune environment. Analysis of intratumoral lymphoid populations revealed decreased
CD4+ T-eff and CD8+ to CD4+, Foxp3+ ratios along with increased expression of CTLA-4
while changes in myeloid populations showed a decreased number of macrophages and an
increased number of granulocytes. Administration of CTLA-4 blocking antibody reversed
changes in the immune infiltrate as well as tumor vasculature and histology suggesting that
observed changes may be rooted in altered tumor immune response after myofibroblast
depletion. Following this observation, the same group published a report of multiplexed Tcell staining that demonstrated that in human samples α-SMA and collagen I staining near
tumor cells does not correlate with a paucity of T-cells in the same region further
supporting these claims [150]. In direct contrast to these findings, Jiang et al. showed that
knockdown of focal adhesion kinase (FAK) signaling in PDAC cells abrogated FAPpositive CAFs and collagen I deposition and allowed for T-cell-dependent inhibition of
tumor progression and increased survival of mice [151]. As in Rhim et al. [136], it is
difficult to demonstrate that stromal depletion was causative of increased T-eff cell
infiltration and tumor inhibition due to the fact that FAK may have multiple other effects
on the PDAC TME. Because of the specificity of α-SMA-positive cell depletion, this study
provides significant insight into the role of myofibroblasts in PDAC progression.
Importantly, the loss of α-SMA-positive fibroblasts from the TME results in changes in
both tumor histology and immune cell infiltrate. The similarity of changes in histology
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between this study and that of Rhim et al. [136], suggests that fibroblasts may directly
modulate the differentiation and EMT statuses of PDAC cells. However, the contribution
of these changes to PDAC progression after stromal depletion is unclear as neither study
demonstrates that these features are causative of poor survival.
Because the model used by Ozdemir and colleagues is specific to α-SMA-positive
CAFs, it cannot comment on the role of other fibroblast subtypes, which is of importance
as FAP-positive fibroblasts have been reported as being a major immunosuppressive
population in PDAC [125]. Additionally, recent evidence shows that pro-tumorigenic,
cytokine-secreting fibroblast populations lose expression of α-SMA and may not be
depleted in this model [152]. Whereas the model used by Ozdemir et al. [149] has
tremendous potential to elucidate the contribution of α-SMA-positive myofibroblasts to
PDAC progression, it is unable to comment on the function of other fibroblast populations
or desmoplasia as a whole.
As in experimental models, correlation of desmoplasia with clinical outcomes show
conflicting results. Using TCGA gene expression, Moffit et al. identified normal and
activated stroma gene signatures; patients with activated stroma signatures had worse
survival compared to patients with similar tumor types and normal stroma signatures [153].
IHC staining of collagen I and hyaluronan in primary tumors correlated with poor survival
(n=53)[154]. In contrast, radiographic assessment of apparent diffusion coefficient (ADC)
correlated inversely with cellularity and positively with stromal content assessed by
Movat’s staining, which is consistent with findings in KPTC (KrasLSLG12D/WT;Ptf1aCRE;Tp53fl/WT;Ela-Tgfa) and other mouse models [136, 149, 155]. Importantly, ADC
correlated with prolonged patient survival in 96 early-stage patients [155].
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An important consequence of these three major studies, which failed to support the
pro-tumorigenic conception of the desmoplastic reaction, was the advent of understanding
fibroblast heterogeneity in the PDAC TME. While there has been much speculation on the
subject, only one study has demonstrated clear differences in the activity of fibroblasts
based on the expression of FAP and α-SMA [152, 156]. Here, it was shown that α-SMA
fibroblasts are most prevalent in close proximity to tumor, both in murine tumor tissue as
well as in organoid culture.

In contrast, fibroblasts located further from cancers

demonstrate decreased α-SMA expression and increased FAP expression. These two
populations of cells were found to be mutually exclusive and have markedly different
activities in the models tested. Importantly, analysis of these two cell populations showed
that FAP-positive fibroblasts secrete a variety of cytokines, including IL-6, which was
shown to profoundly increase the longevity of fibroblasts grown in culture [152, 156] and
has been shown in several other studies to promote the malignant behavior of cancer cells
through a variety of mechanisms [157]. The importance of this study is three-fold: 1) these
results demonstrate the presence of multiple populations of fibroblasts with markedly
different activities and presumably different effects on the progression of PDAC, 2) the
demonstration of these differences allows for extrapolation of results from previous studies
to these two fibroblast populations, and 3) the presence of distinct fibroblast populations
in the setting of PDAC suggests a possible mechanism through which the desmoplastic
reaction may play both tumor-promoting and tumor-restraining roles in PDAC. With
respect to this last point, the findings by Ohlund et al. suggest that depletion of the FAPpositive fibroblasts rather than the desmoplastic reaction as a whole is a promising avenue
for pursuing desmoplasia-targeted therapy in PDAC. Finally, this field of fibroblast

59

heterogeneity is still in its infancy, and more populations of fibroblasts and subclassifications within the existing classes will undoubtedly be identified.
Ultimately, it is too early to accurately discern the role of desmoplasia as a whole
in PDAC progression. Moving forward, an improved understanding of fibroblast biology,
including the cellular origins of fibroblasts in PDAC and the transcription factor networks
driving fibroblast phenotypes both in physiological and pathological conditions, will be
key. This understanding, once gained, can be leveraged for the creation of murine models
specifically designed to identify and characterize heterogeneous CAF populations present
in the PDAC TME. Additionally, such insight will allow the generation of mouse models
with conditional deletion of ECM components to begin to address the role of ECM in
PDAC progression in vivo. Through the use of such studies, a clearer picture of the
complexity of the PDAC desmoplastic reaction will emerge along with an understanding
of the duality of desmoplasia’s role in PDAC progression.
Finally, while various mouse models have suggested that desmoplasia may play a
tumor-restraining role in PDAC, the potential of desmoplasia as a therapeutic target has
not diminished. Recent work demonstrating the presence of multiple CAF populations
indicates that, in the PDAC TME, pro-tumorigenic and tumor-restraining components may
coexist. Therefore, the discovery and characterization of distinct populations of CAFs may
yield promising new targets for therapeutic intervention (Figure 1.6). Similarly, the
activities of CAFs in PDAC have yet to be fully characterized. Because of this, it is
theoretically possible that a single fibroblast cell type may in itself have pro- and antitumor functions. As with targeted therapy against cancer cells, it may not be sufficient to
deplete an entire fibroblast population from a tumor, but rather target a specific activity of
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these cells to undermine the tumor-supporting role or augment the tumor-restraining
activities. Finally, direct modulation of the extracellular matrix properties, through the use
of a recombinant pegylated hyaluronidase, showed promising results in phase II clinical
trials and is now in phase III testing [158]. While the mechanistic basis of the efficacy of
hyaluronidase has yet to be fully elucidated, the findings from clinical trials suggest that
the ECM may be a valid target for drug discovery. Overall, desmoplasia represents a key
facet of PDAC biology, and while the role of desmoplasia in PDAC progression remains
to be fully elucidated, there are numerous aspects of desmoplasia that continue to have
potential as therapeutic targets for the treatment of PDAC.
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Figure 1.6

Figure 1. 6: Model of CAF Heterogeneity in PDAC and Potential Therapeutic Targets
A. Based on the phenotypic characteristics, inflammatory (α-SMA low, FAP high) and
myofibroblast (α-SMA high, FAP low) CAF subsets exist in a dynamic equilibrium during tumor
progression. The crosstalk and secretome of the heterogeneous CAF populations create a unique
microenvironment affecting infiltrating immune cells, tumor vasculature, and cancer cells that
dictate their dichotomous role during early and late phases of tumor development. B. The
depletion of the myofibroblast subset allows the predominance of inflammatory CAFs in the
TME, leading to suppression of anti-tumor immune response, reduced ECM deposition, and
angiogenesis, as well as a poorly differentiated cancer cell phenotype.
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Chapter 1C: Immunologic Cytokines in PDAC
Cytokines have a unique position within TMEs in general and specifically in the
setting of PDAC. Given their classic role in the immune system, the expression of various
cytokines in the setting of PDAC can have profound effects on the tumor immune
microenvironment through modulation of the activities of tumor-infiltrating immune cells.
In addition to this somewhat classical role, many cytokine receptors are expressed on
PDAC cells, and thus, the cancer cells themselves can respond to these environmental cues
resulting in altered cancer cell behavior. Therefore, cytokines sit at a crossroads of cancer
cell biology and antitumor immunity. The number of cytokines combined with their
complex interactions makes a comprehensive review of their functions in pancreatic cancer
unfeasible. Alternatively, there are several cytokines/cytokine receptors that have been
particularly well researched with respect to their functions in PDAC. Moreover, these
particular cytokines serve as poignant exemplars of the critical roles that the cytokines of
various families can play in PDAC and, as such, serve as justification for further
investigation of cytokines in PDAC. The following section presents the data regarding the
functions of interleukin-6 (IL-6), Leukemia inhibitory factor (LIF), CXCR2 ligands, and
CXCL12 in PDAC.
1C.1 Interleukin-6
IL-6 is classically a proinflammatory member of the interleukin family; however,
in the setting of PDAC, it has been shown to inhibit an effective anti-tumor immune
response and promote aggressive behavior in PDAC cells. In PDAC mouse models, the
loss of IL-6 prevented the formation of PDAC from PanINs resulting from the expression
of KrasG12D and expression of KrasG12D in combination with cerulein treatment [159, 160].
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One study found that the prevention of PDAC formation was linked to the loss of
ERK/AKT signaling in neoplastic acinar-derived cells, which resulted in decreased cancer
cell proliferation as measured by Ki-67 staining [159]. The ultimate result of this was
ductal-to-acinar redifferentiation and a loss of ability to resist oxidative stress [159].
Another report further validated the phenotype of IL-6 KO by overexpression of a soluble
GP130, a co-receptor of IL-6. In this model, the trans-signaling of IL-6 is lost. In mice
expressing soluble GP130 along with activated Kras, there was a complete loss of grade 2
and 3 PanINs [160]. Similarly, the loss of STAT3 from the pancreatic acinar compartment
resulted in the loss of all PanIN 2 and 3 lesions as well as a decrease in the total number of
tumors formed and the proliferative index of neoplastic cells [160]. The acinar-specific
KO of STAT3 not only supports the notion that IL-6 plays a critical role in PDAC
progression, but due to the acinar-specificity of the loss of signaling, these studies also
show that IL-6 signaling plays an important role specifically in neoplastic cells.
Following the initiation of PDAC, IL-6 plays important roles with respect to
increasing the malignant potential of the cancer cells. In this setting, the loss of IL-6mediated signaling through inhibition of HSP90 resulted in inhibited growth of orthotopic
PDAC cell line-derived tumors with decreased vascularization [161]; although, the
observed effects are only indirectly tied to the activity of IL-6. Importantly, these results
were supported by several additional studies, including a report by Ohlund and colleagues
in which IL-6 was shown to be critical for the pancreatic fibroblast-mediated maintenance
of primary PDAC cells in organoid culture. These findings suggest that IL-6 may be
important for the maintenance of a progenitor population that supports renewal of PDAC
organoids and the expansion of PDAC in vivo [152].

In addition to putative roles in the
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growth of primary tumors, IL-6 plays key roles in the metastatic process as well. IL-6
treatment rapidly induces the migration of PDAC cells in vitro [162]. These effects on
migration were shown to be dependent on the activation of CDC42 downstream of
JAK2/STAT3 signaling [162]. The role of IL-6 in cancer cell migration indicates that it
may represent a cellular signal with the potential to initiate or augment the early phases of
metastatic dissemination. IL-6 also has some function in the later stages of metastasis.
Production of Il-6 by myeloid cells in response to both PDAC as well as colorectal tumors
causes activation of JAK/STAT signaling in the liver that, in turn, stimulates the synthesis
of acute-phase proteins serum amyloid A1 and A2 (collectively, SAA) [163].
Cumulatively, these malignancy-associated alterations promote the formation of the prometastatic niche in the liver, and genetic ablation of IL6, STAT3, or SAA reduced the
ability of PDAC cells to metastasize to the liver [163]. On the whole, numerous aspects of
the natural progression of PDAC are affected by IL-6 and its downstream signaling through
mechanisms that directly involve the biology of malignant cells making IL-6 an important
factor for understanding the behavior of PDAC cells under a variety of conditions.
In addition to the role of IL-6-mediated signaling in malignant and neoplastic cells,
IL-6 also has roles in modulating the inflammatory microenvironment in PDAC. With
respect to this activity, IL-6 has been shown to affect both innate and adaptive branches of
the anti-tumor immune response; however, it should be noted that much of the effect of IL6 on lymphocytes is mediated through a direct effect on other cell populations. For
instance, CAF-conditioned media promoted the differentiation of myeloid-derived
suppressor cells (MDSC) [126]. The activity of CAF-conditioned media, in terms of both
activation of STAT3 signaling in myeloid lineage cells and in MDSC differentiation, was
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abrogated by IL-6 neutralizing antibody [126]. Moreover, the MDSCs that differentiated
as a result of IL-6 signaling functioned to suppress the activity of CD8+ and CD4+ T-cells
[126]. IL-6 also affected the differentiation and activation of dendritic cells (DCs). Similar
to findings in studies of the activity of IL-6 in MDSCs, it was initially observed that
conditioned media of PDAC cell lines suppressed the differentiation of human monocytes
and CD34-positive hematopoietic stem cells into dendritic cells [164]. The effect of the
PDAC cell-conditioned media was phenocopied by the coincubation of monocytes with
IL-6 and granulocyte-colony stimulating factor (G-CSF) [164]. Further, the depletion of
these two factors from conditioned media rescued DC differentiation [164]. Subsequent
investigation showed that activation of STAT3 during DC differentiation inhibits further
differentiation. Functionally, altered DC differentiation resulted in the loss of the ability of
monocytes to activate T-effector cells [164]. Consistent with these findings, blockade of
IL-6 signaling using an oncolytic adenovirus suppressed the differentiation of MDSCs and
augmented the maturation of DCs while suppressing the expression of PD-L1 and PD-1
[165]. These changes resulting from IL-6 blockade ultimately prolonged the survival of
mice injected with B16 melanoma cells subcutaneously [165]. Moreover, when IL-6
blockade is combined with PD-L1 blockade in mice bearing orthotopic PDAC tumors,
there is enhanced tumor infiltration of CD4+ and CD8+ T-cells in the combination group
over PD-L1 monotherapy suggesting that IL-6 signaling contributes to suppression of the
anti-tumor immune response in ways distinct from immune checkpoints [166]. The
combined blockade ultimately decreased tumor size and increased the survival of KPCBrca2 mice [166].
The previous discussion of the activity of IL-6 in anti-PDAC immunity has focused
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largely on purely immunological mechanisms; however, cancer is a complex disease that
affects the host on a systemic level. Cachexia, a cancer-associated wasting syndrome that
commonly affects PDAC patients, is prime evidence of this fact. In cachectic patients, the
tumor affects multiple organ systems through the secretion of the several soluble factors,
which result in metabolic alterations, ultimately leading to the breakdown of muscle tissue
as an energy source. In murine models of PDAC, IL-6 secreted by cells within the tumor
acts on the liver to suppress peroxisome proliferator-activator receptor-α (PPAR-α) in
hepatocytes; this limits the ketogenic potential of these cells [167]. When mice bearing
PDAC tumors were challenged with caloric deprivation, the lack of ketogenic ability in the
liver causes a massive upregulation of glucocorticoids [167]. In turn, high levels of
glucocorticoids suppressed the anti-tumor immune response as demonstrated by a
decreased number of tumor-infiltrating T-cells and NK-cells and were associated with
failure of PD-L1 blockade [167]. Cumulatively, these results strongly suggest that IL-6
suppresses the anti-tumor immune response by directly altering the activity of myeloid
cells through differentiation of immunosuppressive cells and suppression of immunitystimulating activity, and indirectly through metabolic alterations leading to stress response
and suppressed lymphocyte-mediated immunity.
Despite the apparent immunosuppressive role of IL-6 in PDAC, IL-6 has also been
shown to have tumor immunity-promoting roles as well. Using subcutaneous tumors with
or without ectopic overexpression of IL-6, Gnerlich et al. demonstrated that there was a
loss of T-regulatory cells and an increase in Th17 cells in the tumor with IL-6
overexpression [168]. Ultimately, mice bearing IL-6-overexpressing tumors survived
longer than those bearing tumors derived from cells transfected with empty vector [168].
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Further, there was an increased number of CD8+ T-cells suggesting that the loss of Tregs
rather than the gain of Th17 cells may be the critical feature in this model [168]. While
this study provides an interesting insight into the nuanced function of IL-6 with respect to
anti-tumor immunity, the phenomena demonstrated here do not seem to be general as
several other investigations have not yielded similar results [165-167]. It is, of course,
possible that the findings of this study are meaningful in the context of PDAC progression,
yet continued investigation is required in order to elucidate the underlying reasons for
disparities between the findings of this report and those of other published studies.
1C.2 Leukemia Inhibitory Factor
Leukemia inhibitory factor (LIF) is another member of the IL-6 class of cytokines.
This classification is based on shared signaling mechanisms in which LIF binds to its
receptor, LIFR, which causes the receptor to heterodimerize with a signaling co-receptor
GP130, the same co-receptor required for signaling downstream of the IL-6 receptor.
Because of a shared signal transducer subunit, LIF shares a good deal of functionality with
IL-6. For instance, both LIF and IL-6 activate STAT3 as a component of their downstream
signaling. Because of this, IL-6 and LIF have been linked to STAT3 phosphorylation,
which is critical for PDAC initiation and progression [169]. Despite the similarity in their
signaling mechanisms, there are facets of LIF function in PDAC that are distinct from the
functions of IL-6 due in part to differences in the expression patterns of the ligand, the
receptor, and the downstream signaling. Interestingly, in genetically engineered mouse
models of PDAC with and without KO of LIFR in the acinar compartment, mice lacking
LIFR expression had delayed development of PDAC, as well as a decreased proportion of
pancreas consumed by PDAC lesions [170]. Moreover, granulocyte monocyte-colony
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stimulating factor (GM-CSF) and CCL11 produced by cancer cells and pancreatic
fibroblasts respectively were decreased in LIFR-KO mice suggesting that delayed PDAC
development may be the result of an altered immune response [170]. Finally, LIFR-KO
mice had prolonged survival over mice with functional LIF signaling, and neutralization
of LIF sensitized PDAC cells to gemcitabine likely due to the loss of PDAC stem cells
[170]. To further delineate the differential roles of LIF and IL-6, Wang and colleagues
studied the different functions of the two cytokines in the setting of PDAC. First, LIF, not
IL-6, expression was suppressed by the loss of activated KRAS in PDAC cell lines [171].
Similarly, only LIF was able to rescue sphere-forming ability in the PDAC cell lines
following knockdown of KRASG12D [171]. Finally, only LIF treatment was able to
stimulate signaling through the Hippo/YAP pathway, and knockdown of YAP suppressed
the ability of LIF to rescue the sphere-forming capacity of PDAC cells [171]. In sum, these
studies show that LIF can mediate important events in the process of PDAC progression
both in combination with IL-6 signaling and through mechanisms distinct from IL-6. It is
important to note that while LIF appears to specifically mediate critical signaling events in
PDAC, studies to date have not demonstrated important immunological effects for LIF.
Thus, it is likely that both LIF and IL-6 have critical and distinct roles in PDAC.
1C.3 CXCL12
In the setting of PDAC, CXCL12 (Stromal derived factor 1, SDF-1) is derived
mainly from CAFs and represents one of the most important secreted molecules in terms
of CAF-cancer cell interactions. In contrast to both IL-6 and LIF, which are related to each
other as well as interleukins, CXCL12 is a member of a broad classification of cytokines
termed chemokines or chemotactic cytokines so named for their ability to induce migration
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in a variety of cells. Historically, chemokines have been characterized with respect to their
activity in leukocyte populations. However, like IL-6, CXCL12 has diverse functions in
PDAC, which affect many aspects of the TME and tumor progression. Numerous studies
have shown that CXCL12-mediated signaling promotes the malignant behavior of
neoplastic cells. Perhaps the most prominent feature of CXCL12 and its receptor CXCR4
in PDAC is its identity as a cancer stem cell (CSC) marker [172]. As a CSC marker, a rare
population of CD133-positive, CXCR4-positive cells was shown to have increased
progenitor capacity, though the actual role of CXCR4 in CSC remains to be determined
through direct experimentation [172]. Regardless, the association of CXCR4/CXCL12
signaling with CSCs in PDAC may give rise to many of the functions shown for
CXCR4/CXCL12 in PDAC. Consistent with this hypothesis, CXCL12 and CXCR4 are
expressed during the formation of PanIN lesions [173]. This early expression of CXCR4
appears to be under the control of augmented KRAS signaling as inhibition of the MAPK
pathway downstream of KRAS activation suppresses the expression of CXCR4 in PanINderived cells [173]. During the development of PDAC, the co-expression of both the
receptor and ligand at this early time appears to play an important role in the development
of PDAC; cells derived from PanINs undergo proliferative expansion following treatment
with CXCL12, which increases the probability of the development of additional mutations
required for the progression of PanIN lesions to PDAC [173].
Additionally, CXCL12 plays an important role in the metastatic process. First,
PDAC cell lines derived from metastatic sites have higher expression of CXCR4 [174].
Furthermore, in these CXCR4-expressing cells, CXCL12 promoted migration and
proliferation while suppressing apoptosis. Similarly, CXCR4 overexpression in murine-
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derived PDAC cell line TD-2, increased the migration of overexpressing cells to CXCL12
[175].

Consistent with the ability of CXCR4 to promote cell migration, CXCR4

overexpression increased the metastatic ability of PDAC cells in tail vein-injection models,
and this effect was suppressed by pretreatment with AMD3100, a CXCR4 inhibitor [175].
Finally, CXCR4/CXCL12 signaling plays a role in gemcitabine resistance. Gemcitabine
treatment augments the expression of CXCR4 in PDAC cell lines through reactive oxygen
species-mediated activation of NFκB and HIF-1α [176]. Importantly, this induction of
CXCR4 presumably potentiates chemoresistance in PDAC cells resulting from CXCL12
treatment [177].
In sum, CXCL12 and CXCR4 play critical roles in PDAC from the initiation of
neoplastic lesions to the metastatic process to therapy resistance. Importantly, CXCR4 is
an established marker of PDAC CSCs, and each of these functions of CXCL12 signaling
is associated with the characteristics of cancer stem cells in general. Despite these
associations, the above studies demonstrate a critical role specifically of CXCR4
activation, and while these reports were not conducted specifically in CSCs, the
concordance of the functions of CXCL12 signaling with those of CSCs would strongly
suggest that CXCR4 is functionally critical for CSC activities.
CXCL12 also plays an important role in modulating the TME in PDAC. CXCL12
derived from pancreatic fibroblasts has been implicated in inducing the expression of SHH
in neoplastic cells suggesting that CXCL12 expression may be a key event in initiating the
desmoplastic reaction [178]. Additionally, CXCL12 promotes the invasion of peripheral
glial cells towards the tumor, which is thought to suppress the perception of pain associated
with growing tumors and serves as a potential metastatic route [179]. Finally, CXCR4
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signaling in endothelial cells is an important promoter of angiogenesis in a variety of
malignancies, including PDAC [180].
Anti-tumor immune responses are also modulated by CXCL12/CXCR4 signaling.
In this regard, pancreatic fibroblasts were shown to recruit CD8+ T-cells, and blockade of
CXCL12 suppressed the migration of CD8+ T-cells to pancreatic fibroblasts [57]. While
these results suggest that CXCL12 functions to recruit effector T-cells to the TME, data
from mouse models indicate that this CXCL12 mediated recruitment promotes
accumulation of T-cells in stromal-rich areas rather than surrounding malignant cells [57].
Similarly, in autochthonous, murine models of PDAC, the elimination of FAP-positive
fibroblasts reduced tumor growth in a T-cell dependent manner [125]. The administration
of AMD3100 to mice bearing autochthonous PDAC tumors phenocopied the growth arrest
produced by depletion of FAP-positive fibroblasts from the tumors.

Moreover, the

administration of AMD3100 and AMD3100 with PD-L1 blocking antibody allowed the
accumulation of T-cells in juxtatumoral areas, further supporting the conclusions of EneObong and colleagues [125]. Interestingly, the loss of the p50 subunit of the NFκB
complex in PSCs showed an identical phenotype of CD8+ T-cell dependent reduction of
tumor growth in an orthoptic injection model of PDAC. This was subsequently linked to
the loss of CXCL12 expression in p50-null PSCs [181]. Because of these effects on the
distribution of T-cells within PDAC tumors, inhibition of CXCR4/CXCL12 has been tried
with several stromal-targeted- and immuno-therapies. These studies have provided further
support for the functions of CXCL12 in PDAC immune modulation. AMD3100 treatment
combined with PD-L1 blockade in murine PDAC results in the rapid accumulation of Tcells in the proximity of cancer cells with a marked reduction in the number of cancer cells
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present [125]. Similarly, when PD-1 blockade was combined with AMD3100 treatment,
there was an increase in both CD4+ and CD8+ cell infiltrates as well as a marked increase
in the percentage of cells dying by apoptosis in tissue slice culture models of PDAC [182].
Cumulatively, these data indicate that CXCL12 is not only important for the modulation
of cancer cell biology, but also modulation of the tumor immune infiltrates, and more
broadly, the tumor microenvironment. Because of this positioning at a crossroads of
multiple facets of PDAC biology, CXCL12/CXCR4 signaling is a promising therapeutic
target.
1C.4 CXCR1/2 Ligands
CXCR1 and 2 are the receptors for a large number of CXC chemokines, including
CXCL1, 2, 3, 5, 7, and 8. In the setting of PDAC, many of these chemokines have been
shown to have important roles in PDAC progression through acting on PDAC stem cells,
modulation of angiogenesis, and alteration of tumor infiltration by myeloid immune cell
subsets. While the role of CXCR1/2 ligands in cancer cells has been studied less than their
other activities, it is notable that CXCR1 is expressed on a subset of PDAC CSCs. Here,
CXCR1 was co-expressed with several additional CSC markers, including CD24, CD44,
and CD133. In vitro, treatment of PDAC cells with CXCL8 augmented sphere-forming
ability, which was abrogated by concomitant treatment with CXCR1-inhibiting antibody.
Similar patterns of changes were noted for invasion and migration [183]. Moreover, in a
set of three PDAC cell lines derived from COLO357, differential expression of CXCL8
across the cell lines correlated with primary tumor size, the propensity to form metastatic
lesions, and the size of metastatic lesions [184]. These findings are again consistent with
the promotion of CSC properties in cancer cells, though there are important alternative
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mechanisms by which CXCR1/2 ligands may associate with increased metastatic potential.
For example, CXCL8 plays important roles in tumor angiogenesis. Knockdown of CXCL8
from the same COLO-derived cell lines resulted in decreased angiogenesis in the setting
of hypoxia [184]. Moreover, when positive and negative upstream regulators of CXCR1/2
ligand expression, EGFR and NDRG1 (respectively), are inhibited expression of CXCL1,
5, and 8 are decreased and increased (respectively), resulting in concomitant decreases and
increases (respectively) in tumor microvasculature in orthotopically implanted PDAC
tumors [185-187] further supporting the role of CXCR1/2 signaling in angiogenesis.
Perhaps the most important role of CXCR1/2 ligands in the setting of PDAC is with
respect to its modulation of the myeloid-derived cell infiltration into the tumor
microenvironment. In KPC mice with or without whole-body KO of CXCR2, there was
a substantial loss of neutrophils and MDSCs in the tumor microenvironment in CXCR2
KO animals along with abrogation of metastasis [188].

This was accompanied by

increased infiltration of T-cells into the TME. Interestingly, Ly6G depletion phenocopies
the loss of CXCR2 in terms of changes in myeloid infiltrate and abrogation of metastasis,
suggesting that changes in myeloid cell populations are critical to the CXCR2 KO
phenotype [188]. Ultimately, pharmacological inhibition of CXCR2 copied the phenotype
of CXCR2 loss and revealed that the loss of metastatic potential was due to the changes of
myeloid cell populations in the liver which, according to this report, effectively constitutes
the metastatic niche [188]. Concordantly, ectopic overexpression of NDRG1, a suppressor
of CXCL8 expression, diminished the accumulation of macrophages in the TME [187],
while the expression of GABRP increased macrophage recruitment in a CXCL5-dependent
manner leading to accelerated tumor progression [189].

To further underscore the
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importance of CXCR1/2 signaling in the setting of PDAC, recent studies have
demonstrated that CXCR2 can serve as a promising therapeutic target. Notably, inhibition
of CXCR2 increases the effectiveness of both chemotherapy and immunotherapy in the
primary tumor [188, 190].
Critically, CXCR1, 2, 3, and 4 are all GPCRs, and this fact means that all of these
receptors rely on the highly conserved heterotrimeric G-protein signaling system. As a
result, these receptors could share similar functionality in the setting of PDAC, depending
upon the cell populations in which each receptor is/are expressed. As a poignant example
of this, SPA, a broad spectrum GPCR antagonist, prevented cancer cell growth in
xenografted PDAC cells and cancer cell-induced angiogenesis [191]. These findings
indicate that GPCRs of many varieties, including those of the CXCR family, play critical
roles in PDAC progression, yet the specific contribution of each one remains to be
investigated thoroughly.
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Chapter 2: Analysis of the PDAC Cytokine Expression Profile
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Chapter 2A: Introduction
PDAC is among the most aggressive human malignancies with nearly 80% of
patients being diagnosed with late-stage disease and a 5-year overall survival rate of ~9%.
Metastatic dissemination of PDAC is a critical feature that underlies the lethality of PDAC
and limits the effective treatment of the disease. Inflammation is closely associated with
pancreatic cancer development [36, 192-194]. In its various forms, inflammation also
promotes tumor progression through a variety of mechanisms, including through acting
directly on the cancer cells. In this capacity, various components of the inflammatory
response stimulate proliferation, migration, and invasion of cancer cells. In addition to its
direct effects on PDAC progression, inflammation indirectly influences tumor progression
by modulating tumor immune infiltrates. A multitude of inflammatory processes depresses
anti-tumor immunity mediated by Th1 and cytotoxic T-cells, including increased
expression of immune checkpoint molecules [195], expansion of T-regulatory cells [196],
recruitment of immunosuppressive myeloid cells [197-199] and promotion of ineffective
Th2-mediated/humoral response [198]. Cumulatively, inflammation is an intrinsic process
of PDAC progression, and a more nuanced understanding of inflammation in PDAC is
required to better understand its aggressive behavior.
Cytokines and chemokines are essential products resulting from immune responses,
including inflammation. In turn, they are key regulators at the core of inflammatory
processes and, in PDAC, are critical mediators of the effects of inflammation on disease
progression. The previous chapter enumerated the effects of four cytokine signaling axes
—IL-6, LIF, CXCL12, and CXCR1/2. Through the analysis of the literature reported for
these four cytokines, several themes emerged. First, cytokines and chemokines have a
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unique position in the PDAC TME in which they are able to act on multiple cell populations
resulting in altered cancer cell behavior, tumor angiogenesis, and immune infiltration.
Through these multi-faceted roles, cytokines can promote the metastatic progression of
PDAC. Second, a comparison of the roles of inflammation as a whole and of these
cytokines in the setting of PDAC reveals a remarkable overlap in the roles of each
component indicating that a large component of the role of inflammation in PDAC may, in
fact, be mediated specifically by cytokines/chemokines.
While these findings indicate the clear importance of a set of cytokines in PDAC
progression, they cover only a small proportion of the cytokines that are potentially
involved in modulation of the PDAC TME. Moreover, there have been comparatively few
studies that examine the role of cytokines outside of these select cytokines. This chapter
details an approach to profile the differential expression of 149 cytokines in human
microarray data of PDAC and normal pancreas. Subsequently, the chapter presents
detailed data regarding the expression of CXCR3 and its ligand with respect to multiple
facets of PDAC and CXCR3 biology, including the delineation of CXCR3 splice variant
expression, and tissue compartment of origin for expression of CXCR3 and its ligands in
the PDAC TME. Notably, these analyses were validated through IHC analysis of human
and murine PDAC tissue for CXCR3 to demonstrate protein expression of the receptor in
human PDAC tissues for precise quantification of transcript numbers. In combination,
these analyses showed that CXCR3 ligands are among the most highly and consistently
overexpressed cytokines in human PDAC.

Furthermore, results demonstrate clear

expression of CXCR3 mRNA and protein in the PDAC TME and that both the ligands and
the receptors have distinct patterns of expression across cancer cells and tumor stroma.
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Chapter 2B: Methods and Materials
Chapter 2B.1 Selection of Cytokines
The intent of the studies presented in this chapter was to determine those
immunological cytokines that are differentially expressed in the PDAC TME, thereby
elucidating potentially critical factors in its pathobiology. To do this, we surveyed the
expression of 149 cytokines in human microarrays containing both normal and PDAC
tissues. A listing of the selected cytokines is presented in Table 1. In the generation of this
list of cytokines, we attempted to include all members of the CC, CXC, interleukin,
interferon, and tumor necrosis factor families. Additionally, we included cytokines for
which there was evidence for immune involvement despite this not being associated with
the primary role of the cytokine, including members of the transforming growth factor,
bone morphogenetic protein, and vascular endothelial growth factor families. Additional
cytokines were included in order to maintain consistency with PCR cytokine arrays
presented later in this thesis. Several cytokines were omitted from this study on the basis
of little relation to the immune system, i.e., EGF family members, while others may have
escaped our attention and were excluded errantly.

79

Table 1: Listing of cytokines analyzed for changes in expression relative to normal pancreas in
human PDAC microarrays
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Cytokine
CCL1
CCL2
CCL3
CCL4
CCL5
CCL7
CCL8
CCL11
CCL13
CCL14
CCL15
CCL16
CCL17
CCL18
CCL19
CCL20
CCL21
CCL22
CCL23
CCL24
CCL25
CCL26
CCL27
CCL28
CXCL1
CXCL2
CXCL3
PF4
PF4V1
CXCL5
CXCL6
PPBP
CXCL8
CXCL9
CXCL10
CXCL11
CXCL12
CXCL13
CXCL14
CXCL16
CXCL17
IL1A
IL1B
IL1RN
IL2
IL3
IL4
IL5
IL6
IL7

Number
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Cytokine
IL9
IL10
IL11
IL12A
IL12B
IL13
TXLNA
IL15
IL16
IL17A
IL17B
IL18
IL19
IL20
IL21
IL22
IL23A
IL24
IL25
IL26
IL27
IFNL2
IFNL3
IFNL1
EBI3
IL31
IL32
IL33
IL34
IL36A
IL36B
IL36G
IL37
IL1F10
LTA
TNFA
LTB
TNFSF4
CD40LG
FASLG
CD70
TNFSF8
TNFSF9
TNFSF10
TNFSF11
TNFSF12
TNFSF13
TNFSF13B
TNFSF14
TNFSF15

Number
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149

Cytokine
TNFSF18
EDA
LIF
OSM
TGFB1
TGFB2
TGFB3
BMP2
BMP3
BMP4
BMP5
BMP6
BMP7
BMP8A
BMP8B
BMP10
BMP11
BMP15
CSF1
CSF2
CSF3
VEGFA
THPO
ANGPT1
ANGPT2
ANGPT4
VEGFB
VEGFC
VEGFD
MSTN
NODAL
IFNA1
IFNA2
IFNA4
IFNA5
IFNA6
IFNA7
IFNA8
IFNA10
IFNA13
IFNA14
IFNA16
IFNA17
IFNA21
IFNB1
IFNE
IFNK
IFNW1
IFNG
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Chapter 2B.2 Microarray Data and Relative Cytokine Expression Profiles
PDAC microarray datasets that contain tumor and normal (adjacent or otherwise)
samples were queried and downloaded through NCBI GEO. GSE15471 (n=36 paired
samples) [200], GSE16515 (n= 36 tumor and 16 normal samples) [201], GSE18670 (n=6
paired samples) [202], GSE32676 (n=25 tumor and 7 normal samples) [203], GSE28735
(n=45 paired samples) [204] and GSE62452 (n=24 tumor and 16 normal samples) [205]
were included for analysis. In total, 172 tumor and 126 normal samples were compared
across microarray sets. To avoid the artifactual influence of batch effect, each microarray
dataset was processed and analyzed individually. Here, each ‘.cel’ file containing the gene
expression data of a single patient was RMA normalized and aggregated using
Bioconductor AFFY package and R 3.6.1. Following normalization and aggregation, fold
change (FC) values were calculated for each tumor sample for all cytokines in each
microarray data set independently using the following:
𝐹𝐹𝐶𝐶𝑋𝑋𝑋𝑋 = 2𝑋𝑋𝑇𝑇𝑇𝑇 −𝑋𝑋𝑁𝑁

Where, 𝐹𝐹𝐹𝐹𝑋𝑋𝑋𝑋 is the fold change of gene X in the ith tumor sample, 𝑋𝑋𝑇𝑇𝑇𝑇 is the

expression of X in the ith tumor sample and 𝑋𝑋𝑁𝑁 is the mean expression of gene X in normal

samples. Concordantly, reported mean fold change values are given by the following:
𝐹𝐹𝐹𝐹𝑋𝑋 =

∑𝑛𝑛𝑖𝑖=1 𝐹𝐹𝐹𝐹𝑋𝑋𝑋𝑋
𝑛𝑛

where, 𝐹𝐹𝐹𝐹𝑋𝑋 is the mean fold change of gene X, and 𝑛𝑛 is the number of tumor

samples. It is important to note that there are alternative methods of calculating mean FC

values from these data. Most prominently, it is possible to calculate the mean expression
of tumor samples and the mean expression of normal samples and raise two to the power
of the difference between mean expressions of tumor and normal samples. Invariably, such
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a procedure produces different results than those generated by the procedure outlined and
utilized here. The approach utilized in this chapter is justified by the fact that this procedure
uniformly produced results that were more consistent with actual fold change values
computed for paired tumor and normal samples, in which the difference in expression
between a single patient’s tumor and normal samples could be used to calculate individual
fold change values.
The heatmaps of cytokine/chemokine gene expression data were constructed using
the Bioconductor ComplexHeatmap package. For visual clarity, only genes with mean
FCs greater than 1.5 or less than 0.75 across arrays of a single platform type were included
in the heatmaps. A schematic of the workflow for microarray analysis is presented in Figure
2.1.
Chapter 2B.3 Cytokine PCR Array
KC and KPC mice and their respective wildtype littermates (n=6 for each group)
were sacrificed at histologically matched 25 and 10 wks. of life, respectively. RNA was
isolated from the pancreas of each mouse and pooled for mice with the same genotype.
One µg was used as a template for first-strand synthesis. Qiagen qRT-PCR array was
performed according to manufacturer instructions. This PCR array assesses the expression
of 84 different cytokines (Table 2 for a list of cytokines assayed). The FC for each cytokine
in the array was calculated using the ∆∆Ct method with the respective WT littermates
serving as controls for each comparison.

Figure 2.2 presents a schematic of the

experimental design for cytokine PCR array setup.
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Figure 2.1

Figure 2. 1: Schematic Representation of Workflow for Analysis of Differentially Expressed
Cytokines.
Data for each of the listed datasets were downloaded from NCBI Gene Expression Omnibus. Data
were processed, aggregated, and RMA normalized using the Bioconductor Affy package. FCs for
each cytokine were calculated for each individual PDAC patient relative to the mean expression of
the cytokine in the normal samples present in the same microarray dataset. Mean FC was calculated
for all tumor samples present in a single dataset before mean FC was calculated for all patients
analyzed on the same platform. Subsequently, results from two independent array platforms were
compared to identify the set of cytokines found to be differentially expressed on arrays of both
platform types.
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Table 2. Listing of cytokines, the expressions of which were assayed using qRT-PCR array in
KPC, KC and WT murine pancreas.
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Cytokine
Adipoq
Bmp2
Bmp4
Bmp6
Bmp7
Ccl1
Ccl11
Ccl12
Ccl17
Ccl19
Ccl2
Ccl20
Ccl22
Ccl24
Ccl3
Ccl4
Ccl5
Ccl7
Cd40lg
Cd70
Cntf
Csf1
Csf2
Csf3
Ctf1
Cx3cl1
Cxcl1
Cxcl10
Cxcl11
Cxcl12
Cxcl13
Cxcl16
Cxcl3
Cxcl5
Cxcl9
Fasl
Gpi1
Hc
Ifna2
Ifng
Il10
Il11

Number
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

Cytokine
Il12a
Il12b
Il13
Il15
Il16
Il17a
Il17f
Il18
Il1a
Il1b
Il1rn
Il2
Il21
Il22
Il23a
Il24
Il27
Il3
Il4
Il5
Il6
Il7
Il9
Lif
Lta
Ltb
Mif
Mstn
Nodal
Osm
Pf4
Ppbp
Spp1
Tgfb2
Thpo
Tnf
Tnfrsf11b
Tnfsf10
Tnfsf11
Tnfsf13b
Vegfa
Xcl1
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Figure 2.2

Figure 2. 2 Schematic of experimental setup and analytic process for comparative cytokine
arrays of KC and KPC mice.
Histologically matched 10-week-old KPC and 25-week-old KC mice were sacrificed along with
respective wild type littermates (n=6 in each group). qRT-PCR was performed, and fold change
values were calculated for each genotype relative to their age-matched controls. Differentially
regulated genes in both KPC and KC mice were compared.
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Chapter 2B.4 RNA-Seq Data
TCGA
The PAAD TCGA RNA-Seq dataset was downloaded from the TCGA website and
normalized using the Transcripts per Million method.

Samples were subsequently

excluded on the basis of extremely low fraction of tumor cells, diagnosis other than
adenocarcinoma of the pancreas (including neuroendocrine tumor, and acinar cell
carcinoma), or non-primary sample origin. Of the 182 patient samples in the PAAD dataset,
only 140 patient samples were primary PDAC samples with greater than 1% malignant
cellularity; only these 140 samples were included for analysis. For CXCR3 splice variant
quantification, reads were realigned to the human reference genome (Ensemble 94) using
a high stringency fragment-end-matching algorithm allowing the virtual reconstruction of
full transcripts and thus discrimination between CXCR3A and B variants as described by
West et al. [206]. These full transcripts were normalized using the TPM method before
further analysis.
CUMC Microdissected PDAC Samples
One hundred twenty-three paired, microdissected, epithelial and stromal PDAC
samples were acquired, and RNA-Seq was performed at Columbia University Medical
Center. Reads were mapped to the human genome, and expression data was TPM
normalized. This data was queried for expression of total CXCR3 and CXCR3 ligands in
stromal and epithelial compartments.
Chapter 2B.5 IHC Analysis of CXCR3 Expression in Human and Mouse PDAC
Protein expression of CXCR3 in PDAC samples was confirmed using IHC analysis
of human and mouse PDAC tissues. Human PDAC tissues were acquired in two forms.
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First, a tissue microarray consisting of 23 primary PDAC samples was acquired from the
UNMC PDAC Rapid Autopsy Program. Second, 42 primary PDAC resection samples
were acquired from Dr. Benjamin Swanson of the UNMC Department of Pathology.
Human sections were stained with a 1:200 dilution of Mab160 anti-CXCR3 antibody (R
and D Systems) and HRP-conjugated universal secondary (horse anti-mouse IgG/horse
anti-rabbit IgG, Vector Laboratories) in 2.5% horse serum. Mouse samples were acquired
from the KPC progression model at 7 and 25 weeks of age along with WT littermates at
the same time points (n=3 each group).

Murine samples were stained with rabbit

polyclonal anti-CXCR3 antibody reactive to human and mouse CXCR3 (Novus Biological
NBP2-41250) at a 1:200 dilution in 2.5% horse serum. Both human and mouse tissues
were stained according to the following protocol. Tissues were baked overnight at 58 °C,
deparaffinized in 2 washes of xylenes and rehydrated in graded ethanol (100% x 2, 90%,
70%, 50%, 30% 20%). Tissues were washed twice in 1 X PBS with 0.1% Tween 20 (PBST) followed by permeabilization and quenching of endogenous peroxidase (Human: 50%
methanol, 49.7% PBS-T, 0.3% H2O2 for 30 min, Mouse: 50% methanol, 47% PBS-T, 3%
H2O2 for 60 min). Heat-induced antigen retrieval was carried out using sodium citrate
buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) with microwaving to boiling for
15 min. After antigen retrieval, samples were cooled to room temperature; at which point,
tissue samples were washed twice in PBS-T, outlined with a hydrophobic barrier, and
blocked at room temperature for 1 hour with 2.5 % horse serum. Blocking was removed,
and samples were incubated overnight at 4 °C with the previously indicated primary
antibodies. The following day, the primary antibody was removed, and slides were washed
3X, 10 minutes each wash in PBS-T. Secondary antibody incubation occurred for 1 hour
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at room temperature. Slides were again washed 3X for 10 minutes each wash. Staining
was developed using the Impress DAB staining kit (Vector Laboratories) according to the
manufacturer’s instructions. The staining of each tissue section was developed for 2
minutes; development was stopped by submersion of slides in tap water followed by
vigorous rinsing. Sections were counterstained with hematoxylin. Slides were evaluated
microscopically for CXCR3 staining with respect to tumor cell staining vs. stromal cell
staining based on histological appearance.
Chapter 2B.6 Statistical Analysis
For all comparisons of categorical variables with two groups, non-parametric
Mann-Whitney U tests were performed with an α-value of 0.05 being significant.
Specifically, for testing the deviation from randomness of the factional distribution of
CXCR3 expression between epithelial and stromal compartments, all patients completely
lacking CXCR3 expression were excluded from the CUMC dataset. Subsequently, the
values for stromal expression of CXCR3 were randomized relative to the epithelial
expression of CXCR3, and following randomization, the fraction of the total expression
derived from each compartment was recalculated. The number of patients with singlesource expression resulting from a random combination of epithelial and stromal CXCR3
expression was counted and compared to the original actual dataset. This process was
repeated 10,000 times, and the number of trials with a number of sample pairs with singlesource CXCR3 expression greater than or equal to the number of single-source expressors
in the actual data was counted. The total count was divided by 10,000 to yield a p-value
of having the same number or larger number of single-source CXCR3 expressors based on
a random combination of compartmental CXCR3 expression.
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Chapter 2C: Results
Chapter 2C.1 Analysis of Cytokine Expression in PDAC
Using four GPL570 and two GPL6244 PDAC microarray datasets covering 172
tumor and 126 normal samples, we analyzed the relative expression of 149 immunologic
cytokine/chemokine genes. In GPL570 arrays, 40 cytokines were identified with mean
FC’s greater than 1.5 or less than 0.75 (Figure 2.3A). Furthermore, there was strong
agreement between probes measuring the expression of the same cytokine suggesting
accurate quantification of expression. To confirm these results and increase the number of
samples analyzed, we used two additional arrays from the GPL2644 platform, GSE28735
and GSE62452. Twenty-one cytokines were differentially regulated between tumor and
normal (Figure 2.3B). Of these 21 genes, 20 genes were common between GPL570 and
GPL6244 arrays (Figure 2.4). Importantly, the overlap of these analyses identified several
cytokines that have previously been shown to be upregulated in the setting of PDAC,
including CXCL5, CXCL8 (IL8), LIF, TNFSF10, VEGFA, ANGPT2, TGFB1 and 2. In
addition to confirming previous work in the field, the screen also demonstrated
overexpression of ten cytokines that have not been thoroughly investigated in PDAC.
These novel cytokines include CXCL9, CXCL10, CXCL14, CXCL16, CCL13, CCL18,
CCL19, CCL20, IL1A, IL1RN, IL18, and TNFSF4.

No genes were found to be

downregulated in both platforms, but TNFSF8, CXCL12, and CSF3 were consistently
downregulated in GPL570 arrays.
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Figure 2.3
A.

B.

Figure 2. 3 Heatmap of Cytokine Genes Differentially Expressed Between PDAC and
Normal Pancreas
A) Forty cytokines were found to be differentially expressed in GPL570 arrays showing the
prominence of CXCR3 ligands among other established and novel cytokines in PDAC (n= 103).
Note that the presence of multiples of a given cytokine gene reflects different probe sets for
analyzing that gene’s expression and is indicative of consistent quantification B) Cytokines
identified as differentially expressed between PDAC and normal pancreas in GPL6244 arrays.
Twenty-one cytokines were identified, including CXCL9 and CXCL10.
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Figure 2.4

Figure 2. 4: Analysis of Overlap Between GPL570 and GPL6244.

Of the 21 cytokines identified by the GPL6244 array, 20 were also identified in the analysis
of GPL570 microarrays. The cytokine unique to GPL6244 was IL-6.
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Figure 2.5

Figure 2. 5: Fold-change of Expression of Cytokines Identified in Microarray Screen in
KPC and KC Mouse Tissues.
Of the 12 novel cytokines identified in the microarray-based screen, six were identified as
overexpressed in either KPC or KC pancreata. CXCL14, CCL13, and CCL18 were identified by
the microarray screen but were not a target of the PCR array.
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To validate our findings from this cytokine screen, we performed a qPCR array for
cytokine gene expression in murine WT pancreas as well as KC and KPC tissues. In KPC
mice, overexpression of Cxcr2 ligands Cxcl1, Cxcl3, and Cxcl5 as well as Cxcl10, Cxcl16,
Il1a, Il1rn, and Lif was observed (Figure 2.5). Also, the PCR array in KPC tissue showed
overexpression of CXCL4 (PF4) and marginal overexpression of CXCL9 in KPC tissue,
thereby highlighting additional CXCR3 ligands. In the KC mouse model, overexpression
of Cxcr2 ligands Cxcl5, and Cxcl1, as well as Il1a, Il1rn, Il18, Cxcl16, Ccl20, and TgfB2
was confirmed (Figure 2.5). Overall, these PCR-based screens showed results that were
highly consistent with the analysis of cytokine expression in human PDAC tissues. The
only notable exceptions were Ccl19 and Tnfsf10, which were identified as downregulated
in murine models but were observed as upregulated in human PDAC samples. Finally,
several cytokines that were identified in the analysis of human samples were not assessed
by the PCR array due to the limitations of the PCR array format. The cytokines identified
in the original screen that were not assessed in murine tissues include CCL13, CCL18,
CXCL8, CXCL14, and TNFSF4.
Because CXCR3 ligands emerged as promising candidates in each of the previous
analyses, we determined how the expression of each CXCR3 ligand relates to the others in
PDAC tissue. Figure 2.6 depicts the normalized expression of each CXCR3 ligand in
GPL570 and GPL6244 platforms; Figure 2.7 shows the CXCR3 ligand expression in the
PDAC samples in the TCGA PAAD dataset and the total gene expression from the CUMC
dataset. Throughout these datasets, there is a highly consistent pattern of CXCR3 ligand
expression with PFV1 having substantially lower expression than the other four ligands
(p=8.46x10-13 PF4 v. PF4V1 in TCGA). PF4 and CXCL11, which were not found to be
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consistently overexpressed in human samples, have intermediate expression, while CXCL9
and CXCL10 have the highest expression of the five ligands. Importantly, this pattern is
consistent across two microarray platforms and two RNA-Seq datasets suggesting that this
pattern of CXCR3 ligand expression and the overexpression data reported herein are the
result of biology rather than an artifact of microarray probe sets, batch effect, or
transcriptomic methodology.
In vitro results suggested that CXCL10 is derived almost exclusively from the
fibroblasts that constitute a major portion of the desmoplastic reaction surrounding
malignant cells in a PDAC tumor. Furthermore, previous studies demonstrated that PF4V1
is largely derived from malignant epithelial cells in the setting of PDAC. To date, no study
has examined the tumor compartment of origin of all CXCR3 ligands in the same set of
human samples. We used microdissected RNA-Seq data from 123 paired epithelial and
stromal PDAC samples to determine the compartment(s) of the tumor in which all five
CXCR3 ligands are predominantly expressed (Figure 2.8 A and B). Interestingly, all
CXCR3 ligands were expressed to some extent in epithelial and stromal compartments.
Here, CXCL9 and 10 are largely derived from the stromal compartment (p=9.96x10-8 and
2.30x10-4, respectively), while CXCL11 was derived nearly equally from epithelium and
stroma (Figure 2.8 A). PF4 and PF4V1 were expressed to a slightly greater extent in
epithelial samples (Figure 2.8 B). In TCGA, CXCL9 and CXCL10 had significantly greater
expression in low cellularity samples compared to high cellularity samples, which supports
the results from the CUMC data (Figure 2.9).
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Figure 2.6
A.

B.

Figure 2. 6: Expression Pattern of All Described CXCR3 Ligands in Microarray Data of
Human PDAC.
A) The pattern of CXCR3 ligand expression in PDAC tissue analyzed by GPL570 Microarray.
Note that CXCL9 and CXCL10, the ligands that were consistently overexpressed in both
microarray platforms, show the highest normalized expression of all CXCR3 ligand. Also, PF4V1
has considerably less expression that the other 4 ligands. B). The pattern of CXCR3 ligand
expression in human PDAC tissue analyzed by GLP6244 microarray. Note the consistency of the
pattern between the two platforms indicating strong agreement and accurate quantification of
CXCR3 ligand expression.
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Figure 2.7
A.

B.

Figure 2. 7: Expression Pattern of All Described CXCR3 Ligands in RNA-Seq Data from
Human PDAC.
A) Distribution of CXCR3 ligand expression in PDAC samples in the TCGA PAAD dataset. B).
Distributions of CXCR3 ligand expression in human PDAC tissue analyzed by RNA-Seq at
Columbia University Medical Center. Note the consistency of the pattern of CXCR3 ligand
expression irrespective of the dataset used, and transcriptomic technology employed.
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Figure 2.8
A.

B.

Figure 2. 8: RNA-Seq Analysis of Compartmental Expression of CXCR3 Ligands.
A) Distribution of CXCR3B ligand (PF4 and PF4V1) expression in epithelial and stromal
compartments. Consistent with a previous report, both demonstrate increased expression in the
epithelial compartment compared to the stromal compartment though these differences are not
statistically significant. B) Distribution of CXCR3A ligands CXCL9, 10, and 11 across epithelial
and stromal compartments. CXCL9 and 10 have significantly higher expression in the stromal
compartment. Interestingly CXCL11 is expressed equally in epithelium and stroma.
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Figure 2.9
A.

B.

C.

Figure 2. 9: Analysis of CXCR3 Ligand Expression in Association with Cellularity in TCGA
PDAC Patients
A) Analysis of individual CXCR3A ligand expression in TCGA patients stratified by cellularity.
Note that there is a significant association of higher CXCL9, 10, and 11 expression in low
cellularity samples. B) Analysis of the linear combination of CXCR3A ligand expression in TCGA
patients stratified by cellularity. C) Analysis of PF4 and PF4V1 expression in TCGA patients
stratified by cellularity. Consistent with the microdissected data, the association of these molecules
with a cellular compartment is the least significant of all CXCR3 ligands.
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Chapter 2C.2 Assessment of CXCR3 Expression in PDAC
Biologically, overexpression of CXCL9 and CXCL10 in PDAC requires CXCR3
expression within the tumor to have functional consequences.

We used the same

microarray and RNA-Seq resources to assess CXCR3 expression in PDAC tumors. Figure
2.10A depicts the RMA normalized expression of CXCR3 in GPL570 arrays. In these four
arrays, CXCR3 is expressed in all samples. By comparison, CXCR3 expression was lower
in GPL6244 arrays but still present in all samples (Figure 2.10B). CXCR3 was not
overexpressed relative to normal pancreas samples (Figure 2.11 and Figure 2.12). Because
the biology of CXCR3 signaling is dependent on splice variants, we quantified the
expression of CXCR3 splice variants in TCGA data using stringent alignment of reads to
generate virtual recreations of full transcripts (Figure 2.13).

In TCGA, CXCR3 is

expressed in the majority of PDAC samples. Further, CXCR3 A is the predominant splice
variant of CXCR3 expressed in PDAC samples (p<2.2x10-16). Finally, previous reports
indicate that CXCR3 is expressed on cancer and immune cells. To delineate the
approximate cellular origin of CXCR3 transcripts in PDAC samples, we used CUMC
RNA-Seq data to demonstrate that CXCR3 is expressed in the majority of samples
(108/123) and in both epithelial (73/123) and stromal (94/123) compartments with
substantially higher expression in the stromal compartment (Figure 2.14, Median TPM all:
0.543 vs. 2.6, Median TPM CXCR3+: 2.76 vs. 5.98 for epithelial and stromal expression
respectively). Higher CXCR3 expression in low cellularity TCGA samples supported these
findings (Figure 2.15). Interestingly, few tumors had comparable CXCR3 expression in
epithelial and stromal compartments (Figure 2.16A and B), suggesting that high expression
in epithelium suppresses stromal expression and vice versa (p<0.004).
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Figure 2.10
A.

B.

Figure 2. 10: Microarray Quantification of CXCR3 mRNA Expression in Human PDAC.
A) Distribution of CXCR3 expression in 4 independent GPL570 microarray datasets demonstrating
CXCR3 expression in all tested patients. B) Distribution of CXCR3 expression in 2 GPL6244
microarray datasets show somewhat diminished expression overall, but CXCR3 transcripts are
present in all samples.
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Figure 2.11
A.

B.

C.
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Figure 2.11 Continued
D.

Figure 2. 11: Relative Expression of CXCR3 in Normal and Tumor Samples in Each
GPL570 Array.

A-D) Relative expression of CXCR3 mRNA as measured by two distinct probe sets in A)
GSE15471, B) GSE16515, C) GSE18670, and D) GSE32676. In GPL570 arrays, CXCR3
is consistently shown to be downregulated, but present in tumor samples (T) compared to
normal samples (N). This is consistent across each array, and all but one specific probe set
(207681_at) in GSE18670, which has the smallest sample size (n=6) of all sets used.
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Figure 2.12
A.

B.

Figure 2. 12: Relative Expression of CXCR3 in Normal and Tumor Samples in Each
GPL6244 Array.
A-B) Relative expression of CXCR3 mRNA as measured by a single probe set in A) GSE28735
and B) GSE62452. There is greater variability in the pattern of CXCR3 expression in GPL6244
arrays compared to GPL570 arrays. Nonetheless, CXCR3 is not upregulated at the mRNA level in
PDAC according to microarray data.
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Figure 2.13

Figure 2. 13: Analysis of Differential Expression of CXCR3 Splice Variants in the TCGA
PDAC Dataset.
Stringent realignment of reads facilitated the quantification of CXCR3 splice variant expression.
Analysis of the resulting data indicates that the vast majority of patients express CXCR3 and
specifically CXCR3A. Moreover, the median level of CXCR3A expression is significantly higher
than that of CXCR3B. Thus, CXCR3A is expressed in more patients and at a generally higher
level.
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Figure 2.14

Figure 2. 14: Analysis of Compartmental Expression of CXCR3 in Microdissected PDAC
RNA-Seq Data.
In the microdissected CUMC RNA-Seq dataset, we interrogated the compartment-specific
expression of CXCR3. This analysis demonstrates that CXCR3 is expressed at the mRNA level in
both the epithelial and stromal compartments. Stromal expression of CXCR3 is significantly higher
than epithelial expression.
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Figure 2.15

Figure 2. 15: Association of CXCR3 Expression with Cellularity in TCGA PDAC Data
Analysis of CXCR3 expression in TCGA data stratified by cellularity reveals significantly
increased expression of CXCR3 in low cellularity samples compared to high cellularity samples.
These findings support the data gathered from the CUMC data set in which CXCR3 expression
was significantly higher in the stromal compartment.
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Figure 2.16
A.

B.

Figure 2. 16: Non-random Interaction of Epithelial and Stromal Expression of CXCR3 in
Paired, Microdissected, PDAC Samples.
A) Dot plot representing epithelial CXCR3 expression on the left, stromal expression on the right
with lines connecting paired epithelial and stromal samples. Comparatively few lines have
horizontal trajectories, while lines slanting up or down from left to right are more prevalent. B)
Histogram depicting the distribution of each patient’s fraction of CXCR3 derived from the
epithelial compartment. Note the polarization of the highest frequency groups towards 1.0 and 0.0.
Iterative randomization of stromal data points relative to epithelial data points and re-calculation
of epithelial-derived fraction was used to compute an empiric p-value that specifically tests if this
polar distribution is greater than would be expected by random chance.
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To support our findings in microarray and RNA-Seq datasets, we stained human
and murine PDAC tissues for CXCR3. In the murine pancreas, there is little to no CXCR3
expression in the pancreata of 7-and 25-week-old WT mice. In KPC mice, by comparison,
there is some epithelial and stromal CXCR3 expression by seven weeks of life, and robust
expression in both compartments by 25 weeks (Figure 2.17A) suggesting that CXCR3
expression may increase with disease progression. Similarly, in human samples, there was
little or no CXCR3 expression in normal pancreas, but PDAC showed robust CXCR3
expression focally in PDAC stroma with moderate staining diffusely in the malignant
epithelium in a subset of samples (Figure 2.17B).

When resection samples were

categorized by the origin of CXCR3 staining (mixed origin, epithelial predominant, or
stromal predominant), stromal predominant was the most frequent classification (16/40),
followed by epithelial predominant (13/40), with mixed origin being the least frequent
(9/40); two specimens were essentially devoid of CXCR3 staining in both compartments
(Figure 2.18).
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Figure 2.17
A.

B.

Figure 2. 17: IHC Analysis of CXCR3 Protein Expression in Murine and Human PDAC.
A) CXCR3 staining at 7 and 25 weeks in the KPC progression model of PDAC and age-matched
WT pancreas. CXCR3 expression in the WT pancreas is not altered between 7 and 25 weeks of
age. Moreover, the staining observed is minimal. In contrast, CXCR3 protein expression appears
to be augmented in the KPC pancreas by seven weeks in the epithelial and stromal compartments.
By 25 weeks, CXCR3 expression appears to increase, suggesting that CXCR3 expression correlates
with disease progression. B) CXCR3 staining in normal (right) and malignant (left) human
pancreas samples. Staining in this sample is robust in both tissue compartments, which is consistent
with findings in the murine model.
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Figure 2.18

Figure 2. 18: Analysis of CXCR3 Staining Patterns in Epithelial and Stromal Tissue
Compartments.
Human PDAC samples stained for CXCR3 were analyzed for compartment-specific expression of
CXCR3 and the interaction between CXCR3 expression epithelial and stromal compartments, as
was observed in microdissected RNA-Seq data. Overall, 40% of samples had significantly more
stromal staining for CXCR3 than epithelial staining. Roughly 30% of tumors had very limited
stromal staining with robust staining of the malignant epithelium.
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Chapter 2D: Discussion
We used microarray data in an unbiased manner to determine the expression of 149
cytokines in PDAC relative to normal pancreas. The workflow implemented here was
designed to provide a maximally robust analysis. The measures that were taken to ensure
this robustness are two-fold. First, the use of multiple datasets on a single array platform
increases both the number of total samples and ensures that differentially regulated
cytokines identified for a single platform are not the product of batch effect, the term used
to describe artifactual quantifications produced by minute variances that occur between
trials of a single experiment. There are alternative means of adjusting for batch effect,
most notably COMBAT, which rely on mathematical adjustment of gene expression on the
basis of reducing systematic alterations in gene expression data across batches [207]; these
systematic alterations include shifts in expression as well as increased variances. However,
these approaches were designed for and validated on experiments with an extremely high
degree of internal validity, i.e., RNA was isolated from consecutive, identical in vitro
experiments on cell lines. In these cases, true biological variability is negligible, and
mathematical adjustment is warranted. In contrast, the biological variability observed in
patients with potentially different disease etiologies and subtypes is astounding, which is
potentially reflected systematically through the data due to spatiotemporal differences in
poorly understood disease parameters. In this setting, mathematical adjustment cannot
distinguish between true variability and experimental artifact. The corollary of this is that
performing such adjustments on patient samples run a tremendous risk of producing
artifactually homogenous data rather than reducing the artifact present between runs on the
same platform. For this reason, the analysis presented in this chapter relied on comparisons
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of PDAC and normal tissue present within a single microarray study. In this way, the batch
effect is completely eliminated. The cost of such an analysis is reduced sample size and,
thus, statistical power, which is only augmented by cross-referencing the findings from all
used array studies. Ultimately the effect of these two factors is two-fold. Because of the
reduced statistical power and cross-referencing of studies, it is likely that a good number
of cytokines that are truly upregulated in a subset of PDAC patients are not identified by
this analysis. In contrast, the stringency of this method increases the confidence that the
cytokines identified here as upregulated are truly upregulated and are upregulated in a large
majority, if not all, PDAC patients.
Second, microarrays rely on probe-RNA hybridization, and each array platform is
subject to a somewhat unique profile of off-target binding and thus artificial augmentation
or suppression of the resultant gene expression quantification. The analysis presented in
this chapter not only relied on findings from multiple studies conducted using a single array
platform but also used different microarray platforms. Off-target binding is contingent on
the probe set itself, the resulting in errant identification of differentially regulated cytokines
is minimized to the extent possible by using multiple array platforms; though it must be
stated that there is overlap between the probes used in first- and second-generation
Affymetrix arrays (GPL570 and GPL6244 respectively). This measure increases the
overall stringency of the analysis and simultaneously causes an increase in the falsenegative rate and an increase in the confidence of identified cytokines.
Evidence of the adequacy of methods applied here to ensure a robust analysis comes
from the fact that the results of this in silico screen were highly consistent with changes
already reported in the literature. For instance, this screen found high expression of TGF-
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β1, CXCR2 ligands, LIF, and TNFSF10 [169-171, 183, 184]. Such findings provide
tangential evidence for quantification of cytokine expression that is both accurate and
representative of PDAC as a whole. Moreover, the fact that these cytokines have such
prominent roles in modulating PDAC biology in terms of tumor immune response and
cancer cell behavior suggests that the setup for this analysis may enrich for cytokines with
important functions in the PDAC TME.
While this analysis showed several cytokines that have already been identified as
being upregulated and having important functions in the setting of PDAC, it also
demonstrated upregulation of several cytokines that are poorly characterized in PDAC:
mainly CXCL9, CXCL10, CXCL14, CXCL16, CCL13, CCL18, CCL19, CCL20, IL1A,
IL1RN, IL18, and TNFSF4. Additional analysis of cytokine expression in murine PDAC
models and WT pancreas was conducted in order to increase the confidence in cytokines
that were identified by both human and murine cytokine analyses. Cytokine/chemokine
PCR array demonstrated similar overexpression for several of the novel cytokines
identified in the human tissue microarrays. These included Cxcl10, Cxcl16, Il1a, Il1rn,
Ccl20, and Il-18, thereby further bolstering the potential importance of these cytokines in
the setting of PDAC. This PCR array data did deviate from the microarray data in that
CCL19 and TNFSF10 were both found to be downregulated in murine PDAC compared to
strong upregulation in human tissues. The underlying reasons for these discrepancies are
unknown, but it could represent differences in biology between human and mouse or be
the product of differences in the time point at which tissues were isolated in the sense that
murine pancreas was isolated during the late pre-malignant/early malignant stages while
human tissue is collected following the diagnosis of frank pancreatic carcinoma.
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Additionally, these differences could be the result of artifact specifically present in
conducting the PCR array or the PCR array platform. Similar artifacts in the microarray
data are unlikely given the consistency of these findings across numerous datasets and two
microarray platforms. The fact that it is difficult to distinguish between organismal
differences in biology and potential artifacts present in performing the PCR array protocol
or the PCR array platform indicates that this is not a good method for eliminating
candidates from consideration; however, the disparate findings by no means increase the
confidence in these two cytokines and would thus they would be considered less promising
candidates.

Moreover, if these differences between murine and human CCL19 and

TNFSF10 expression are genuine, that is to say, that each analysis identified the correct
expression of these cytokines in the respective organisms, the ramifications on data
interpretation would be two-fold. First, both these cytokines would continue to be of
interest in the setting of PDAC; second, neither cytokine would be able to be studied
conveniently in murine models. For cytokines, in vivo study can be critical for the
development of an understanding of a cytokine’s multifaceted roles in the TME, so while
these two cytokines would be of interest in PDAC, practically, they would be extremely
difficult to study. Notably, this PCR array was not able to validate differential expression
of several cytokines; however, these remain promising candidates in the setting of PDAC
and therefore warrant more conclusive study in murine models of PDAC.
While there were several strong candidate cytokines that emerged from these
analyses of human and murine PDAC tissues, the analyses presented here focus on CXCR3
and its ligands. This choice was made based on the fact that several CXCR3 ligands
appeared in each round of analysis —including CXCL10 in all rounds, CXCL9 in the two
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human sets of analysis and to a minor extent in KPC mice, and CXCL4 (PF4) in KPC
mice— the extent and consistency with which these ligands were upregulated, the specific
association of CXCR3 ligands with the aggressive KPC model of PDAC, and the lack of
current research regarding CXCR3 and its ligands in PDAC.

Admittedly the other

candidates elucidated here may indeed play an important role in PDAC and are intended
to be the subject of future investigations.
Two CXCR3 ligands, CXCL9 and CXCL10, had significant overexpression in 3/6
and 4/6 datasets, respectively. Moreover, we found CXCL4 and CXCL10, as well as
CXCL9, to a minimal extent, to be overexpressed in the KPC murine model of PDAC,
thereby providing further validation for the microarray screen. Because of these findings
of CXCR3 ligand overexpression, the subsequent analyses focused on characterizing the
expression patterns of all CXCR3 ligands with respect to the expression of ligands relative
to each other and the compartmental expression of ligands. These analyses utilized the
original microarray data as well as two additional RNA-Seq datasets. Across each of the
eight datasets, two microarray platforms, and two distinct transcriptomic technologies,
there was remarkable consistency in the pattern of CXCR3 ligand expression; CXCL9 and
CXCL10 were the most highly expressed CXCR3 ligands followed by CXCL11 and PF4,
and PF4V1 having very little expression in the PDAC samples analyzed. We were able to
show that CXCL9 and 10 had minimal expression in the epithelium and with robust stromal
expression. These findings are consistent with the observation that CXCL9, CXCL10 and
to a lesser extent CXCL11 have higher expression in TCGA patients with low cellularity
compared to those with high cellularity indicating that CXCL9 and 10 may be derived from
CAFs in the setting of PDAC, which is consistent with previously published data in cell
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lines [208]. In contrast to CXCL9 and 10, PF4 and PF4V1 had greater expression in the
epithelial compartment as compared to the stroma; though, these changes were not
significant owing largely to the low overall expression. These studies are the first to
demonstrate the origins of CXCR3 ligands with respect to tissue compartment in PDAC in
vivo, let alone in human samples.
Overexpression of CXCR3 ligands in the PDAC TME is devoid of meaning if
CXCR3 is not expressed within the same biological setting. Importantly, CXCR3 is
expressed in PDAC, as assessed by microarray, RNA-seq, and IHC analyses. Thus, the
requisite components of a functional CXCR3 signaling axis are present within the PDAC
TME. Additionally, the function of CXCR3 is broadly defined by the splice variant that is
expressed as the two splice variants have been shown to mediate opposite signaling
cascades and functional effects. Analysis of TCGA data with stringent transcript
reconstruction demonstrated that CXCR3A is the predominant variant of CXCR3 that is
expressed in PDAC. Finally, the tissue compartment in which CXCR3 is expressed has
broad functional consequences for the CXCR3 signaling axis in PDAC. The preceding
analyses demonstrated that CXCR3 is expressed in epithelial and stromal compartments of
PDAC, but its expression was generally higher in the stroma.

This compartmental

distribution of CXCR3 expression was found in both RNA-Seq of microdissected PDAC
samples as well as IHC for CXCR3. Interestingly, strong epithelial expression of CXCR3
seemed to be partially exclusive of strong stromal expression and vice versa, thus there
appear to be two populations of PDAC patients with respect to CXCR3 expression and the
functional consequences of CXCR3 signaling in each of these populations is expected to
be different.
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Cumulatively, the results presented in this chapter suggest a multifaceted CXCR3
signaling axis present in the PDAC TME. Previous reports have shown that in vitro CAFs
produce a large quantity of CXCR3A ligands. The findings presented here support this
origin of CXCR3 ligands in vivo. Moreover, CXCR3A was originally found to be the highaffinity receptor for CXCL9, 10, and 11 and was predominately expressed on T-cells with
comparatively less expression being observed in minor subsets of NK cells, B-cells,
dendritic cells and inflamed epithelium.

The observations that CXCR3A is the

predominant splice variant in PDAC and that CXCR3 expression is largely derived from
the stromal compartment are consistent with this initial characterization of CXCR3
expression. The corollary of these observations is that one arm of the CXCR3 signaling
axis in PDAC likely involves CAF-mediated modulation of tumor immune infiltrates by
secretion of CXCR3 ligands. Secondly, the results in this chapter also show cancer cell
expression of CXCR3, which is consistent with reports of CXCR3 expression in other
cancers. The finding that CXCR3 expression in the epithelium partially precludes robust
expression in the stromal compartment may indicate that CXCR3 ligand-mediated
crosstalk between cancer cells and CAFs indirectly modulates the tumor immune response.
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Chapter 3: A Review of Literature for Roles of CXCR3 in
Cancer
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Chapter 3A: Introduction
The previous chapter highlighted CXCR3 and its ligands as cytokines that represent
a potentially important signaling axis in PDAC. Like CXCR1, 2, and 4, CXCR3 is the
receptor for C-X-C domain-containing chemokines that signals downstream through the
activation of heterotrimeric G-proteins. As a result, depending upon the cell type(s) in
which it is expressed, CXCR3 could share a great deal of biochemical signaling and cellular
functionality with the other CXC chemokine family receptors. Despite this, CXCR3
specifically has not been thoroughly researched in the setting of PDAC. Nonetheless,
several studies have been conducted that elucidated an astounding diversity in the functions
of CXCR3 in a variety of other cancers. These functions include modulation of tumor
immune infiltrate, promotion of cancer growth and the metastatic process, and influencing
tumor angiogenesis. This chapter presents an overview of CXCR3 and CXCR3 ligand
biochemistry along with a comprehensive review of the role of CXCR3 in the setting of
numerous malignant neoplasms with a focus on its role in the metastatic process.
Chapter 3B: Biochemistry of the CXCR3 Axis
Chapter 3B.1 CXCR3 Biochemistry
The gene encoding CXCR3 is located on the short arm of the X chromosome in
human, mouse, and rat genomes. The structure of this gene is comparatively simple with
a short 5’UTR, two exons separated by a single intron, and a relatively long 3’UTR, all
occupying the 2593 bp from 71,618,511 to 71,615,919 on the X chromosome (in humans).
There are currently three described splice variants of CXCR3: CXCR3A, CXCR3B, and
CXCR3 Alt, though there is some debate regarding the veracity of this third variant.
CXCR3, as it was originally described, is now referred to as CXCR3A. This splice variant
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consists of a 63 bp 5’-UTR and nine protein-coding nucleotides in the first exon, a 978 bp
intron, and a second much larger exon consisting of 1095 protein-coding nucleotides
followed by 446 bp of 3’UTR, which translates to a 368 aa protein. In contrast, the entire
protein-coding sequence for CXCR3B is contained within the second exon. Specifically,
the first 165 bp of the mRNA sequence are included in the 5’-UTR, which included all 74
nucleotides of the first exon. The first and second exons are separated by a shorter intron
(734 bp), indicating that, in CXCR3B, there is a substantial, 234 bp, portion of the first
intron in CXCR3A that is included as an exonic sequence in the second exon of CXCR3B.
The first 90 of these 234 nucleotides are constituents of the 5’UTR; the remaining 144
contribute to the protein-coding sequence of exon 2 in the CXCR3B mRNA. Following
this 144 bp stretch of included intron 1, the transcripts for CXCR3A and B are identical.
The result of this alternate splicing is that the CXCR3B variant is 48 aa longer than
CXCR3A with the major alterations between the two occurring in the extracellular, Nterminal domains of the proteins. Figure 3.1 presents an overall schematic of differences
in the coding sequences of CXCR3A and CXCR3B. Later, the impact of these alterations
on ligand binding and overall biochemistry will be discussed.
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Figure 3.1

Figure 3. 1: Schematic Representation of CXCR3 A and B Splice Variant Transcripts.
Schematic depicts major differences in the coding sequences of CXCR3A and B; Mainly, the loss
of Exon 1 as a coding sequence (though technically present in the transcript of CXCR3B) and the
retention of a portion of intron 1 at the 5’ end of the RNA.
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At the protein level, both splice variants of CXCR3 are predicted to have seven
transmembrane domains and have been shown to couple with heterotrimeric G-proteins
(HTGPs) as mediators of the receptors’ downstream signaling.

Interestingly, the

differences in splicing between CXCR3A and B are believed to alter the coupling of the
two receptors to heterotrimeric G-proteins. CXCR3A is believed to couple to Gαi and
Gαq (though credible data for Gαq coupling is extremely limited) HTGPs on the basis that
treatment of cells with pertussis toxin and KO of Gαi both inhibit the cellular effects of
activation of CXCR3A. In contrast, CXCR3B is thought to couple to Gαs based on
findings that activation of CXCR3B in cells ectopically expressing CXCR3B, specifically,
results in a rise in intracellular cAMP production which is augmented in the presence of
forskolin. While this evidence is technically circumstantial, it is likely that CXCR3B does
couple to Gαs, as the only other HTGP with the ability to stimulate adenylate cyclase
activity is Gαolf, the expression of which is limited to olfactory epithelium. Interestingly,
the changes in splicing between CXCR3 A and B cannot directly account for differences
in HTGP coupling as the transmembrane domains and intracellular loops that have been
identified as being important for the determination of HTGP coupling are sequentially
identical in both variants (Figure 3.2). Moreover, this cannot be the result of a ‘biased’
signaling mechanism, which is specific to a particular ligand/ set of ligands, as all CXCR3
ligands increase intracellular cAMP levels to a similar extent in CXCR3B-overexpressing
cells (albeit with increased concentration for ligands with lower affinity). Thus, the altered
predilection of CXCR3B for Gαs over Gαi must result either from underlying changes in
the 3D structure of the CXCR3B second or third intracellular loop and C-terminus or from
differences in conformational changes in these same domains resultant of ligand binding.
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A cursory analysis of structural predictions for CXCR3 indicates changes in the secondary
structure of the 2nd intracellular loop as well as the C terminus in CXCR3B, which result
in the loss of solute accessibility of 9 residues in the proximal C-terminus, an area known
to be critical for dimerization with Gα proteins [209]. This structural prediction presents
an interesting hypothesis regarding the selectivity of CXCR3 splice variants for HTGPs
but requires additional mutation-based studies to validate this hypothesis.
Downstream of CXCR3A activation and subsequent coupling to Gαi and Gαq, the
understanding of signaling is fragmented. However, there are several observations that
have been consistently noted in the literature that provide insight into the later events of
CXCR3A signaling. Here it is believed that activation of Gαi results in downstream
activation of SRC kinase and subsequently activation of MAPK and PI3K/AKT signaling
leading to increased proliferation of cells and resistance to apoptosis, respectively.
Activation of Gαq downstream of CXCR3 results in the activation of phospholipase C-β
(PLC-β) and subsequent cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to form
diacylglycerol (DAG) and inositol-triphosphate (IP3), which act as second messengers that
stimulate the release of calcium from the endoplasmic reticulum resulting in pleiotropic
cellular effects including activation of calpains which may be an important part of cell
migration.
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Figure 3.2
A.

B.

Figure 3. 2: Hydropathy Plots of CXCR3A and B are Identical with the Exception of the
First 48 Amino Acids
Hydropathy plots for CXCR3A (A) and CXCR3B (B) were calculated using the Kyte and
Doolittle method by ProtScale. Hydrophobicity/hydrophilicity scores are not affected by the Nterminal sequence of CXCR3B relative to CXCR3A. Thus, predicted transmembrane and
intracellular domains are identical, in terms of sequence, between the two proteins.
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Not surprisingly, the signaling downstream of CXCR3B is quite different from that
induced by activation of CXCR3A, given the oppositional nature of the Gα subunits
transmitting their respective signals. In the case of CXCR3B, downstream signaling occurs
through activation of PKA mediated by adenylate cyclase’s production of cAMP. While
the roles of PKA have been widely researched as a whole, its function in the setting of
malignant diseases is less well defined; though, it is generally believed to suppress the
malignant features of cancer cells. Additionally, CXCR3B activates p38, which, in turn,
activates Bach1 and p21, which in turn sensitize cells to the redox environment and
suppress cell progression through the cell cycle, respectively. It must also be mentioned
that activation of any HTGP results in the release, and therefore activation, of Gβγ subunits
from the trimeric complex resulting in the activation of the PLC-β and ultimately the
release of calcium from the endoplasmic reticulum. Thus, both CXCR3A and B signal
through this mechanism. Despite this solitary similarity, the overall signaling of CXCR3B
is quite different from that of CXCR3A as the outcome is suppression of cell proliferation
and sensitization of cells to apoptosis under standard culture conditions.
Chapter 3B.2 CXCR3 Ligand Biochemistry
There are five distinct CXCR3 ligands; the genes encoding each chemokine are
located on chromosome 4 in the human genome. Despite the small size of the encoded
proteins, the structures of these genes are somewhat more complex than their cognate
receptor. CXCL9, 10, and 11 all have four exons separated by three introns, each with
variable lengths, while CXCL4 and CXCL4L1 (PF4 and PF4V1) each have three exons
separated by two introns. Like CXCR3, there are observed splice variants for CXCL4 as
well as CXCL11; however, the biological importance of these variants has not been
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investigated and does not contribute substantially to the current understanding of the
CXCR3 signaling axis in terms of the literature or the work presented here. For this reason,
these splice variants will not be discussed in greater detail.
By far, the most important aspect of CXCR3 ligand biochemistry is the differential
affinity of each ligand for the two CXCR3 splice variants. CXCL9, CXCL10, and
CXCL11 are all high-affinity ligands for CXCR3A [210]. Furthermore, with the exception
of one report of the existence of a yet unidentified receptor of CXCL10, which has not been
reproduced [211], CXCR3 is the sole receptor for CXCL9 and 10. CXCL11, however, has
recently been found to interact with the atypical CXC chemokine receptor CXCR7 [212].
In binding to CXCR3A, CXCL11 has the highest affinity with an IC50 of 1 nM for calcium
mobilization and T-cell migration. CXCL9 was the next highest affinity CXCR3A ligand
with an IC50 of 70 nM for calcium release as well as T-cell migration. CXCL10 was the
lowest affinity of the tested ligands with an IC50 of 300 nM. Interestingly, treatment of
cells transfected with CXCR3A with CXCL11 completely desensitized them to subsequent
treatment with CXCL9 and CXCL10 in terms of both ligand binding to the cell surface and
calcium release. In contrast, the same CXCR3A transfected cells treated with CXCL9 or
CXCL10 were still able to bind CXCL11 and release additional calcium in response to
CXCL11 binding. Subsequent competition studies of cells saturated with radiolabeled
CXCL11 showed the inability of increasing concentrations of CXCL9 and CXCL10 to
displace CXCL11. Conversely, CXCL11 displaced radiolabeled CXCL9 and CXCL10 at
modest concentrations. These competitive binding studies clearly demonstrated a higher
affinity of CXCL11 over CXCL9 and CXCL10 for CXCR3 [210]. Moreover, the inability
of CXCL9 and CXCL10 to efficiently displace CXCL11 is consistent with their diminished
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relative affinity for the receptor. Interestingly, Scatchard analysis suggested high and lowaffinity binding sites on the cell surface for CXCL11. While the authors speculated as to
the existence of multiple binding sites for CXCL11 on CXCR3 (including one that is
distinct from the site utilized by CXCL9 and CXCL10), recent reports demonstrating
alternative receptors for CXCL11, including CXCR7 and CXCR4 [212, 213], suggest the
potential that the alternate site identified in this report may not be located on CXCR3.
Moreover, the fact that untransfected and/or mock-transfected cells were not shown as
controls, which further limits the ability of this experimentation to delineate CXCL11
binding to CXCR3 versus other cell surface receptors and the relative affinities of these
interactions.
Once CXCR3B was identified and validated as a splice variant of CXCR3, its
ligand affinities were studied in comparison to CXCR3A. At the time CXCL4 had no
identified receptor; however, it did share a great deal in common with other CXCR3 ligands
including the conserved C-X-C motif, the lack of an ELR motif (which only CXCL9,
CXCL10 and CXCL11 lack among the C-X-C chemokines), and the ability to suppress
angiogenesis in vivo.

Because of these similarities, CXCL4 binding to CXCR3B was

studied in addition to the other already identified CXCR3 ligands. In competitive binding
studies, CXCL4 was able to displace radiolabeled CXCL10 from CXCR3B-overexpressing
cells at a concentration of 7.5 nM; by comparison, the displacement of CXCL10 from
CXCR3A transfected cells was 448 nM, representing a 60-fold greater affinity of CXCL4
for CXCR3B over CXCR3A [214]. Moreover, CXCL9, CXCL10, and CXCL11 displace
radiolabeled CXCL10 from CXCR3A more readily than from CXCR3B with IC50s of 33
nM vs. 133 nM, 0.35nM vs. 6.9 nM, and 0.41 nM vs. 32 nM, for CXCR3A and CXCR3B
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respectively. The combination of these findings strongly suggests that CXCL9, CXCL10,
and CXCL11 serve as the dominant ligands for CXCR3A, as demonstrated by their
substantially lower ligand binding affinities for CXCR3A than for CXCR3B and the low
binding affinity of CXCL4 for CXCR3A. CXCL4 and CXCL10, on the other hand, serve
as the dominant ligands of CXCR3B based on their substantially lower binding
concentrations (roughly four-fold). Importantly, all CXCR3 ligands show a modest affinity
for CXCR3B and have the ability to activate this receptor. In contrast, CXCL4 does not
appear to bind to or activate CXCR3A. As a final note, the signaling downstream of
CXCR3B activation is consistent irrespective of the activating ligand. While the signaling
downstream of CXCR3A is largely consistent across ligands, there have been reports of
biased signaling downstream of this receptor variant [215, 216].
Chapter 3C: Role of CXCR3 Axis in Modulation of Tumor Immune Infiltrate
Chapter 3C.1 Introduction to CXCR3 in the Tumor Immune Response
CXCR3 was originally characterized as a chemokine receptor of CXCL9, CXCL10,
and CXCL11 that guides the migration of lymphocytes towards sites of inflammation. In
concordance with this function, CXCR3 is expressed mainly on activated CD4+ and CD8+
T-cells and a small subset of NK cells [217]. In the setting of cancer, numerous studies
have investigated the immunological roles of CXCR3. Because this falls under the
classical function of CXCR3, there is a vast body of literature regarding this aspect of
CXCR3’s immunological function in cancer. This section of the dissertation will not
present a comprehensive review of CXCR3’s immune functions, but rather discuss several
key studies which demonstrate the current understanding of CXCR3 signaling as it pertains
to the tumor immune response.
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Chapter 3C.2 Pro-Immune Functions of CXCR3
In ovarian cancer, high expression of CXCL9 and CXCL10 was associated with an
increased number of tumor-infiltrating immune cells, including T- and NK cells. These
changes in the tumor microenvironment were further associated with increased survival
[218]. Similar studies were carried out in gastric cancer, which showed strong associations
of CXCR3 expression with infiltration of CD4+ and CD8+ T-cells and a corresponding
increase in patient survival [219]. However, these differences in survival may be related
either to the altered immune infiltrate or with changes in lymph node metastasis and
invasive depth, both of which were significantly decreased in association with high CXCR3
expression. In the setting of melanoma, cell lines that expressed CXCR3 ligands recruited
CD8+ T-cells both in vitro as well as when transplanted into mice [220]. Moreover, in
CXCR3-/- mice bearing melanoma, T-cell infiltration of tumors was diminished, and
checkpoint therapy failed to produce tumor progression as a result [221]. Similar findings
were confirmed in TCGA data for melanoma, and high CXCR3 ligand expression was
associated with improved survival in melanoma patients [222]. In contrast, the loss of
expression of CXCR3 from Th1 helper T-cells was associated with the progression of
Barrett esophagus to esophageal cancer [223]. Cumulatively, these studies demonstrate a
critical role for CXCR3 in the recruitment of T-cells to the tumor microenvironment in a
variety of cancers. Interestingly, however, this may not be ligand-dependent; one study
demonstrated a loss of CXCR3-/--derived CD8+ T-cell migration to murine melanoma
tumors that lacked the expression of CXCR3 ligands. Ultimately the loss of CXCR3
expression from the CD8+ T-cells resulted in defects in adhesion to tumor-associated
vasculature.

These findings suggest that CXCR3 expression may be a functional
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requirement for tumor infiltration by CD8+ T-cells irrespective of ligand expression [224].
Chapter 3C.3 Immunosuppressive Functions of CXCR3
In contrast to these studies that would suggest that CXCR3 signaling promotes the
recruitment of CXCR3 effector T-cells to tumors and thus augments the anti-tumor
immune response, other studies demonstrate that CXCR3 signaling may also have a role
in immunosuppression. In ovarian cancer, the majority of FOXP3+ T-regulatory cells
(Tregs) were also CXCR3+ and also believed to be derived from natural Tregs based on the
expression of Helios. Interestingly, these Tregs also expressed the classical Th1 cell
transcription factor Tbet but did not secrete IFN-γ. Functionally, this population of
CXCR3+ Tregs suppressed both the proliferation of effector T-cells as well as the
production of IFN-γ from these cell populations. Importantly the presence of these
CXCR3+ Tregs was correlated with the expression of CXCR3 ligands and the recruitment
of CXCR3+ effector cells to the TME [225]. Overall, these findings suggest that CXCR3+
Tregs are recruited to tumor along with CXCR3+ effector cells, thereby providing
concomitant pro-tumor and anti-tumor immune response signals. Similarly, in HCC,
CXCL10/CXCR3 signaling was associated with tumor recurrence following liver
transplantation in humans and rodents [226, 227]. Most notably, this association was
found for small-for-size graft recipients, which displayed increased rates of liver injury
following transplantation. Moreover, when graft experiments were performed in CXCL10/-

or CXCR3-/- mice, there was a significant decrease in tumor recurrence in small-for-size

graft recipients compared to WT counterparts. Similarly, the depletion of Tregs in WT
mice phenocopied the loss of CXCL10 and CXCR3, suggesting that the CXCR3 axis
functioned through promoting Treg recruitment and immunosuppression [226]. However,
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these studies were conducted in the setting of transplantation, and as a result, it is likely
that CXCR3 and CXCL10, in some way allowed, recolonization of the primary site cancer
cells following transplant. Whether this re-colonization was related directly to
immunological phenomena remains questionable and difficult to investigate.
Finally, CXCR3 has been shown to alter tumor immune response through an
indirect mechanism involving CXCR3 signaling in cancer cells as opposed to lymphocytes.
One report in gastric cancer showed that CXCR3 expression was associated with PD-L1
expression in RNA-seq data. Moreover, in vitro, treatment of a gastric cancer cell line with
CXCL9, CXCL10, or CXCL11 resulted in the upregulation of PD-L1 expression via a
STAT3 Akt-dependent mechanism. Inhibition of CXCR3 signaling abrogated the effects
of CXCL9, 10, and 11 treatment on PD-L1 expression in the cells [215]. Functional
consequences of this upregulation were not specifically investigated in this study; however,
it is likely that this expression would decrease effector T-cell-mediated killing of CXCL9, 10- and 11-treated gastric cancer cells.
Chapter 3C.4 Conclusions
Overall, the influence of CXCR3 signaling over anti-tumor immune response is
complex. While CXCR3 and its ligands represent a significant mechanism by which
effector immune cells are recruited to the TME, it is also involved in the recruitment of
immune-suppressive lymphoid cell populations to the tumor. For this reason, it remains
unclear whether CXCR3 augments tumor immune response or suppresses it. If only
considering the potential of CXCR3 to recruit immune cells to the tumor, the effect of
CXCR3 on the anti-tumor immune response is likely dependent upon other factors present
within the tumor microenvironment or the individual host immune system. For instance,
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if a patient were to have high proportions of CXCR3+ T-effector cells at baseline or as a
result of tumor-secreted factors, it is likely that CXCR3-mediated immune cell recruitment
would result in an accumulation of pro-immune cell types. If the opposite underlying
circulating immune cell profile were to exist, then the recruitment of Tregs to the tumor
would likely outweigh the recruitment of effector cells resulting in an overall
immunosuppressive environment. However, the effect of CXCR3 in alternative cell types
and the association with immunosuppressive molecules would indicate that CXCR3 may
concomitantly heighten effector cell recruitment and, at the same time, provide
mechanisms for dampening the immune response. It is likely for this reason that CXCR3
is expressed in epithelial cells. In non-malignant conditions, CXCR3 signaling would
indicate impending immune infiltration; the detection of this signal by epithelium would
allow cells to protect against incident damage caused by inflammation. In malignancy, it
seems that this function may serve the same purpose, but it is the malignant cells that are
protected against an immune response. Finally, the functions outlined above focus largely
on the recruitment of immune cells mediated by CXCR3 rather than the effect of CXCR3
signaling on T-cell polarization or functionality. While this aspect of CXCR3 biology has
not been investigated in cancer, evidence that CXCR3 signaling in T-cells alters their
polarization, activation, or effector phenotype exists in other settings, including
experimental autoimmune encephalitis. This particular aspect of CXCR3 biology may
represent a critical component of understanding its function as it pertains to the anti-tumor
immune response.
Chapter 3D: Role of CXCR3 Axis in Metastasis
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Chapter 3D.1 Introduction
The metastatic dissemination of malignant cells is a defining feature of cancer as a
category of diseases. The metastatic process is a complex, multistep process that begins
with the invasion of malignant cells through the basement membrane into surrounding
tissues. Following invasion, cancer cells can proceed to enter blood or lymphatic vessels
through the process called intravasation. The entrance into the blood or lymph vessels
marks a critical time for disseminating cancer cells as they are carried downstream to their
final destination but must also survive conditions rich in immune cells as well as the loss
of attachment to the matrix. For carcinomas, this represents a substantial challenge, in
contrast to lymphoma, leukemias, and sarcomas, which do not require matrix attachment
for survival. At the final destination of a metastasizing cancer cell, the cell must adhere to
the endothelium and ultimately exit the vessel in order to begin the colonization of the
distant organ parenchyma. The CXCR3 signaling axis has been shown to have important
roles in several steps of this metastatic process. In the setting of PDAC metastasis, both
splice variants of CXCR3 have been shown to have important roles. The function of
CXCR3 in tumor metastasis is complex for two main reasons. First, both splice variants
have roles in the metastatic process. Second, the roles of CXCR3 in metastasis are
frequently confounded by the functions of CXCR3 in cancer cells, immune cells, and
endothelial cells. This multifaceted expression pattern makes it difficult yet critical to
parse the cancer cell-intrinsic and extrinsic mechanisms of CXCR3’s involvement in
cancer metastasis.

This section of the dissertation presents a review of the positive and

negative contributions of CXCR3 to the metastatic process in several cancers.
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Chapter 3D.2 A Note on Experimental Methods of Measuring Metastasis
The study of metastasis, and specifically the effect of a given molecule on the
metastatic process, is difficult due to the complexity of the metastatic process. Because
metastasis, as it is currently conceptualized, is a multi-step process, it is possible that a
given treatment or molecule will positively or negatively affect the ability of cancer cells
to overcome the challenges presented by each of these phases. Animal models that
encompass the entirety of the metastatic process are currently the best measures of the
overall effect of a molecule on the metastatic process as a whole. For these purposes,
subcutaneous and orthotopic implantation models, as well as genetically engineered,
spontaneous models generally represent adequate methods. Furthermore, these models are
important for elucidating cell-extrinsic effects that can also affect the metastatic process,
and which may not be reliably inferred from other models. However, even these models
have limitations. Most notably, these models do not facilitate precise determination of
phase-specific effects of a molecule on the metastatic process. Given a molecule that
facilitates successful completion of one phase of metastasis and impedes that of another,
the spatiotemporal regulation of the expression and/or activity of the molecule in the actual
process of metastasis is critical to understanding its role in metastasis. In this case, if the
molecule is solely expressed or active during the phase in which it promotes metastasis,
then its actual role would promote metastasis. However, in a hypothetical model which
forces expression, the spatiotemporal regulation is lost, and the study would conclude that
the molecule has 1) diminished (compared to reality) pro-metastatic effects due to
artifactual, albeit smaller, effects due to forced expression during the phase of metastasis
in which the molecule has an anti-metastatic effect, 2) no effect on metastasis if the pro-
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and anti-metastatic effects are or equal magnitude, or 3) anti-metastatic effects if the effect
during the phase of metastasis in which the molecule is not naturally expressed is greater
than that in which it is. Thus, while animal models that encompass the entire spectrum of
the metastatic process provide a useful means of understanding, in the broadest sense, the
effect of a molecule on the entire metastatic process, additional studies are required to
ensure accurate interpretation of these results. In this setting, tail vein injection and splenic
injection models of metastasis represent an important means of understanding
contributions to the metastatic process post-intravasation, and when these are combined
with appropriate invasion/migration assays are particularly powerful in terms of
elucidating effects on early and late metastatic events. Even within tail-vein/splenic
injection models, the time point at which animals are sacrificed can elucidate different
aspects of the metastatic process. Animals sacrificed shortly after injection of cells (e.g.,
12-36 hours) with subsequent analysis of viable cells in the target organ can elucidate the
ability of these cells to survive in circulation and adhere to endothelium and potentially
extravasate. Animals sacrificed later (weeks) may provide insight into the ability of cells
to adapt to and expand in the metastatic environment. While it is tempting to equate the
number of lesions to the number of clones able both survive in circulation and grow in the
organ, the time between injection and sacrifice would mean that metastatic reseeding of
successful clones and thus any cellular feature affecting those clones, such as proliferation
rate, angiogenic ability, invasion, and migration, etc.,

would become confounding

influences on the results of this experiment, making conclusions about these earlier aspects
of metastasis significantly less confident. Finally, the various aspects of these injection
models of metastasis can be further subdivided by several in vitro assays, including the use
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of low attachment survival, fluid shear stress, endothelial adhesion, and endothelial
transmigration. This systematic approach can elucidate the phase-specific activities in
which a molecule is involved in metastasis. Discrepancies regarding whether a molecule
or signaling pathway promotes or inhibits metastasis based on opposing findings can be
further investigated through determining when the molecule is expressed or active and
though a comparison of the appropriate animal models of metastasis.
The point here is that thorough investigation of a molecule’s involvement in
metastasis is an arduous process that is rarely completed. In the absence of such a thorough
analysis, data regarding metastasis must be interpreted with care. Concerning animal
models, the observed effects of treatment, or overexpression/knockdown system, can be
stated to have affected metastasis, though even in these models, without further
investigation, it is unclear if the observed effects reflect those contributions of the molecule
in the actual pathological condition. Similarly, for tail vein- or splenic-injection models,
findings from these studies should likely be qualified as likely pertaining to a limited set
of metastatic phases that were surmounted by the cells in the experiment. The corollary of
this is that these models alone cannot reliably demonstrate the net contribution of a
molecule to the overall process of metastasis as the initial steps were bypassed by the
experimental procedure. Finally, in vitro assays including the commonly used invasion
and migration assays alone likely only suggest the potential for altered metastatic potential,
and in the absence of other experimentation, especially animal models, are difficult to
interpret as the amount of data regarding the various phases of metastasis far outweighs
that which can be elucidated from these assays alone. Finally, it is worth noting that
because of the complexity of metastasis, studies that correlate the expression or activation
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of a molecule or therapy with patient clinicopathological features are of considerable use
as these can demonstrate associations that, while not necessarily causative, exist in
association with the actual metastatic process as it occurs in humans. While they are subject
to a host of their own limitations, these studies are particularly useful in aiding with the
interpretation of results of a more experimental nature.
Chapter 3D.3 CXCR3 in Breast Cancer Metastasis
In breast cancer, CXCR3 has robust expression on cancer cells as well as immune
cells. Importantly, both splice variants are expressed on cancer cells, and studies have
found that both variants are involved in breast cancer metastasis. However, there is
controversy as to whether CXCR3 promotes or suppresses the metastatic dissemination of
breast cancer. Inhibition of CXCR3 either through tail vein injection or by intraperitoneal
injection in recipient mice inhibited lung colonization [228, 229]. This suppression of
metastatic colony formation caused by inhibition of CXCR3 was slightly abrogated by
depletion of NK cells from recipient mice; though, this was a small percentage of the total
change, and the major effect of CXCR3 in this model was likely mediated by signaling in
other cell types as well as NK cells [228, 229]. Similarly, CXCR3 inhibition did not
abrogate metastasis in mice lacking IFN-γ further implicating the immune system [229].
Notably, high CXCR3 expression was associated with poor overall survival in a subset of
breast cancer patients with local disease [229]. These findings in both humans and mice
were confirmed by an additional study utilizing a 4T1 model of breast cancer in which the
KO of CXCR3 form the background of mice implanted with tumors resulted in decreased
the formation of metastasis due to an augmented immune response secondary to a loss of
myeloid cell-mediated immune suppression [230]. Again, this decrease in metastasis was
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dependent upon the function of IFN-γ.
In a subsequent study, however, 66.1 stably overexpressing CXCL9 had reduced
metastasis and improved survival compared to 66.1 cells that were not transfected or were
transfected with vector control. Moreover, these changes in metastasis and survival were
strongly associated with increased infiltration of T- and NK cells, and the changes were
not observed in immunocompromised mice or mice depleted of NK cells [231]. Though it
must be noted that in this model, CXCL9-overexpressing tumors were significantly
reduced in size compared to non-overexpressing tumors, indicating that the suppression of
metastasis may be related to the suppression of the primary tumor growth as compared to
directly affecting breast cancer metastasis. Because of these findings, gene therapies
involving the overexpression of CXCR3A ligands have been considered as potential
therapeutic avenues. Mice vaccinated with CXCL11-overexpressing 4T1 breast cancer
cells or vector control transfected cells had reduced metastasis, which was linked to
increased immune response against implanted tumors as indicated by increased IFN-γ and
TNF-α expression in CXCL11-vaccinating tumor cells [232]. This immune response
against tumors in vaccinated mice resulted in a significant improvement in the survival of
CXCL11-vaccinated mice. Similar findings were found for the overexpression of CXCL10
[233, 234]. The metastatic suppression resulting from cancer cell-derived overexpression
was abrogated largely by depletion of CD8 T-cells and partially by the depletion of CD4+
T-cells and NK cells, suggesting immune involvement. Importantly, microvessel density
was also decreased in this model, and thus, inhibition of angiogenesis may also serve as a
contributing mechanism [234]. However, in each of these systems, there was control of the
local tumor as well as the abrogation of metastasis [233, 234]. Nonetheless, there is
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substantial controversy regarding the immunological function of CXCR3A in terms of
suppressing metastasis. Several studies point to a CXCR3-mediated immunosuppressive
effect that when activated permits metastatic dissemination. However, overexpression of
CXCR3 ligands suppresses both tumor growth and metastatic dissemination.
In contrast to the studies regarding CXCR3A and its ligands, one study
demonstrated a unique role for CXCL4 with respect to breast cancer metastasis. Here KO
of PF4 increased the formation of metastatic lung lesions [235]. This increase in metastasis
was associated with increased vascular permeability in the absence of PF4 and increased
recruitment of myeloid suppressor cells to the premetastatic lung; though, it should be
noted that mice do not express CXCR3B, which makes interpretation of this study difficult.
In addition to the immunological functions of CXCR3 in the process of metastasis,
several studies have focused on the role of CXCR3 signaling in cancer cells. In this setting,
the function of CXCR3 in breast cancer metastasis is considerably more consistent.
Treatment of breast cancer cell lines with CXCL9, 10, or 11 promoted CXCR3 signaling,
which promoted the migration of these cells in vitro [228, 230]. Moreover, inhibition of
CXCR3 activity in cancer cells resulted in decreased expression of RANKL while
activation of CXCR3 resulted in the upregulation of cathepsin B; both of these molecules
have been implicated in breast cancer metastasis [236, 237]. Additionally, and consistent
with its regulation of RANKL, CXCL10 was found to be a critical mediator of
osteoclastogenesis in the setting of breast cancer and melanoma bone metastasis [238].
Here the loss of CXCR3 from cancer cells, or neutralization of host-derived CXCL10, led
to fewer osteolytic lesions in cardiac injection models. Subsequently, it was found that
CXCL10 signaling was critical for the recruitment of cancer cells to the bone as well as
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subsequent generation of osteoclasts [238]. Moreover, loss of CXCR3 from 4T1 cells
inhibited the ability of these cells to produce lytic bone lesions. Additionally, there is a
role for CXCR3B in the direct promotion of breast cancer metastasis. While activation of
CXCR3B inhibited the invasive and proliferative capacity of bulk breast cancer cells, it
promoted the stemness properties, including mammosphere formation in breast cancer
stem-like cells [239]. Consistent with these findings, additional studies demonstrated
increased expression of CXCR3B on breast cancer CSCs, and that silencing of CXCR3B
resulted in decreased ALDH activity and suppressed metastasis in an experimental model
[240]. Finally, in a relatively large cohort study, CXCR3B was associated with increased
tumor grade, and expression of CXCR3B and CXCL4 were associated with poor prognosis
[241].
In sum, CXCR3 plays multiple, diverse, and important roles in the process of breast
cancer metastasis. Immunologically, data from multiple groups suggest that CXCR3 may
promote the suppression of anti-tumor immune response, which permits metastatic
dissemination. Curiously, expression of CXCR3A ligands appeared to have the opposite
effect. While the function of CXCR3 with respect to the immune response remains
somewhat confounding, the role of CXCR3 signaling in breast cancer cells is clearer. In
cancer cells, CXCR3A appears to promote the migration/invasion of breast cancer cells.
Despite its opposite signaling, CXCR3B may also promote breast cancer metastasis
through the promotion of stem-like properties in cancer cells.
Chapter 3D.4 CXCR3 in Prostate Cancer Metastasis
In prostate cancer, comparatively little emphasis has been placed on the
immunological functions of CXCR3. Despite this, the findings of studies conducted on
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CXCR3-mediated immune modulation as it applies to metastasis provide important
insights into the overall role of CXCR3 in the metastatic process, which may apply to
multiple cancers. This study demonstrated that prostate cancer cells recruit CD4+ T-cells
through the secretion of CXCL9. In turn, the recruitment of CD4+ cells resulted in the
upregulation of FGF11 and downregulation of androgen receptor [242]. Together, the
changes in the expression of these molecules increased the invasion and migration of
prostate cancer cell lines in vitro and increased the metastatic spread of cancer cell lines
implanted in the prostates of nude mice co-transplanted with CD4+ T-cell cell lines. These
findings are consistent with those conducted in breast cancer, which showed that CXCR3
expression might promote the spread of cancer cells through a mechanism involving the
host immune system. Despite this potential role of T-cells in promoting the malignant
behavior of prostate cancer cells, it is difficult to know if this metastasis-promoting
mechanism would outweigh the effect of increased immune cell infiltrate in the presence
of a complete host immune system.
In prostate cancer cells, the function of CXCR3 in promoting metastatic spread or
features highly associated spread appears to be divided between the splice variants. One
study found that in DU-145, a metastatic prostate cancer cell line, compared to RWPE-1,
an immortalized, non-cancerous, prostate epithelial line, and LNCaP, a primary tumorderived prostate cancer line, there was an upregulation of CXCR3A compared to CXCR3B
at the mRNA level [243]. In DU-145, the treatment with CXCL10 or CXCL4 increased
cellular motility and invasiveness in vitro, which was not observed in RWPE-1 cells.
Interestingly, overexpression of CXCR3B in DU-145 resulted in an abrogation of both
motility and invasiveness, suggesting that the pro-metastatic effects of CXCR3 in PDAC
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cells is mediated by CXCR3A and is opposed by CXCR3B signaling. Consistent with
these findings, knockdown of CXCR3A in the PC-3 prostate cancer cell line and
upregulation of CXCR3B inhibited proliferation and invasion in vitro [244], further
suggesting the disparate roles of CXCR3A and B in prostate cancer metastasis. In patient
samples, CXCL4L1, which has intermediate-affinity for both receptor variants, showed
that low CXCL4L1 expression was associated with higher pathologic stage, greater
Gleason score, and poor overall survival [245]. These findings in patient samples suggest
that the anti-metastatic role of CXCR3B may predominate in human prostate cancer;
though, this conclusion is somewhat confounded by potential changes in tumor immune
response produced by CXCR3 activation that would occur in this setting. Additionally,
further study of the contributions of CXCR3 to other aspects of the invasion-metastasis
cascade may reveal other functions regarding CXCR3A and B, which oppose those
functions described here as was the case in breast cancer.
Chapter 3D.5 CXCR3 in Ovarian Cancer Metastasis
Studies of CXCR3 in ovarian cancer are limited and focused on its role, specifically
in cancer cells. Here, the expression of CXCR3 ligands was found to be induced in CAFs
through the signaling of Lymphotoxin B/ Lymphotoxin B Receptor [246]. In vitro,
treatment of OVCAR3 or SKOV3 with fluid from malignant ascites resulted in increased
migration towards ascitic fluid, which was significantly abrogated when cells were treated
with CXCR3-neutralizing antibodies [247]. Moreover, in patient samples, high expression
of CXCR3 was associated with high grade, positive lymph node status, and reduced OS
and PFS [245, 246], thereby supporting a pro-metastatic role of CXCR3 in ovarian cancer
cells. CXCR3 is also associated with a suppressive immunological role in ovarian cancer
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through the recruitment of T-regs to the primary tumor [225]. While the study of the
immunological role of CXCR3 in ovarian cancer did not dissect the functional contribution
of this role to metastasis, it does not appear that the metastasis-promoting functions of
CXCR3 in cancer cells found in the above studies would be counteracted by the function
of CXCR3 in the immune system in ovarian cancer. Despite this, additional studies
utilizing animal models are required to bolster this hypothesis.
Chapter 3D.6 CXCR3 in Lung Cancer Metastasis
In contrast to the previous studies which focused largely on the role of CXCR3 in
either malignant cells or in immune cells, the studies of the function of CXCR3 in lung
cancer metastasis demonstrate yet another mechanism through which the CXCR3 signaling
axis can affect metastatic dissemination. Even before the identification of CXCR3 as the
receptor for CXCL4, 9, 10, and 11, the angiostatic functions of these chemokines had been
well characterized. Study of CXCL10 in lung cancer showed that CXCL10 was highly
expressed in squamous cell carcinoma of the lung compared to normal lung tissue and lung
adenocarcinomas [248]. Such findings are consistent with the strong association of
squamous lung cancer with smoking and the profound inflammatory effect of cigarette
smoke in lung tissue. In primary squamous lung cancer samples, neutralization of CXCL10
augmented angiogenic activities of cancer cells in vitro. Furthermore, tumor growth in a
murine model of non-small cell lung cancer in severe combined immunodeficient (SCID)
showed that tumor growth was inversely correlated with plasma and tumor levels of
CXCL10, despite the fact that tumor cell proliferation was not influenced by CXCL10 in
vitro. Importantly inhibition of CXCL10 augmented tumor growth and metastasis [248]
and was associated with increased vascular density. Similarly, PF4-overexpressing Lewis
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lung carcinoma cells also demonstrated fewer lung metastasis in a tail vein injection and
in subcutaneous models compared to vector controls, which was thought to occur through
suppression of angiogenesis [249]. It should be noted that mice were sacrificed 28 days
after tail vein injection of cancer cells. This time frame is consistent with detecting
differences in the number of cells capable of successfully colonizing the lungs and being
observed macroscopically. However, it is not sufficiently small to understand the effect of
PF4 on early steps of the metastatic process —largely the intravascular, extravasation, and
early colonization phases. Moreover, this extended growth period allows tumors to become
sufficiently large that they require angiogenesis despite being located in one of the most
densely vascular regions of the body. The result of this is that differences in the number of
grossly observable metastatic lesions may be the product of decreased growth of lesions
rather than difference in the ability of cells to successfully colonize the lungs. Similar
findings were also demonstrated using subcutaneous injection models with human A549
as well as murine Lewis lung carcinoma cells that were treated with CXCL4L1. Notably,
in these cases both primary tumor growth as well as the number of metastatic cells in distant
organs were suppressed by CXCR3 ligand treatment [250]. Suppression of angiogenesis
was suggested to be the mechanism by which CXCR3 inhibited metastasis by decreased
intratumor microvessel density, but rescue of angiogenesis in these tumors was not
performed so as to confirm the involvement of the anti-angiogenic activity CXCL4L1 as
the underlying cause of reduced metastatic spread. Regardless, the combination of these
findings is consistent with CXCR3-mediated suppression of angiogenesis as a predominant
mechanism underlying CXCR3’s ability to suppress metastasis in lung cancer.
Furthermore, this role of CXCR3 is consistent with the current understanding of
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angiogenesis as a critical factor in metastatic dissemination as the vasculature is the conduit
by which metastasis occurs.
While CXCR3 appears to inhibit lung cancer metastasis through signaling in
endothelial cells, it is also expressed on malignant cells in about 90% of lung cancer
patients. In these cells, the function of CXCR3 appears to oppose that in endothelial cells.
For instance, A549 cells that express CXCR3 migrated towards CXCL10 in a CXCR3dependent manner. Despite these in vitro findings and the expression of CXCR3 on lung
cancer cells in patients, CXCR3 expression was not associated with lymph node status in
these patients suggesting that of the two studied roles of CXCR3 in lung cancer the
angiostatic role may predominate [251].

However, the immunological functions of

CXCR3 in lung cancer metastasis have not been explicitly studied; thus, it is unknown if
this aspect of CXCR3 function, which is prominent in other disease settings, also
contributes to the phenotype observed in lung cancer.
Chapter 3D.7 CXCR3 in Melanoma Metastasis
Melanoma represents one of the most thoroughly researched malignancies in terms
of the function of CXCR3.

Interestingly, it is also a disease in which metastatic

dissemination has a tremendous prognostic impact. That is to say that node-positive
disease has a drastically worse prognosis than node-negative disease representing an
exaggerated form of the trend seen in many malignancies. Moreover, immunotherapy in
recent years has been shown to be highly effective in the setting of melanoma, which is
associated with particularly robust immune responses. These factors indicate that, in
melanoma, CXCR3 may play a critical role in multiple facets of the metastatic process and
have profound implications for patient outcomes.

145

The original investigation of cytokine expression and the histological correlations
thereof showed that CXCL9 and CXCL10, to a lesser extent, were highly associated with
T-cell infiltrates [252]. These findings implicated CXCR3 in a strong immune response in
melanoma. Subsequently, administration of CXCL10 expression plasmid to mice bearing
B16F10 melanoma tumors showed loss of pulmonary metastasis in a tail vein injection
model through an NK cell-dependent manner [253]. Finally, the administration of human
adipose mesenchymal stem cells ectopically expressing CXCL10 resulted in the loss of
metastatic lesions from the lungs in a tail vein injection model.

Here, CXCL10-

overexpressing cells were shown to potentially affect numerous factors in the metastatic
microenvironment, including melanoma cell apoptosis, suppressed Treg infiltration,
increased activated T-cell infiltration, and reduced angiogenesis in lung colonies [254].
Though in this setting of established metastases, the effects are likely mediated by a
combination of angiostatic effects as well as an augmented immune response rather than
by directly acting on melanoma cells.
The role of CXCR3 expression and signaling in melanoma cells is less clear than
its apparent function in immunological cells. In a seminal study by Kawada et al.,
knockdown of CXCR3 in B16F10 melanoma cells followed by subcutaneous injection
showed the CXCR3 KD cells produced fewer lymph node metastases compared to WT
CXCR3 expressing cells [255]. Consistently, treatment of mice with Freund’s adjuvant
resulted in the upregulation of CXCL9 and 10 in tumor-draining lymph nodes and, in turn,
caused a dramatic increase in the number of positive lymph nodes, which was abrogated
by the neutralization of CXCL9 and CXCL10 [255]. Subsequent studies showed that
CXCR3 induced activation of the ERK signaling pathway and cellular invasion, as well as
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increased lymph node metastasis in vivo [256]. Similarly, one group studied highly
metastatic and non-metastatic subclones of B16F10 cells and found a strong expression of
CXCL10 in the metastatic subclones. Follow-up analyses demonstrated that silencing of
CXCL10 or CXCR3 suppressed the metastatic ability of both sub-lines compared to nontargeted siRNA in tail vein models [257]. Finally, a very recent study suggested that
CXCL10 expressed by glial cells of melanoma patients acts to promote brain-tropic
metastasis of melanoma. Here, the knockdown of CXCR3 in melanoma cells nearly
completely abrogated brain metastasis in a murine model. Mechanistically, the function of
CXCR3 in melanoma brain metastasis was theorized to occur through the activation of
integrins in a fashion parallel to that of T-cell migration. However, the details of this
mechanism, as well as those regarding the mechanism underlying CXCL10 expression in
the brain, remain poorly characterized [258].
Despite numerous studies supporting a pro-metastatic role of CXCR3 signaling
melanoma cells, other studies report findings that are nearly opposite of the conclusions
from the above papers. Antonicelli and colleagues demonstrated that treatment of B16F1
murine melanoma cells with CXCL10 modestly suppressed their invasive capacity in vitro
[259]. Moreover, the authors showed an association of high PBMC cell expression of
CXCL10 with patients in remission, which was, in turn, associated with advanced stage at
diagnosis, indicating a plausible effect of CXCL10 on metastasis [259]. Despite this, it
remains unclear if this association is the result of the effect of CXCL10/CXCR3 signaling
in cancer cells or in immune cells as tumor-infiltrating lymphocytes were not assessed in
patients nor where similar studies conducted in mice lacking critical immune components.
Similarly, the treatment of lymphatic endothelial cells and melanoma cell lines with IFN-
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β caused marked upregulation of CXCL10 and CXCL11 [260]. In turn, CXCL10
suppressed the proliferation and invasion of melanoma independently but also consistent
with the effects of IFN-β in these cells [260]. Moreover, loss of CXCL10 through genetic
ablation resulted in the decreased sensitivity to IFN-β; notably, these effects were thought
to be mediated by CXCR3B [260].
Such disparate findings regarding the function of CXCR3 signaling in melanoma
cells raises important considerations for studying and ultimately understanding the role of
CXCR3 in complex biological systems. Of all the studies investigating CXCR3-mediated
signaling in melanoma cells as it pertains to metastasis, only one study delineated the
possibility of the differential functioning of the CXCR3 splice variants. While the splice
variants are a difficult aspect to study —especially given that mice do not express CXCR3B
yet appear to maintain a substantial portion of the functionality of CXCR3—that is
attributable to CXCR3B in humans, it remains critical to do so. Cancer cells have the
ability to express any combination of CXCR3A and B isoforms, ranging from no
expression of CXCR3 to expression of a single splice variant, to mixed expression of both
variants.

This fact makes the determination of this expression pattern particularly

important for understanding the broader role of CXCR3 in an experimental system.
Moreover, in cancer cell lines, the CXCR3A: B ratios do not appear to be constant across
samples of a single cell line, let alone across multiple cell lines, thereby adding to the
variability that can be present within an experiment and across experiments. For this
reason, delineation of the expression of the splice variants can greatly inform the
interpretation of a set of experimental results. Because this information was lacking from
the majority of studies discussed, it remains unclear if the disparities reflect differences in
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the functions of the splice variants that are predominant in the respective experimental
systems, experimental error, or simply true variability that remains to be explained
mechanistically.
While the underlying reasons for the opposing findings regarding the function of
CXCR3 signaling in melanoma metastasis remain obscure, analysis of the associations of
clinicopathological features of melanoma patients with their expression levels may suggest
which of these potential effects predominates in the human disease. One study of
melanoma cell CXCR3 expression in 82 patients demonstrated that high CXCR3
expression was associated with increased Breslow depth, decreased lymphocyte
infiltration, and the presence of distant metastasis [261]. These findings suggest that
CXCR3 function in melanoma cells may predominately function to promote metastatic
dissemination over the various reported anti-metastatic function found in several studies.
Though again, it remains unclear which of the receptor variants is more prevalent. More
interestingly is the observation that the expression of CXCR3 in cancer cells suppresses
lymphocytic infiltrate and non-cancer cell expression of CXCR3 due to a lack of lymphoid
cells in the TME. Such findings are consistent with PD-L1 regulation by CXCR3 that was
observed in gastric cancer.
Chapter 3D.8 CXCR3 in Renal Cell Carcinoma Metastasis
In renal cell carcinoma, the most common type of primary kidney malignancy,
CXCR3 appears to play a role in tumor cell dissemination. With regards to the anti-tumor
immune response and/or angiogenesis and their role in metastasis, the majority of studies
are observational, and as a result, it is difficult to determine the underlying mechanisms.
Patient samples demonstrated that in patients with advanced-stage disease, there was a

149

decrease in the expression of CXCL10 compared to patients with local disease in the
primary tumors. These changes were in association with the loss of other immunological
cytokines, including SDF-1 (CXCL12) and IFN-γ, further suggesting an immunological
mechanism [262]. Despite this, other studies have suggested that the anti-angiogenic
activity of CXCR3 and its ligands may be responsible for this activity against cancer. Here
it was noted that metastatic renal cell patients receiving high dose IL-2 had higher
expression of CXCR3 ligands in PBMCs [263]. Neither study examined changes in
angiogenesis or immune cell infiltrates associated with high CXCR3 ligands, so in both
cases, the associations found may be attributed to either effect or the combination of
effects.
In contrast to the studies regarding CXCR3 and its ligands role in non-cancer-cellautonomous pathways, the studies regarding CXCR3 signaling in cancer cells delve
substantially into the cellular and molecular mechanisms giving rise to observed metastatic
phenotypes. In renal cancer tissue, CXCR3 ligands were overexpressed compared to
normal tissue, and the CXCR3A to B ratio was 1.5 times higher in cancer compared to
normal kidney tissue. Moreover, CXCL10 treatment of renal cancer cell lines induced
migration and invasion in these cells, which was presumably mediated by CXCR3A [264].
These effects were later shown to occur through the activation of RhoA and downstream
production of matrix metalloproteinase 9 (MMP9). Importantly, activation of HIF-1α
through hypoxia or cobalt chloride upregulated CXCR3A expression.

In contrast,

treatment of the same cell lines with calcineurin inhibitors caused downregulation of
CXCR3B, and this change also augmented the invasive and proliferative capacity of these
cells [265]. These results cumulatively suggest that CXCR3A expression and downstream
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signaling promote the initial stages of metastasis, while signaling mediated by CXCR3B
may suppress them. Further studies confirmed the effect of CXCR3B as suppressing the
malignant properties of renal cancer cell line by demonstrating that CXCR3B
overexpression suppressed tumor cell proliferation and promoted apoptosis through
downregulation of heme-oxygenase 1 [266]. Consistent with the findings that CXCR3A is
the predominant form of CXCR3 expressed by renal cancer cells and that this variant of
the protein promotes metastasis, two studies of renal cancer patient samples showed that
CXCR3 expression in cancer cells themselves and specifically CXCR3A expression was
significantly associated with metastatic renal cancer [264, 267]. Finally, it is important to
note that in the absence of animal models, or in vivo assays regarding metastasis, it is
difficult to understand how either CXCR3 splice variant or their ligands affect metastasis
in general.

Though the in vitro studies and association of CXCR3 with patient

clinicopathological features provide a framework for understanding that CXCR3A
potentially promotes and CXCR3 B potentially inhibits the metastatic spread of renal
carcinoma cells.
Chapter 3D.9 Colorectal Cancer Metastasis
In colorectal cancer (CRC), CXCR3 has been intensely studied for its involvement
in metastasis. Despite this body of research, the majority of studies in this setting have
focused on the role of CXCR3 signaling in cancer cells. As a result, there are substantial
gaps regarding the function of CXCR3 in other cell types, which may also contribute to
CRC metastasis. However, substantial analysis of multiple CRC patient cohorts has been
done with respect to expression of CXCR3 and its ligands in association with clinical
features and outcomes, which provide significant insight into potential overarching roles

151

of the CXCR3 axis in the CRC metastatic process.
As in several other cancers, three reports in CRC indicated that CXCR3 is involved
in an antitumor immune response, which suppresses the formation of metastasis. The first
report found that CXCR3, along with CCR5, mRNA expression correlated with CD3+ Tcell infiltrate in CRC tumors, particularly at the invasive edge of the tumor [268].
Subsequent flow cytometric analysis of immune cells from patient tumors revealed that,
on average, 75% of infiltrating CD8+ T-cells within tumors were positive for CXCR3,
whereas 28% of CD4+ T-cells present within tumors were CXCR3+ [268]. These findings
suggested that CXCR3 and CCR5 were important for the recruitment and/or function of
CD8+ T-cells within tumors.

Based on these findings, a subsequent study by an

independent group showed that CXCL10 and CCR5 ligands were associated with more
robust Th1 type immune signatures in CRC samples and that this high Th1 type response
was associated with high expression of IFN-γ and Granzyme B in CD8+ T-cells suggesting
augmented effector capabilities. Moreover, high vs. low Th1 signature and associated
changes in CD8+ T-cell gene expression were associated with reduced TNM stage,
particularly the presence of distant metastases at diagnosis [269]. It is important to note
however, that in this study patients were stratified and analyzed by a gene signature that is
the composite of several genes, including CXCL9, CXCL10, and CXCL11. Because of
this, it is likely that stratification reflects overall type 1 response rather than specifically
CXCL9, 10, 11 expression, and clinicopathological associations are not directly related to
CXCL9, 10 and/or 11 but rather to an immune infiltrate phenotype. Nonetheless, CXCL10
appears to be strongly associated with the enhanced Th1 phenotype and is thus indirectly
associated with a decreased prevalence of metastasis in CRC samples with a strong
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expression of Th1-related markers. Along similar lines, forced expression of CXCL10 in
CT26 murine CRC cells suppressed the growth of subcutaneous tumors as well as the
metastatic lesion arising from splenic injection model of metastasis. For both effects,
depletion of NK cells was shown to abrogate this suppressive effect, though this effect
appeared to only partially abrogate the formation of liver metastasis in the splenic injection
model [270]. Overall these studies suggest that CXCR3 activity in CRC may be associated
with an enhanced anti-tumor immune response that ultimately has a suppressive effect on
metastasis.
The function of CXCR3 signaling in CRC cells is by far its most thoroughly
researched function with respect to its role in colorectal cancer metastasis. Initially,
Kawada and colleagues demonstrated that CXCR3-overexpressing DLD-1 cells had more
rapid dissemination through the lymphatic system in rectal transplantation models [271].
Interestingly, metastasis to the liver and lung were infrequent during the reported study and
was not different between CXCR3 overexpressing and WT control cells. In patient
samples, they found that CXCR3 was associated with lymph node metastasis and poor
overall survival compared to patients with tumors lacking CXCR3 expression [271]. In a
follow-up study, this same group demonstrated that CXCR3 and CXCR4 expression was
higher in lymph node and liver metastases in patient samples and that CXCR3 activation
cooperated with CXCR4 activity to produce increased migration in a manner that was
dependent on CXCR4 [272, 273]. Later this association of the two receptors was shown
to occur through an atypical interaction of the two receptors in which CXCR3 preserved
CXCR4 surface expression, thereby mediating augmented signaling downstream of
CXCR4 [273]. In vivo, the loss of CXCR3, CXCR4, or both receptors abrogated both
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lymph node and liver metastasis in rectal transplantation models [272].

Similarly,

knockdown of CXCL11 from CRC cell lines resulted in a loss of invasive/migratory
potential corresponding to a loss of epithelial-mesenchymal transition (EMT) phenotype
in vitro, which was mirrored in vivo with decreased tumor growth in subcutaneous models
(in nude mice) as well as decreased tail vein metastasis [274]. These in vivo findings were
shown to occur in relation to the EMT phenotype as rescue of N-cadherin expression in
CXCL11-knockdown cells abrogated the abrogation of cell proliferation and
invasion/migration in cell culture [274]. Partially consistent with these findings, another
group demonstrated treatment of CRC cells with CXCL9, 10, or 11 caused an increase in
the proliferation and migration of these cells, which was lost with inhibition of CXCR3
[275, 276]. Together these findings support multiple metastasis-promoting roles for the
CXCR3 axis in CRC, which may be important for the overall metastatic process in the
early and the late phases. Interestingly in vivo studies using tail vein and portal vein
injections of CRC lines with and without inhibition of CXCR3 demonstrated that CXCR3
inhibition resulted in suppression of the formation of pulmonary but not hepatic metastases.
While this was interpreted by the authors as CXCR3-mediated organ tropism, this
conclusion is not well supported by experimental data. Most notably, the use of different
metastatic models to arrive at conclusion of organotropism is troubling. In these models
there are numerous differences, which include not only the final site, but also the path of
the cells to arrive at this final site. For instance, in order for the cell to colonize the liver in
this case, they must survival a short stretch in circulation before reaching their final site.
In contrast, for a cell to colonize the lung, they must travel through the entire venous
system, pass through the high-pressure system of the right heart and finally land in the lung
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capillary bed. Thus, while it is explicitly clear that CXCR3 inhibition suppresses the
colonies formed following tail vein injection, it is not clear that this was related specifically
to the target tissue rather than the model used. To bolster such claims of CXCR3 tropism,
left ventricular cardiac injection may be a better xenograft type model, and these studies
would benefit greatly by demonstrating that cells expressing CXCR3 show a predilection
for lung colonization (or fail to colonize the liver) whereas cells lacking CXCR3 either
have no predilection regarding the final site of metastasis or favor the liver. Finally, a
single study has examined potential differences in the function of CXCR3 splice variants
in CRC metastasis. Here, the authors demonstrated that while CXCR3 (total protein) was
upregulated in CRC tissues, and positively associated with TNM staging, CXCR3B was
under-expressed in CRC tissue (at the mRNA level) compared to adjacent normal tissue
and correlated inversely with stage [277]. Studies using overexpression of the receptor
variants in vitro, showed decreased proliferation, invasion, and migration with CXCR3B
expression and opposite findings for CXCR3A. While this study did not explicitly study
metastasis in animal models, they did study tumorigenicity, which is frequently used as an
assay to demonstrate functional activity of cancer stem cells. In this setting, CXCR3A
again was associated with increased tumorigenicity whereas CXCR3B appeared to inhibit
tumor formation [277]. These findings are in contrast to findings in breast cancer that
suggested that CXCR3B positive cells had CSC phenotypes. Though, in this report,
specific investigation of CSC phenotype and association with known CSC markers were
lacking.
In addition to the above mechanistic studies, there are numerous reports of the
associations of CXCR3 with clinical features in CRC patients. In these analyses, CXCR3
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expression was positively associated with recurrence in multiple studies [278, 279] as well
as the presence of lymph node and distant metastases [278]. CXCR3 ligands have also
been thoroughly studied in human CRC tissues, but the outcomes of these studies are
conflicting. One study demonstrated that CXCL9 was associated with decreased
metastases as well as improved overall survival in Kaplan-Meier as well as Cox
Proportional hazards analyses [280]. These findings were supported by additional studies
in human CRC tissue, which demonstrated that low expression of CXCL10 in stage II and
III CRC patients was associated with an increased likelihood of recurrence as well as worse
overall survival [281]. These findings suggest that CXCR3 ligands may have a metastasissuppressing role in CRC, though molecular associations with CXCR3 were not
investigated leaving considerable questions regarding the biology underlying these
associations. However, two studies focusing on CXCL10 showed that high CXCL10
expression in the tumor and concentration in the blood were both positively associated with
metastatic disease, indicating a potential metastasis-promoting role for CXCR3 ligands.
The underlying reason for these discrepancies is unclear; however, it is certain that further
analysis of patient data is needed to better understand how the expression of these
molecules and the resulting activation of CXCR3 affect the CRC metastatic process [282,
283].
Chapter 3D.10 CXCR3 in Gastric Cancer Metastasis
In contrast to melanoma, breast cancer, and colon cancer, the role of CXCR3 in the
metastatic process of gastric cancer has only recently begun to be elucidated. Because of
this, only a few studies on CXCR3 have been conducted, but these studies cover aspects of
CXCR3’s function with respect to the anti-tumor immune response as well as directly
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promoting the metastatic features of cancer. In immune cells, correlative studies in human
gastric cancer samples demonstrated that in gastric cancer, both CXCR3A and CXCR3B,
as assessed by qRT-PCR, were upregulated in cancer compared to normal adjacent tissue
[284]. These changes were confirmed at the protein level by multiple studies [219, 285].
Comparison of CXCR3 staining in tumors to infiltrating immune cells demonstrated a
positive association of CXCR3 expression with the presence of DCs [285], as well as CD4+
and CD8+ T-cells [219, 285]. Consistently, high expression of CXCR3 was shown to be
associated with decreased invasive depth, advanced TNM stage and lymph node-negative
disease, and well-differentiated tumor cell histology [219, 285]. This translated into
significantly improved overall survival for patients with high CXCR3 expression [219,
285]. Cumulatively, these findings suggest that CXCR3 may have a role in promoting
metastasis-limiting immune response. Though the specific mechanisms underlying these
changes in tumor immune infiltration remain to be determined. Interestingly the findings
of these studies that suggest that CXCR3 promotes tumor immune response are in contrast
to one study that showed that CXCR3 signaling in gastric cancer cells promotes the
expression of PD-L1, a critical immune checkpoint, which implies that CXCR3 in these
cells plays a more suppressive role [215].
The studies of CXCR3 in gastric cancer cells tend to be more mechanistic in nature.
Initial studies demonstrated that treatment of gastric cancer cells with CXCL10 was
increased production of MMP2 and 9 by gastric cancer cells; this effect was shown to be
CXCR3 dependent as knockdown of CXCR3 with siRNA attenuated this effect.
Functionally, overexpression of CXCR3 resulted in increased invasion, migration, and
MMP production in response to CXCL10. Overall, these effects of CXCL10 treatment
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were shown to be dependent upon PI3K/AKT signaling stimulated downstream of CXCR3
[286]. Interestingly, and in contrast to studies examining the association of CXCR3
expression with immune infiltrates and survival, this study found that CXCR3 staining in
gastric cancer tissue was associated with poor OS and advanced stage at diagnosis. This
disparity is likely related to methodological differences in the quantification and
subsequent stratification of patients. While none of the studies reported methods regarding
IHC-based quantification of CXCR3 expression in sufficient detail to confirm this, IHC
data presented suggests that these studies quantified CXCR3 staining in different
compartments.
While the role of CXCR3 splice variants was not determined in this study, a
separate analysis analyzed this aspect of CXCR3 function in gastric cancer. Here, and in
contrast to previous other studies, the authors demonstrated that CXCR3A was upregulated
in gastric cancer cell lines and tissue, whereas CXCR3B was downregulated [287].
Analysis of CXCR3 splice variant functions in gastric cancer cell line showed that
knockdown of CXCR3A inhibited CXCL10-stimulated migration and invasion, whereas
knockdown of CXCR3B had little effect on the migration and invasion of gastric cancer
cells. Furthermore, the loss of CXCR3A inhibited CXCL10-induced phosphorylation of
ERK1/2, as well as the expression of MMP13 and 16. Importantly, in a subcutaneous
tumor model, mice bearing tumors derived from CXCR3A-knockdown cells had
significantly fewer liver metastasis compared to mice with WT tumors [287].
These disparate results regarding the function of CXCR3 with respect to tumor
immune response depending upon cellular context are not, in actuality, contradictory, but
rather suggest an element of balance in terms of the immune response. The corollary of
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this balance is that stratification of patients based on total CXCR3 expression may be
improved upon by the inclusion of compartment-specific scoring. Nonetheless, the fact
that studies in patients found that CXCR3 was associated positively with tumor immune
infiltrate as well as improved prognosis indicates that the pro-immune functions of CXCR3
predominate in human gastric cancer.

In these studies, the distribution of CXCR3

expression across patients and across cell types within those patients remains unclear.
Thus, the associations of CXCR3 expression with augmented anti-tumor immune
responses may arise from the level of the patient ––in which a greater percentage of patients
have expression of CXCR3 in immune cells than in cancer cells–– the tissue level ––in
which the expression of CXCR3 is in general much greater in immune cells such that
stratification by CXCR3 is functionally stratification by immune cell infiltrates–– or the
level of receptor activity ––for instance, the activity of CXCR3 in immune cells dominates
over CXCR3 activity in cancer cells. Regardless, further study of the CXCR3 with respect
to the gastric cancer-specific immune response is required to better understand the
observed associations with the signaling axis.
Chapter 3D.11 CXCR3 In Hepatocellular Carcinoma Metastasis
As with gastric cancer, the role of CXCR3 in hepatocellular carcinoma (HCC) is a
more recent development of the field. The studies of CXCR3 in HCC have largely focused
on its role in cancer cells with minimal coverage of the angiogenic and immune
involvement of the signaling axis. Regardless, these studies have yielded interesting
insights into the role of CXCR3 in this setting.
The first study reporting the involvement of CXCR3 in HCC samples came from a
study of tumor recurrence following liver transplantation [227]. In this study, patients who
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received small-for-size liver grafts had increased tumor recurrence accompanied by an
increase in circulating endothelial progenitor cells and CXCL10. CXCL10- and CXCR3KO animals that received similar liver transplants had significantly reduced recurrence.
Most importantly, in an orthotopic nude animal model, the administration of CXCL10 in
the portal vein augmented the number of lung metastases formed. In this study, the authors
claim that CXCL10 administration augmented angiogenesis in tumors resulting in
increased metastatic spread [227]. However, this contradicts the classical understanding
of CXCR3’s functions, and while there was an increased number of CD34-positive cells
within tumors of CXCL10-treated mice, these areas appeared to be smaller in comparison
to untreated mice. Moreover, mice injected with endothelial progenitor cells had larger
tumors and multiple lesions in the liver but did not appear to have increased rates of
metastases to the lungs. Because of these findings, the involvement of angiogenesis in
metastases observed in this study is questionable and likely requires further investigation
[227].

While this study was conducted in nude mice, thereby likely limiting the

involvement of the immune system in mediating the effects of CXCL10, a separate study
showed that CXCL10 in this same setting was associated with increased Treg recruitment
to the liver graft [226]. For this reason, the study of metastasis using a similar orthotopic
HCC model with portal vein CXCL10 injection in immunocompetent animals would
certainly be of interest.
Subsequent studies have highlighted alternative mechanisms by which CXCR3
may promote HCC metastasis; these studies highlight the ability of CXCR3 signaling to
act through the AKT/PI3K pathways as well as ERK1/2 signaling to promote the invasive
and migratory phenotype of HCC cells [288-290]. Notably, two studies found that CXCR3-
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mediated upregulation of MMP2 and 9 production, which augmented the in vitro invasive
properties of cells and augmented colonization of the lung in tail-vein injection models
[289, 290]. These findings parallel those observed in gastric cancer, suggesting that
CXCR3-mediated regulation of MMPs may be an essential component of its function not
only in metastasis but also in lymphocytes. Despite the fact that MMPs have been
characterized as an important part of the initial process of metastasis, additional studies in
CXCR3 are likely warranted to determine what fraction of CXCR3 activity in terms of
invasion are mediated by MMPs. Finally, another study suggested that Gβγ-mediated
activation of RAC downstream of CXCR3 augments expression of PREX2, leading to
increased migratory/invasive behavior in cancer cells.

This knockdown of PREX2

suppressed invasion in vitro, but it was not tested if, or to what extent, loss of PREX2
abrogates the invasion stimulated by activation of CXCR3 [288].
Chapter 3D.12 CXCR3 in the Metastasis of Other Malignancies
Because of its abilities to regulate cancer cell behavior, tumor immune response,
and angiogenesis, CXCR3 has been studied in numerous cancers and in the more general
setting of malignancy. While the body of literature with regards to these other cancers and
in terms of general functions of CXCR3 in malignancy is not sufficiently robust to merit
independent discussion of each study, collectively, these studies highlight important
features regarding CXCR3 in the process of metastasis which may generally be applicable
to solid malignancies.
Numerous studies of the role of CXCR3 in metastasis spread across several specific
cancer types highlight trends and mechanisms consistent with those reported for more
thoroughly investigated cancers. These commonalities across studies and cancer types are,
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while not expressly investigated for this purpose, indicative of critical aspects at the core
of CXCR3’s involvement in metastasis, which may play a role in many, if not most, solid
malignancies. The most notable example of this is the ability of CXCR3 activation to
promote the invasion of cancer cells through cell-autonomous mechanisms. Studies in
pancreatic cancer [291], oral squamous cell carcinoma [292], malignant glioma [293], as
well as in osteosarcoma [294] demonstrate that CXCR3 activation promotes the invasion
and/or migration of cancer cells.

Moreover, several of these studies independently

demonstrate that CXCR3 functions to promote this activity through similar pathways
including activation of AKT [292] and ERK [291], as well as increased expression of
MMPs [294] thereby further highlighting these pathways as being at the core of this
particular function of CXCR3. In the settings of pancreatic cancer [291], osteosarcoma,
and oral squamous cell carcinomas, CXCR3 further connected to metastatic phenotype
through demonstrating robust expression of CXCR3 in metastatic lesions, suppressed
metastasis in a tail vein injection model with loss of CXCR3 [294], and association of
primary tumor CXCR3 expression with the presence of metastatic disease at diagnosis
[292]. Finally, one study conducted an analysis of CXCL11-mediated chemotaxis in
several different cell lines derived from different cancers (including breast prostate,
cervical, lung, and colorectal) in parallel [213]. Here, they found that CXCR3 inhibition
suppressed cancer cell chemotaxis, specifically in cancer cells that had comparatively high
CXCR3A: CXCR3B ratios. Interestingly, in those cells that had low CXCR3A: CXCR3B
ratios, CXCL11 still promoted chemotaxis, which was suppressed by the inhibition of
CXCR7 signaling and augmented by inhibition of CXCR3. These findings demonstrate
the prominence of CXCR3’s role in chemotaxis in a multitude of cancers. Furthermore,
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this study aptly demonstrates the necessity of understanding the differential contributions
of CXCR3 splice variants to CXCR3-mediated phenotypes.
Despite several studies providing strong evidence for CXCR3-mediated promotion
of cancer cell invasion and/or migration, it must be noted that these effects were not
observed in all studies indicating that this role of CXCR3 is potentially context-dependent
[295]. However, in this study, it should be noted that the characterization of CXCR3
expression was minimal, especially with regards to splice-variant specific expression.
Suppression of angiogenesis is another role of the CXCR3 signaling axis in
physiologic and pathologic settings and has been shown to have roles in the metastatic
processes in numerous cancers. In the setting of PDAC, CXCL4L1 appears to play a
particularly important role in this aspect of CXCR3’s function. Here, CXCL4L1 was
shown to inhibit both angiogenesis and lymphangiogenesis [291, 296]. While the role of
CXCL4L1-mediated suppression of angiogenesis in the PDAC metastatic process was not
specifically investigated, its suppression of lymphangiogenesis was shown to suppress the
formation of lymph node metastasis in subcutaneous models of PDAC [296].
Finally, CXCR3 has important immunological functions that have been shown to
impact the metastatic process of multiple carcinomas. The immunologic functions of
CXCR3 appear to play important roles in sarcomas as well.

In hemangiosarcoma,

treatment of cancer cells with parvovirus modified for the transduction of CXCL10
increased survival and reduced the number of metastases formed in comparison to an
unmodified form of the virus [297]. The association of CXCL10-transducing virus with
improved outcomes in murine models was thought to occur through the recruitment of
immune cells based on differences in transcriptional signatures [297]. Similarly, in

163

osteosarcoma patients, CXCR3 expression correlated positively with survival [298].
Additional analysis of the TCGA osteosarcoma data set indicated that CXCR3 expression
correlated strongly with immune cell-related pathways and in CIBERSORT analysis with
increased CD8+ T-cells among other cell populations.
Chapter 3D.13 Conclusion
Overall, the function of CXCR3 signaling in cancer metastasis is extremely
complex. This complexity largely arises from the opposing roles of CXCR3 splice variants
coupled to diverse patterns of expression in multiple different cell types (Figure 3.3). In
patients and murine models, such complexity manifests itself in the form of seemingly
incongruous findings from studies conducted in similar patient populations and models
with respect to the effects of CXCR3 on the overall metastatic process. However, analysis
of the mechanism governing the observed phenotypes in a splice variant-, cell type-, and
phase of metastasis-specific manner reveals trends that appear to be largely consistent
across cancers. From these studies, three guiding principles emerge. First, CXCR3A
signaling in cancer cells appears to promote the invasion and migration of these cells
representing a metastasis-promoting function of CXCR3. Second, CXCR3B-mediated
inhibition of angiogenesis suppresses the formation of metastatic lesions. Finally, the
immune response associated with CXCR3A attenuates the formation of metastasis. Thus,
the overall role of CXCR3 in a given cancer is a balance of the pro- and anti-metastatic
activities of CXCR3 in that cancer, and the extent to which each particular activity is
required to produce or suppress metastases in that model. Thus, the effects of the CXCR3
signaling axis on cancer metastasis are ultimately dependent upon tumor- and host-specific
biology. This context-dependence is frequently magnified in model systems used to study
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metastasis.

The use of immunocompetent animal models vs. immunocompromised

animals, tail-vein injection models vs. spontaneous or orthotopic implantation models, and
variable CXCR3 splice variant expression in cell lines all exemplify effects in which study
outcomes may differ based on the alteration of either the balance of pro- and anti-metastatic
effects of CXCR3 or host features that alter the relative importance of one of those effects.
While these represent a useful framework for continued study of the involvement of
CXCR3 in cancer, they are merely a general conceptualization, and each aspect has several
exceptions evidenced in the literature. For this reason, continued study of the details of the
CXCR3 signaling axis in each disease setting is critical.
Furthermore, these trends observed in the literature pertain to only a small
proportion of the features involved in the metastatic process as a whole.

Specific

investigation of the contribution of CXCR3 to intravasation, survival in circulation,
extravasation, and early events in the colonization is underrepresented in the literature. The
corollary of this is that CXCR3 may have roles in each of these aspects that represent
critical aspects of its contribution to a cancer’s metastatic process. This knowledge gap
may contribute substantially to differences between similar studies.
In conclusion, the CXCR3 signaling axis is intimately involved in several aspects
of metastasis in a wide variety of cancers. Despite extensive study, there is no clear
conclusion as to whether CXCR3 promotes or inhibits metastasis in general. This is likely
the result of the influence of multiple extraneous factors that influence the overall activity
and importance of that activity within a tumor. Mechanistically, CXCR3 has several
functions that appear consistently throughout the literature. These include the pro-invasive
and/or migratory effects of CXCR3 that may promote malignant cell dissemination, while
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augmented anti-tumor immune response and suppression of angiogenesis may inhibit this
same process. Moving forward, specific experimentation to further delineate the roles of
CXCR3 splice variants in multiple phases of metastasis is required to further our
understanding of the axis and reconcile seemingly opposing results currently present in the
literature.
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Figure 3.3

Figure 3. 3: Schematic of the multifaceted roles of CXCR3 in cancer progression and
metastasis.
The role of CXCR3 in cancer metastasis is complex due to the differential functions of the splice
variants and the different cell types that express CXCR3. CXCR3A has been shown to function
largely in the context of tumor-infiltrating lymphocytes and cancer cells themselves. In immune
cells, CXCR3 functions to recruit both effector and suppressor cells to the tumor
microenvironment. CXCR3A expression in cancer cells has been shown to promote the
proliferative and invasive behavior of these cells, thereby promoting cancer cell metastasis.
CXCR3B has been shown to be expressed in cancer cells as well as endothelial cells. CXCR3B
expression in cancer cells has been shown to suppress proliferation as well as invasive phenotypes,
but it is also associated with the promotion of stemness features. Thus, the role of CXCR3B in
cancer cells with respect to cancer metastasis is mixed between promoting and suppressing effects.
In contrast, CXCR3B in endothelial cells has been shown to suppress angiogenesis. Note that green
bullet points denote a general metastasis-suppressing effect while red bullet points denote a
metastasis-promoting effect.
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Chapter 3E: Role of CXCR3 Axis in Tumor Angiogenesis
Chapter 3E.1 Introduction
Cancer, like any other human tissue, requires oxygen to carry out metabolic
functions. The rapid growth rates and high metabolic demands of cancer cells require that
they develop their own vascular supply [299]. This is largely accomplished through the
process of angiogenesis, which is the process of forming new branches from an existing
vascular network. Not surprisingly, hypoxia is a critical microenvironmental feature that
drives angiogenesis through stimulation of the production of VEGFA, which in turn
stimulates endothelial cell migration and invasion down the VEGFA gradient to lead the
formation of a new blood vessel [300]. While VEGFA is undoubtedly an important
molecule in the angiogenic process, in reality, it is a part of a much larger network of
signaling molecules derived from both cancer cells as well as the surrounding stroma that
regulates the process. This fact manifests itself in part through the lack of general efficacy
of VEGF blockades as a cancer therapy. Cytokines and chemokines, including CXC
chemokines, make up an important part of this network of signaling by acting as both
promoters and suppressors of angiogenesis [301, 302]. CXC chemokines are broadly
classified by the presence or absence of an ELR (Aspartate, Leucine, Arginine) motif. This
classification scheme is functionally meaningful as it divides chemokine with respect to
their role in angiogenesis —ELR-negative chemokines suppresses angiogenesis while
ELR-positive chemokines promote angiogenesis, though CXCL2 is the exception to this
rule [303]. CXCR3 ligands are ELR-negative chemokines with veritable angiostatic
functions. This section of Chapter 3 will briefly discuss the current understanding of
CXCR3 involvement in angiostasis, as well as the roles that this activity plays in the setting
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of malignancy. For the sake of brevity, this is not meant to be an exhaustive discussion as
the body of literature regarding CXCR3-mediated angiostasis is extensive, and this aspect
of CXCR3 functionality is not critical to the data reported herein.
Chapter 3E.2 CXCR3 Signaling in Angiostasis
These functions appear to be predominately mediated by CXCR3B, but before the
identification of CXCR3B, the angiostatic function of CXCR3 had been characterized
[304, 305]. In these studies, the authors found that treatment of endothelial cells with
CXCL10 and PF4 reduced the proliferation of endothelial cell line HUVEC [304, 305].
Furthermore, treatment of endothelial cell lines with CXCL10 inhibited tube formation in
vitro [305]. Importantly, in vivo Matrigel angiogenesis assays demonstrated the CXCL10
significantly inhibited vessel formation in Matrigel plugs containing bFGF [305]. Upon
identification of CXCR3B, it was discovered that this splice variant represented the
majority of CXCR3 expressed on endothelial cells. Further, using overexpression systems
for the splice variants independently, Lasagni et al. demonstrated that CXCR3B
overexpression combined with CXCL10 or CXCL4 treatment resulted in suppression of
endothelial tube formation and proliferation [214]. In contrast, overexpression of CXCR3A
enhanced endothelial cell proliferation when treated with CXCL10. Additional studies
demonstrated that treatment of endothelial cells with CXCL10 or CXCL4L1 suppressed
the migration and/or invasion of endothelial cells [248, 250, 291, 296, 306]. Cumulatively,
these studies indicate that CXCR3 signaling in the endothelial cells suppresses the three
major in vitro correlates of angiogenesis.
Mechanistic studies regarding the specific signaling downstream of CXCR3 that
suppresses angiogenesis are limited but useful. CXCR3B-mediated cAMP production was
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shown to be enhanced by concomitant treatment with forskolin. This is a strong indication
that CXCR3B signals through Gαs, and this pathway potentially mediates the angiostatic
effects of CXCR3B [214]. Further investigation of the role of integrin in angiogenesis
showed that activation of PKA in endothelial cells drove the cell death associated with loss
of integrin binding and that inhibition of PKA suppressed the cell death induced by
inhibition of integrin signaling [307]. The role of PKA as a driver of cell death in
endothelial cells is consistent with the canonical signaling downstream of CXCR3B
through Gαs. Moreover, treatment of cells with a stable, cell-permeable analogue of cAMP
(the second messenger downstream of Gαs-mediated activation of adenylate cyclase)
phenocopied the inhibition of integrin signaling, and the overexpression of the catalytic
subunit of PKA, and produced results opposite results of inhibition of PKA in a similar
setting [307]. These results further solidify the connection between canonical CXCR3B
signaling and angiostasis through demonstrating consistent effects for the signaling
intermediates from adenylate cyclase —as elucidated by Lasagni et al.— and PKA
activation. Despite these independent data that strongly support PKA as a mediator of
CXCR3’s angiostatic activity, further investigation is required to understand what role
PKA plays in angiostasis specifically downstream of CXCR3 activation. Furthermore,
investigation regarding the mechanism involved in PKA-mediated activation of caspase 8
is warranted as this mechanism is not well supported by the literature. Additional studies
have suggested modulation of the cell cycle as an underlying mechanism for the CXCR3
axis’s angiostatic activity. Notably, CXCR3 expression is limited to endothelial cells in S,
G2, and M phases of the cell cycle [304]. Consistent with this expression pattern, activation
of CXCR3 in these proliferating cells with CXCL10 resulted in arrest in the same phases

170

of the cells cycle [304]. Furthermore, PF4 treatment was independently found to augment
and prolong the expression of p21Cip1/Waf1 in endothelial cells. Later it was found that this
effect was specific for cells expressing CXCR3B [214]. These findings corroborate cell
cycle arrest as a potential mechanism of CXCR3-mediated angiostasis and are in accord
with the specific phases of the cell cycle during which CXCR3 is expressed [308]. Despite
the fact that cell cycle arrest and apoptosis are frequently closely related events, this
mechanism does not likely represent a continuation of the PKA-mediated mechanisms
discussed earlier, as p21 generally suppresses apoptosis [309].
While these findings are all generally supportive of the angiostatic role of CXCR3,
there is considerable variability in the reported cellular effects and molecular mechanisms
leading to angiostasis. For instance, in the initial characterization of CXCR3’s angiostatic
properties, Romagnani et al. reported that CXCR3 signaling caused cell-cycle arrest
leading explicitly to reduced proliferation in HUVEC [304]. However, Angiolini et al.
report that CXCL10 had no impact on HUVEC proliferation and that impaired tube
formation is the underlying angiostatic mechanism [304]. Other studies have suggested
the endothelial cell apoptosis may be important [310] while still others have reported
defects in multiple of the above aspects of angiogenesis [214]. Some of this variation may
be accounted for by differential expression of CXCR3 splice variants. CXCR3B was
discovered after the majority of the characterization of CXCR3’s function in endothelial
cells had been completed, and not all endothelial cell lines express only CXCR3B.
Additionally, understanding of the variability of CXCR3 expression in cultured cells is a
more recent development in the field and not accounted for in seminal studies of the
angiostatic activities of CXCR3. Likewise, the signaling downstream of CXCR3B has
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been reasonably well characterized in the general sense, and this could yield important
insight into the cellular and the molecular mechanism of CXCR3-mediated angiostasis.
However, studies explicitly demonstrating the relative contributions of the various
pathways downstream of CXCR3 activation to angiostasis have not been conducted. In
sum, the literature strongly supports an angiostatic role of CXCR3 but differs substantially
in the reported alterations in endothelial cell behavior and CXCR3-mediated signaling that
gives rise to this angiostasis. Ultimately, repetition of the original, seminal studies
regarding this aspect of CXCR3 biology may benefit our understanding greatly as the
incorporation of modern methodologies as well as understanding of CXCR3 would
facilitate the development of study designs capable of parsing the complex effects of
CXCR3 signaling in endothelial cells.
Chapter 3E.3 CXCR3-mediated Angiostasis in Cancer
The importance of angiogenesis in cancer stems from its required contributions to
local tumor growth and the early part of the metastatic process. Thus, the involvement of
CXCR3 in angiostasis has critical implications for this signaling axis in numerous
malignancies. Despite the fact that this activity has implications for many cancers, it has
only been thoroughly investigated in lung, renal, and pancreatic cancers. Nonetheless,
these studies have highlighted important repercussions of CXCR3-mediated angiostasis
that likely have some impact on the biology of many tumors.
Angiogenesis is required for the effective delivery of oxygen to tumors, which is
critical for supporting the long-term metabolic activities of cancer cells and, in turn, the
growth of tumors. Accordingly, inhibition of angiogenesis by the CXCR3 signaling axis
has been linked to the local tumor control in animal models. Homogenates of NSCLC
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samples induced minimal levels of angiogenesis on avascular rat corneas; however
neutralization of CXCL10 in the homogenate increased angiogenesis markedly; in vitro
lyophilized squamous cell lung cancer homogenate increased endothelial cell proliferation
to a modest degree, however homogenates with CXCL10 neutralization increased
angiogenesis to the level of purified CXCL8 [248]. In subcutaneous tumors derived from
NSCLC cell line A549 and squamous cell lung cancer line Calu-1 loss of CXCL10
expression correlated with increasing tumor volume indicating a relation between tumor
size and a potential need for increasing vascular formation thereby necessitating the need
for reduced activity of the CXCR3 axis [248]. Consistent with this hypothesis, treatment
of these cell lines with CXCL10 in vitro does not affect growth. In mice, however, CXCL10
intratumor injections caused tumors of diminished volume and mass [248]. Critically,
homogenates derived from CXCL10-treated A549 tumors exhibited reduced angiogenic
activity when implanted in rat corneas. Together, the findings of this study insinuate a
two-fold mechanism of angiogenesis. The first mechanism is through the direct activity of
CXCL10 in endothelial cells, as demonstrated by CXCL10 neutralization having a direct
positive impact on endothelial cell proliferation and corneal angiogenesis. The second
mechanism is indirect; CXCL10 signaling within the tumor suppresses the expression of
molecules that act to promote angiogenesis [248].
Like CXCL10, CXCL4 and CXCL4L1 also have angiostatic activity in the settings
of lung cancer and melanoma. As previously reported, CXCL4 and CXCL4L1 suppressed
the migration of endothelial cells induced by CXCL8 and bFGF in vitro [250, 306]. In this
assay, CXCL4L1 produced a more potent effect on the suppression of endothelial cell
migration, that is to say, that the greater inhibition was achieved by CXCL4L1 at lower
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concentrations. However, the effect of CXCL4 was greater in magnitude than that of
CXCL4L1 at very high concentrations [250]. In B16-derived subcutaneous melanoma
tumors, both chemokines suppressed tumor volume to nearly the same extent, but higher
concentrations of CXCL4 were used compared to CXCL4L1.

In this model, only

CXCL4L1 treatment resulted in suppressed angiogenesis, which begs the question of how
CXCL4 treatment reduced tumor size. Evidence from A549-derived subcutaneous tumors
treated with either CXCL4 or CXCL4L1 indicates that reduced tumor volume is a function
of reduced tumor vascularity with CXCL4/CXCL4L1 treatment, as measured by the
percentage of cells positive for endothelial marker MECA-32 [250].
Renal cell carcinoma is amenable to immunotherapy and is historically important
as one of the first cancers to have successful responses to early immunotherapies in the
form of IL-2 and IFN-α. In a murine model of renal cell carcinoma, Pan et al. found that
systemic administration of IL-2 induced the expression of CXCR3 and its ligands in
peripheral blood mononuclear cells (PBMCs) and in serum, respectively, and suppressed
tumor growth over a four-week period [311]. When the same study was conducted in
CXCR3-null mice, there was minimal effect on tumor growth and a complete abrogation
of tumor necrosis induced by IL-2 treatment [311]. Intratumoral injection of CXCL9, on
the other hand, suppressed tumor growth as monotherapy and in combination with IL-2.
Further analysis demonstrated that CXCL9 and combination therapy increased necrotic
tumor area and decreased the percentage of cells positive for endothelial cell marker
MECA-32. Despite these data, which convincingly implicate angiostasis as a mechanism
of local tumor control in this model, CXCL9 also augmented the antitumor immune
response [311]. Thus, it is unclear to what extent the effects of CXCL9 were mediated by
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angiostasis. The fact that CXCL9 treatment augments, and CXCR3 KO nearly completely
abrogates, the presence of necrosis in the tumor indicates that angiogenesis is involved to
some extent as necrosis is not typically a feature of immune cell-mediated cell killing.
Unfortunately, neither rescue of angiogenesis nor depletion of immune cells was performed
to further parse the contributions of these CXCR3 functions to the tumor control conferred
by CXCL9 and IL-2. In renal cancer patients, high dose IL-2 therapy increased expression
of CXCR3 in PBMCs and its ligands in serum [263]. The increase in CXCR3 ligand
expression resulted in a decrease in the relative abundance of angiostatic in comparison to
angiogenic cytokines in the serum of patients [263]. Generally, these findings from the
analysis of human serum were consistent with those from the mouse model. However,
further analysis of human tumor samples was not performed to demonstrate changes in
tumor necrosis, microvessel density, or immune infiltrate. Such analyses would have been
particularly useful for demonstrating both the underlying mechanism as well as the validity
of the murine model.
Finally,

CXCL4L1

has

been

shown

to

suppress

angiogenesis

and

lymphangiogenesis in PDAC [291, 296]. In this setting, CXCL4L1 caused decreased
proliferation [291, 296], migration and or invasion [291, 296], and tube formation [296] of
HUVEC cells in vitro. In Capan-1-derived xenograft tumors, overexpression of CXCL4L1
suppressed tumor growth and CD31-positive vessel density to roughly the same extent as
classical angiostatic molecules fibstatin and endostatin, suggesting that, as in other cancers,
CXCR3 signaling potently suppresses angiogenesis resulting in diminished tumor
outgrowth. Subsequent studies confirmed that the angiostatic effects were mediated by
CXCR3B [291].
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Because access to lymphatic and blood vessels is a critical feature for metastatic
dissemination, the ability of CXCR3 to suppress angiogenesis has important implications
for metastasis as well as tumor growth. In lung cancer tumors derived from A549 cells,
treatment with CXCL10 or CXCL4L1 by intratumoral injection markedly reduced
angiogenic activity within the tumor, which was associated with decreased numbers and
size of lung metastases, as well as decreased total number of cancer cells present at
secondary sites [248, 250, 312]. Here the decrease in the number and size of metastatic
colonies may reflect the difference in the number of cells initiating the metastatic process
or the ability of cells to successfully and stably colonize the lungs [248] [312]. While not
conclusive, increased rates of cancer cell apoptosis observed in primary tumors but not in
cell culture or metastatic sites suggest that reduced metastasis may be a reflection of
decreased access to the vasculature and overall diminished malignant cell population at the
primary site, which is expected given that intratumoral injection was the mode of CXCL10
administration [312]. Finally, mice treated with intratumor CXCL10 had significantly
improved survival indicating that CXCR3-mediated angiostasis and subsequent reduction
of metastasis may be important prognostically. Similarly, Lewis lung carcinoma cells
ectopically overexpressing PF4 had fewer lung lesions and decreased lung mass following
tail vein injections and a 28-day growth period; though, this study did not investigate
associations with angiogenesis at the metastatic site [249].
While the results of this study and those focused on CXCL10 and CXCL4L1 had
similar outcomes with respect to metastasis, they may actually comment on entirely
different aspects of the metastatic process. In the CXCL10 and CXCL4L1 studies, the
chemokines were administered through direct injection, and as a result, there was increased
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cell death at the site of the primary tumor but not the metastatic sites in the CXCL10
treatment group. Therefore, in this experiment, it is likely that loss of angiogenesis at the
primary site reduced metastasis through decreased access to the vasculature or fewer cells
in the tumor overall, thereby reducing the potential metastatic cell population. The study
of PF4 differs from these studies in two main ways. First, the use of a tail-vein injection
model prevents any effect of the treatment in the primary tumor because it does not exist.
Because of this, this study provides information directly related to the metastatic process
with reduced likelihood of confounding effects derived from changes in the primary tumor.
Second, the site of PF4 expression is intrinsically linked to the location of tumor cells.
Because of these two features, this study allows one to draw the conclusion that PF4
directly attenuates the ability of Lewis lung cancer cells to colonize and/or proliferate in
the lungs, whereas the studies of CXCL10 and CXCL4L1 indicate that these ligands
indirectly suppress lung metastasis through alterations in the primary tumor. When
interpreted together, these studies strongly suggest that the angiostatic function of the
CXCR3 signaling axis may suppress metastasis by acting during the early phases of
hematogenous dissemination as well as the colonization of the final metastatic site.
CXCL4L1 also mediated suppression of angiogenesis in PDAC.

However,

investigation of metastasis in PDAC murine models demonstrated that CXCL4L1
treatment suppressed regional lymph node metastases rather than distant metastases [296].
As a note, this observation is likely the product of the fact that subcutaneous models of
PDAC almost never give rise to distant metastases.

Regardless, this prompted an

evaluation of the role of CXCL4L1 in lymphangiogenesis in addition to angiogenesis. As
expected, CXCL4L1-treated animals had decreased lymphatic vessel density within
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tumors, as assessed by Lyve-1 staining [296].
The relatively consistent angiostatic, and to some extent, the immunological effects
of CXCR3 in the setting of cancer has promoted a modest level of interest in this signaling
axis as a potential therapeutic target, mainly in lung and colorectal cancer. Consistent with
previous reports, CXCL10 suppressed angiogenesis in Lewis lung cancer- and CT26 colon
cancer-derived tumors as measured by in vivo alginate bead vascularization assays as well
as CD31 staining within tumor samples [313]. When CXCL10 treatment was combined
with cisplatin, the combination significantly decreased tumor volume over controls and
single-agent arms, and improved survival in the murine models. In accordance with these
findings, the combination of CXCL10 and cisplatin increased tumor cell TUNEL staining.
Additionally, CXCL10 treatment was associated with significantly increased immune
infiltration leading to the possibility that survival effects and reduced tumor volumes were
mediated by augmented immune response to some extent [313]. Similarly, in the process
of investigating the anticancer activity of a novel anti-cancer agent, DMXAA, Cao and
colleagues found that the drug strongly and rapidly induced CXCL10 expression in normal
murine spleen as well as in patient-derived xenografts of colorectal cancer [314].
Interestingly, this induction of CXCL10 was independent of IFN-γ-mediated regulation as
mice lacking IFN-γ produced similar levels of CXCL10 upon DMXAA treatment as wild
type mice. Furthermore, DMXAA treatment nearly completely abrogated vascularization
of Matrigel plugs containing pro-angiogenic factor bFGF. Finally, neutralization of
CXCL10 alone reduced nearly 60% of the angiostatic effect of DMXAA, further
supporting the critical involvement of CXCL10/CXCR3 in mediating the angiostatic
effects of DMXAA [314]. Unfortunately, the effect of DMXAA treatment on tumor
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growth and survival of tumor-bearing mice was not reported in this study. However, in the
initial characterization of the drug, it produced greater than 90% necrosis within 24 hours
of administration in the C38 colon xenograft model indicating the potential involvement of
vascular collapse based on time frame as well as the method of cell death [315].
Chapter 3E.4 Conclusion
In sum, the association of CXCR3 with angiostasis and resulting tumor growth
suppression are highly consistent and are one of the most prominent antitumor effects
mediated by CXCR3. Despite this consistency, there are gaps present within each of these
studies, mainly that the suppression of angiogenesis was never directly tested as the
mechanism of CXCR3-mediated suppression of tumor growth, nor were the expression
patterns of CXCR3 and CXCR3 ligands investigated in these murine models. Given the
diversity that can be present in the cell types that express CXCR3 and pleiotropic effects
of CXCR3 in each of these cell types, this is a critical step in demonstrating the functional
contribution of CXCR3-mediated angiostasis in tumor biology.
The interplay between CXCR3, angiogenesis, and metastasis are also consistent in
terms of outcomes across multiple studies and tumor types. This consistency gives
confidence that CXCR3 likely has some form of antimetastatic role in cancers through its
activity in endothelial cells. This is not to say that CXCR3 suppresses metastasis overall,
as CXCR3A has clear pro-metastatic roles. Additionally, each of these studies has
significant gaps in terms of angiostasis mediating the antimetastatic effects of CXCR3 in
these models. Most notably, the rescue of angiogenesis either through desensitizing
endothelial cells to angiostatic CXCR3 signals or through overriding them, perhaps
through high dose treatment with VEGFA, CXCL12, or CXCL8, would be useful for
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determining a causal relationship between CXCR3-mediated angiostasis and reduced
metastasis in each of these models.
With respect to therapy, it is undeniable that the studies discussed here show some
promise for the therapeutic targeting of CXCR3 signaling in the setting of malignancy.
Despite this, CXCR3 and its ligands represent a complex biological system with pleiotropic
effects. Within this chapter, there is strong evidence indicating that CXCR3 has pro- and
anti-cancer activities that vary from cancer type to cancer type. For CXCR3 to be a
legitimate target for cancer therapy, several advances must be made. First and most
importantly, research must elucidate the specific contexts in which the pro- and anti-cancer
properties of CXCR3 predominate. Initially, analysis of multiple malignancies may
elucidate patterns that can predict how CXCR3 and CXCR3 ligand expression and activity
associate with survival. However, this is merely the initial step, and subsequent analysis
will likely require large scale observational studies in humans to hone these broad
predictive heuristics to define not only the disease setting but also specific patient
populations.

Superficially, this step may seem extreme or idealistic; however, few

therapies are used in humans who have the potential to either suppress tumor growth or
increase the likelihood of disease progression. Thus, patient selection for CXCR3-based
therapies is tantamount to patient safety. Finally, understanding precisely the contributions
of the CXCR3 splice variants is critical as the different functions associated with each
variant are likely to increase the therapeutic window in the sense that targeting the function
of a single splice variant may afford the opportunity to promote anti-cancer activity or
suppress pro-cancer activity while leaving the other functions of the signaling axis intact.
As a poignant hypothetical, promoting the angiostatic activity of CXCR3 through
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specifically activating the B receptor may have therapeutic benefit while avoiding the
potential to increase metastasis by activating migration and invasion pathways downstream
of CXCR3A.
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Chapter 4: Analysis of Transcriptomic Associations of
CXCR3A and its Ligands CXCL9, CXCL10 and CXCL11
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Chapter 4A: Introduction
Chapter 2 of this dissertation presents the findings of a large scale in silico cytokine
screen, which identified several cytokines/chemokines that were upregulated in PDAC
compared to normal pancreas in several independent microarray datasets. Amongst the
identified cytokines were CXCR3 ligands CXCL9 and CXCL10, and this signaling axis
was selected for further investigation. This investigation consists of three parts: 1)
thorough dissection of CXCR3 ligand expression profiles in microarray and RNA seq
datasets, 2) validation of upregulation of CXCL9 and CXCL10 in murine PDAC models,
and 3) analysis of CXCR3 expression at the mRNA and protein levels through microarray
and RNA-Seq data for the former and IHC for the later. The confluence of these data
supported the presence of an intact CXCR3 signaling axis in PDAC that functions within
the stromal as well as the epithelial compartments of PDAC tumors. These findings were
highly consistent with the subsequent review of the literature regarding the roles of CXCR3
in other cancers. In Chapter 3 of this dissertation, the literature review showed that CXCR3
has diverse roles in various cancers, including modulation of the immune system,
suppression of angiogenesis, and promotion of tumor metastasis.
On the basis of the findings in Chapters 2 and 3, subsequent analyses of the role of
CXCR3A axis in the PDAC TME were performed including 1) assessment of disparate
survival on the basis of differential gene expression, 2) transcriptome-wide gene
associations coupled with pathway analysis, 3) gene set enrichment analysis (GSEA), 4)
CIBERSORT immune cell gene signature quantification, and 5) multicolor immune cell
marker staining in PDAC resection samples. These analyses demonstrated a positive
survival association for high CXCR3A expression, which was likely related to robust
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immune infiltration associated with CXCR3A expression, as demonstrated by pathway,
GSEA, CIBERSORT, and IF analyses. In contrast, high CXCR3A ligand expression was
associated with poor survival outcomes in patients, with predominant immune associations,
specifically with T-cell exhaustion and immune suppression, in both pathway and GSEA
analyses. These results were, in part, confirmed by observations of depleted NK cells in
the setting of high CXCR3 Ligands by CIBERSORT analysis.
Chapter 4B: Methods and Materials
Chapter 4B.1 Survival Analysis
All 140 patients present in the original TCGA PDAC data set were stratified
according to the median of CXCR3A expression. Additionally, patients were stratified by
both CXCR3A as well as cellularity in an independent analysis on the basis of predominant
CXCR3 expression in the stromal compartment. Similarly, patients were stratified by the
linear combination of all CXCR3A ligands: CXCL9, CXCL10, and CXCL11. KaplanMeier survival analysis was performed for the following comparisons: CXCR3A high vs.
CXCR3A low, high cellularity high CXCR3A vs. high cellularity low CXCR3A, low
cellularity high CXCR3A vs. low cellularity low CXCR3A, and high CXCL9,10 and 11
vs. low CXCL9,10, and 11. For Kaplan-Meier analysis, both log-rank and Wilcoxon
statistics were computed to highlight group-dependent differences in late and early events,
respectively. Survival differences were considered statistically significant at a p-value of
less than or equal to 0.05 (Figure 4.1).
Chapter 4B.2 Pathway Analysis
Spearman ρ correlation coefficients and corresponding p-values between CXCR3
and each gene represented in the TCGA PDAC dataset as well as 5/6 microarray datasets
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described in Chapter 2 (GSE18670 was excluded from these analyses due to small sample
size) were computed in all patients (For TCGA and microarray data) as well as in high and
low cellularity patient subsets (TCGA only as microarray datasets do not have a
quantification of cellularity). Similarly, transcriptome-wide correlations were conducted
for each CXCR3A ligand as well as the linear combination of CXCL9, CXCL10, and
CXCL11 for TCGA and microarray datasets. Genes that were strongly correlated (p ≤
0.001) with any of the genes of interest were included for further analysis thereby
generating three sets of correlated genes for CXCR3A (total, high cellularity, and low
cellularity) and four sets of genes for CXCR3A ligands (one for each ligand plus and
additional gene set for the linear combination of all ligands). Each gene set was then split
into positive and negative correlation subsets on the basis of the Spearman’s ρ value.
Subsequently, each positive and negative subset was passed to individually into IPA for
analysis. The top 10 most significant pathways returned by IPA for each subset of genes
were considered for each gene/set of genes analyzed (Figure 4.2).
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Figure 4.1
A.

B.

Figure 4. 1: Schematic representations of survival analyses.
A) Representation of the general methodology of survival analyses conducted on all PDAC patients
in the TCGA PAAD dataset. Here genes of interest include CXCR3A, CXCL9, CXCL10,
CXCL11, and the linear combination of CXCL9, CXCL10, and CXCL11. B) Representation of the
methodology used for high and low cellularity patient subsets with respect to CXCR3A expression.
As a final note, these methodologies are used for multiple analyses, including CIBERSORT
analysis, in which Kaplan-Meier analysis is replaced by a different analytical method.
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Figure 4.2
A.

B.

Figure 4. 2: Schematic of workflow for analysis of transcriptome-wide gene expression
correlations using Ingenuity Pathway Analysis.
A) Workflow for general gene expression correlations followed by pathway analysis in TCGA. The
same workflow applies to microarray data. GOI is gene of interest; in this chapter, these include
CXCR3A, CXCL9, CXCL10, CXCL11, and the linear combination of CXCR3A ligands. B) the
workflow for correlation analysis by IPA for low and high cellularity patient subsets. This
workflow is specific to analyses of CXCR3A in TCGA data.
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Chapter 4B.3 Gene Set Enrichment Analysis
Similar to survival analysis, TCGA patients were stratified by the median
expression of CXCR3A and the linear combination of CXCR3A ligands to 2 comparison
sets (CXCR3A high vs. low and CXCR3A ligands high vs. low). These two comparison
sets were passed to GSEA (broad institute) along with the entirety of gene expression data
for each patient. GSEA was then run for 1000 permutations with differential gene
expression being inferred based on unsupervised Student’s t-test (α=0.05). GSEA results
were then filtered to restrict identified gene sets to those curated by the Gene Ontology
Consortium (GO terms). This restriction was imposed to limit the number of redundant
terms elucidated, while GO terms were chosen as this is the largest and most
comprehensive gene set library curated by a single source, thereby ensuring maximal
robustness, continuity, and gene set coverage.
Chapter 4B.4 CIBERSORT
Quantifications of relative immune cell gene expression signatures for 22 immune
cell types in the 140 primary PDAC samples in the PAAD TCGA dataset as well as in the
five microarray datasets were calculated using CIBERSORT and the LM22 signature
matrix. Samples were subsequently stratified by the median expression for CXCR3A as
well as median cellularity and the sum of CXCL9, 10, and 11 to produce groups consistent
with those used in survival analysis. Mann-Whitney U tests were used to compare the
distributions of immune cell infiltrate scores of high and low expression groups with a pvalue of less than 0.05 being significant.
Chapter 4B.5 Multicolor Immunofluorescence
To validate bioinformatic findings, multicolor immunofluorescence staining was
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done to test the associations of CXCR3 protein expression with various expression of
markers of immune cell populations found in CIBERSORT analysis. Twenty-three human
primary PDAC resection samples were stained for the following molecules with the
indicated antibodies at the stated concentrations: CXCR3 (mab160 R&D Systems 1:200),
CD8 (AMC908 ThermoFisher 1:100) CD20 (D-10 Santa Cruz Biotechnology 1:100), and
CD138 (PA5-16918 ThermoFisher 1:100). Staining was initially optimized on normal
human tissue microarrays, which allowed the use of human cerebral tissue as a negative
control (due to the immune-privileged status of CNS tissue) as well as secondary lymphoid
organs as positive controls. Staining was considered optimized based on the maximization
of signal to background ratio between positive and negative controls and spatial separation
of staining across CD8, CD20, and CD138.
Staining was carried out via a novel 3-stage staining protocol. Briefly, sections
were deparaffinized by baking at 58 °C followed by two washes in xylenes (10 min each).
Deparaffinized tissues were rehydrated in graded ethanol washes (10 min each at 100%
100%, 90%, 70%, 50%, and 30% ethanol) followed by two washes in TBS-TX (Tris
Buffered Saline with 0.025% Triton X 100) for 5 minutes each wash. Tissues were not
permeabilized in order to preserve surface staining of antigens to the greatest extent
possible. Antigen retrieval was carried out in 10 mM sodium citrate, pH 6.0, 0.05% Tween
20 with microwaving for 15 minutes total minutes of boiling time. Specimens were blocked
in 10% normal goat serum (NGS) in TBS-TX for one hour at room temperature. After
blocking, tissues were incubated with primary CXCR3 and CD138 antibodies suspended
to the indicated concentrations in 10% NGS overnight at 4°C. Following three washes (10
min each in TBS-TX), slides were incubated with AlexaFluor-405 (AF-405) conjugated
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anti-mouse IgG and AF-568 conjugated anti-rabbit IgG antibodies at a 1:400 dilution in
10% NGS for 1 hour at room temperature. The slides were washed three times 10 min
each followed by a 20-minute blocking period in 10% NGS. Immediately following this
second blocking step, slides were incubated with the second round of fluorophoreconjugated, primary antibodies against CD8 (AF-488) and CD20 (AF-647) at the indicated
concentration suspended in 10% NGS. The second round of primary antibody incubation
was carried out for 6 hours, after which slides were again washed three times for 10 min
each time in TBS-TX. Following the final TBS-TX wash, slides were incubated briefly
with Tru Black (autofluorescence quenching agent Biotium) for 1 min followed by
mounting in an aqueous mounting medium without DAPI. Mounted slides were then
sealed with clear nail polish (Sally Hanson Hard as Nails).
Stained slides were imaged on a Zeiss LSM 800 confocal microscope using a 40X
immersion objective with 10X ‘ocular lens’; identical microscope settings were used in the
acquisition of all images. Images of 10 high-power fields were acquired per specimen and
processed using Zen Blue software (Zeiss); all images were processed identically and by
two distinct methods. The first method was used to produce images that, after processing,
had negligible staining of negative control tissues and robust staining in positive control
tissues; the second method was in all senses an overexposure of the image that allowed
inference of histological context. After processing, images were exported, and cells were
manually counted.

Anti-CXCR3 and -CD8 antibodies showed highly specific staining

patterns for cells resembling lymphocytes with robust membranous staining such that
individual cells could be counted. For these two stains, the cellular origin of expression
was confirmed in images processed via the second method. Subsequently, all cells that
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had expression of either or both molecules in images processed via the first method were
counted, and cellular immunophenotypes (CD8+CXCR3+, CD8+CXCR3- and CXCR3+
CD8-) were recorded. CD138 also showed robust membranous staining allowing the
counting of individual cells; however, it was not specific for the plasma cell fraction, with
many malignant cells also demonstrating expression. For this histological context of
CD138 expression was determined via images processed via the second method, followed
by confirmation of veritable CD138 staining in images processed via the first method. Due
to expression in PDAC cells, only cells not of obvious epithelial origin were counted for
subsequent analysis. CD20 demonstrated strong but punctate expression, which made
quantification of positive cells impossible. Moreover, CD20 staining within areas
containing malignant cells or associated desmoplastic stroma were very rare in our
analysis. Because lymphoid aggregates are the predominant source of B-cells within the
TME, we assessed the number and size of each lymphoid aggregates present in
hematoxylin stained tissue sections using image J instead of quantifying the CD20+ cells
present within the tumor. Quantified immune cell data was then compared to CXCR3
expression data from immunofluorescence staining through stratification based on the
median number of expressing cells or correlated directly with immune cell populations
using Spearman’s rho.
Chapter 4C: Results
Chapter 4C.1 CXCR3A and Its Ligands are Associated with Altered Survival in
PDAC
To understand how the differential expression of CXCR3 ligands relates to PDAC
prognosis, we performed Kaplan-Meier survival analyses in TCGA data stratified by the
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sum of CXCL9, CXCL10, and CXCL11 expression (Figure 4.3). Patients expressing
higher than median CXCR3A ligands had significantly worse OS (Wilcoxon p=0.04).
Similarly, when patients were stratified by the median, high CXCR3A-expressing patients
had improved OS; however, these findings were not statistically significant (Figure 4.4).
Because CXCR3A is expressed in epithelial and stromal tumor compartments and the
differential cellular source of expression may dictate its function, we assessed CXCR3A
expression in PDAC samples divided by median cellularity and CXCR3A expression
(Figure 4.5). Importantly, in this sub-analysis, high CXCR3 expression was insignificantly
associated with worse OS in high cellularity patients; in the low cellularity comparison,
there is a marked improvement in the OS of high CXCR3A expressors over low expressors
suggesting that CXCR3A has different prognostic importance depending on compartmentspecific expression or upon the tumor context in which it is expressed.
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Figure 4.3

Figure 4. 3: Kaplan-Meier Survival Analysis of TCGA Patients Stratified by CXCR3A
Ligand Expression.
The linear combination of normalized expression values of CXCL9, 10, and 11was used to stratify
PDAC patients in the PAAD TCGA dataset. Wilcoxon and log-rank p-values were calculated.
High expression of CXCR3A ligands was associated with worse overall survival in PDAC patients.

193

Figure 4.4

Figure 4. 4: Kaplan-Meier Survival Analysis of TCGA Patients Stratified by CXCR3A
Expression.
PDAC patients in the PAAD TCGA dataset were stratified by CXCR3A. Wilcoxon and log-rank
p-values were calculated. High expression of CXCR3A was associated insignificantly with
improved OS in PDAC patients.
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Figure 4.5
A.

B.

Figure 4. 5: Kaplan-Meier Survival Analysis of TCGA Patients Stratified by CXCR3A
Expression and Cellularity.
Because CXCR3A has expression in both epithelial and stromal tumor compartments and its
function may differ depending on the context or cell in which is activated, we analyzed the
association of CXCR3 in a cellularity-dependent manner. PDAC patients in the PAAD TCGA
dataset were stratified by CXCR3A and subsequently by cellularity. Wilcoxon and log-rank pvalues were calculated. A) CXCR3A in high cellularity patients was not associated with outcomes.
B) CXCR3A in low cellularity patients was associated with markedly improved overall survival.
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Finally, we performed a cytokine qRT-PCR array in two murine models of PDAC
with markedly different phenotypes at histologically matched time points. The KPC model
represents a highly aggressive model with a high degree of penetrance, and rapid
progression of tumors to metastatic disease in roughly 20 weeks and death by 25 weeks.
In contrast, the KC model represents more indolent disease with lower penetrance, rare
metastases, and survival of greater than 50 weeks. By comparing the cytokines that are
differentially expressed in each of these models relative to WT littermates, we again see
that CXCL10 was upregulated specifically in the more aggressive KPC model (Figure 4.6).
Notably, CXCL9 had comparatively higher expression in KPC tumors relative to KC
tumors but was not overexpressed in KPC tumors compared to pancreas of WT littermates.
These results represent an association of CXCR3A ligands with aggressive PDAC, which
is consistent with findings from the survival analysis of TCGA data. In sum, these results
suggest that CXCR3A ligands are upregulated specifically in the more aggressive model
and may contribute to this aggressive phenotype.
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Figure 4.6

Figure 4. 6: Investigation of CXCR3 Ligand Expression in Aggressive and Indolent Murine
PDAC Models via qRT-PCR Array.

The heatmap color depicts the fold change of expression of each cytokine relative to agematched WT murine pancreas. The cytokines appear in order of decreasing difference
between KPC and KC fold-changes. Cxcl10, Pf4, and Cxcl9 all have a higher relative
expression in KPC compared to KC mice.
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Chapter 4C.2 Pathway analysis of Genes Associated with CXCR3 and its Ligands
We used Spearman’s rho correlations to generate sets of genes, the expressions of
which are highly correlated with the expression of CXCR3A ligands, and CXCR3A in
TCGA PDAC samples. These gene sets were analyzed via Ingenuity Pathway Analysis.
From these analyses, several trends emerged. First, CXCR3 A and B had similar associated
pathways, with T-cell pathways being the most prominent component of both gene sets
(Figure 4.7A and B). Second, T-cell related gene sets were more prominent in low
cellularity samples with high CXCR3A expression as compared to high cellularity samples
with high CXCR3A expression (Figure 4.7C and D). Third, T-cell related genes were also
prominent in CXCL9, 10, 11 correlated sets (Figure 4.8). Notably, T-cell exhaustion and
PD-1 PD-L1 related terms appear as being top hits only for the CXCL9, 10, and 11
correlated geneset. To demonstrate the robustness of these data, we repeated this analysis
using a different p-value cutoff; here, genes correlated with CXCR3A or its ligands with
p-values less than or equal to 0.0001 were included. Results from this second iteration of
analysis were largely consistent with the first (Figure 4.9). Moreover, the immune-related
signatures of CXCR3 and CXCR3 ligands were largely consistent across identical analyses
conducted using microarray datasets, and T-cell exhaustion pathways remained a
prominent component of gene pathways specifically associated with CXCR3A ligands
(Table 3 and 4). Finally, detailed analysis of the correlation of genes present in the T-cell
Exhaustion Pathway in IPA with CXCR3A and CXCR3A ligand expression revealed a
general trend toward a stronger association of CXCR3A ligands with the
immunosuppressive genes of this pathway as compared to CXCR3, which was more
strongly associated with the general immune response genes (Figure 4.10).
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Figure 4.7
A.

B.

C.

D.

Figure 4. 7: Pathway Analysis of Genes that are Highly Correlated with CXCR3 Splice
Variants.
A) CXCR3A expression was correlated with the expression of all genes represented in the TCGA
PDAC dataset using Spearman’s rho correlations. Genes correlating with CXCR3A with a p-value
of less than 0.001 were further split based on the directionality of the correlation and analyzed for
common functions using IPA. CXCR3A correlated strongly with T-cell related gene signature. B)
CXCR3B expression was correlated with genes as in ‘A’ and analyzed via IPA. Surprisingly
CXCR3B also correlated well with many pathways relating to T-cell functions. Notably, this may
be the product of a strong correlation between CXCR3A and CXCR3B. C) CXCR3A expression
was correlated as previously described in the high cellularity subset of patients. In this analysis,
CXCR3A lost nearly all significant correlations with T-cell-related pathways. D) CXCR3A
expression was correlated as previously described in the low cellularity subset of patients. Here Tcell related pathways were strongly correlated with CXCR3A in stark contrast to the high cellularity
comparison.
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Figure 4.8

Figure 4. 8: Pathway Analysis of Genes that Are Highly Correlated with CXCR3A Ligands.
The linear combination of expression values for CXCL9, 10, and 11 was correlated with expression
values for all genes present in the TCGA PDAC dataset. Highly correlated genes were analyzed
as in Figure 4.5. CXCR3A ligands, like CXCR3A, were strongly associated with T-cell related
pathways. Critically, CXCR3A correlated with genes present in immunosuppression pathways,
including T-cell exhaustion and PD-1/PD-L1-related pathways, thereby indicating a potential role
in immunosuppression for CXCR3A ligands.
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Figure 4.9
A.

B.

Figure 4. 9: Pathway Analysis of Genes Highly Correlated with CXCR3A or CXCL9, 10,
and 11 using p-Value Cutoff of 0.0001 or less.
A) CXCR3A expression was correlated with the expression of all genes represented in the TCGA
PDAC dataset using spearman’s rho correlations. Gene correlating with CXCR3A with a p-value
less than 0.0001 were further split based on the directionality of the correlation and analyzed for
common functions using IPA. CXCR3A correlated strongly with T-cell related gene signature. B)
CXCR3A ligands, like CXCR3A, were strongly associated with T-cell related pathways. Critically,
CXCR3A correlated with genes present in immunosuppression pathways, including T-cell
Exhaustion, thereby indicating a potential role in immunosuppression for CXCR3A ligands.
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Table 3. Listing of the 15 most significant pathways returned by IPA analysis conducted on
genes highly correlated with CXCR3 expression in microarray datasets.
Dataset

GSE15471

GSE16515

GSE32676

CXCR3
Positive Correlations
Th1 and Th2 Activation Pathway
Th1 Pathway
iCOS-iCOSL Signaling in T Helper Cells
Th2 Pathway
CD28 Signaling in T Helper Cells
T Cell Receptor Signaling
Role of NFAT in Regulation of the Immune Response
PKCŒ∏ Signaling in T Lymphocytes
B Cell Development
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis
Calcium-induced T Lymphocyte Apoptosis
B Cell Receptor Signaling
PD-1, PD-L1 cancer immunotherapy pathway
T Cell Exhaustion Signaling Pathway
Primary Immunodeficiency Signaling
Role of NFAT in Regulation of the Immune Response
IL-2 Signaling
ErbB2-ErbB3 Signaling
GM-CSF Signaling
Erythropoietin Signaling
IL-7 Signaling Pathway
JAK/Stat Signaling
Prolactin Signaling
Tec Kinase Signaling
3-phosphoinositide Biosynthesis
FLT3 Signaling in Hematopoietic Progenitor Cells
Acute Myeloid Leukemia Signaling
Neuregulin Signaling
IL-9 Signaling
SAPK/JNK Signaling
Pathogenesis of Multiple Sclerosis
tRNA Splicing
Crosstalk between Dendritic Cells and Natural Killer Cells
Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency
RhoA Signaling
Th1 Pathway
Cardiac Œ≤-adrenergic Signaling
Relaxin Signaling
Gustation Pathway
Th1 and Th2 Activation Pathway
RhoGDI Signaling
Hepatic Fibrosis / Hepatic Stellate Cell Activation

-Log10 p-value
2.39E+01
2.38E+01
2.38E+01
2.23E+01
2.03E+01
1.81E+01
1.77E+01
1.63E+01
1.37E+01
1.36E+01
1.36E+01
1.35E+01
1.34E+01
1.31E+01
1.29E+01
3.03E+00
2.67E+00
2.60E+00
2.50E+00
2.40E+00
2.37E+00
2.34E+00
2.33E+00
2.32E+00
2.31E+00
2.30E+00
2.22E+00
2.14E+00
2.07E+00
2.06E+00
2.55E+00
1.88E+00
1.56E+00
1.43E+00
1.42E+00
1.42E+00
1.36E+00
1.33E+00
1.33E+00
1.27E+00
1.26E+00
1.24E+00
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GSE28735

GSE62452

Leukocyte Extravasation Signaling
cAMP-mediated signaling
G-Protein Coupled Receptor Signaling
Neuroprotective Role of THOP1 in Alzheimer's Disease
Primary Immunodeficiency Signaling
Gustation Pathway
Methylglyoxal Degradation I
Airway Inflammation in Asthma
Spermine and Spermidine Degradation I
Human Embryonic Stem Cell Pluripotency
Glycine Cleavage Complex
Regulation of the Epithelial-Mesenchymal Transition Pathway
FGF Signaling
Intrinsic Prothrombin Activation Pathway
Histidine Degradation III
Pathogenesis of Multiple Sclerosis
Mineralocorticoid Biosynthesis
Thyroid Cancer Signaling
Pathogenesis of Multiple Sclerosis
Endocannabinoid Neuronal Synapse Pathway
Phagosome Maturation
Extrinsic Prothrombin Activation Pathway
Th1 and Th2 Activation Pathway
Gap Junction Signaling
Coagulation System
tRNA Splicing
Dermatan Sulfate Biosynthesis (Late Stages)
Chondroitin Sulfate Biosynthesis (Late Stages)
Chondroitin Sulfate Biosynthesis
Glutamate Receptor Signaling
Dermatan Sulfate Biosynthesis
SPINK1 Pancreatic Cancer Pathway
Remodeling of Epithelial Adherens Junctions

1.21E+00
1.16E+00
1.08E+00
2.73E+00
1.75E+00
1.56E+00
1.48E+00
1.36E+00
1.36E+00
1.19E+00
1.19E+00
1.19E+00
1.17E+00
1.10E+00
1.07E+00
1.02E+00
9.79E-01
9.63E-01
1.93E+00
1.92E+00
1.79E+00
1.68E+00
1.67E+00
1.56E+00
1.35E+00
1.27E+00
1.23E+00
1.21E+00
1.15E+00
1.14E+00
1.13E+00
1.12E+00
1.06E+00
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Table 4. Listing of the 15 most significant pathways returned by IPA analysis conducted on
genes highly correlated with the linear combination of CXCR3A ligand expression in microarray
datasets.
Dataset

GSE15471

GSE16515

GSE32676

CXCL9, 10 and 11
Positive Correlations
Neuroinflammation Signaling Pathway
Antigen Presentation Pathway
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis
Th1 and Th2 Activation Pathway
Th1 Pathway
Th2 Pathway
Graft-versus-Host Disease Signaling
Allograft Rejection Signaling
Autoimmune Thyroid Disease Signaling
Type I Diabetes Mellitus Signaling
PD-1, PD-L1 cancer immunotherapy pathway
Communication between Innate and Adaptive Immune Cells
T Cell Exhaustion Signaling Pathway
Dendritic Cell Maturation
T Helper Cell Differentiation
Th1 and Th2 Activation Pathway
Th1 Pathway
Type I Diabetes Mellitus Signaling
Communication between Innate and Adaptive Immune Cells
Dendritic Cell Maturation
Crosstalk between Dendritic Cells and Natural Killer Cells
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis
Neuroinflammation Signaling Pathway
Pattern Recognition Receptors in Recognition of Bacteria/ Viruses
Th2 Pathway
TREM1 Signaling
Pathogenesis of Multiple Sclerosis
T Cell Exhaustion Signaling Pathway
T Helper Cell Differentiation
Graft-versus-Host Disease Signaling
T Cell Receptor Signaling
iCOS-iCOSL Signaling in T Helper Cells
CTLA4 Signaling in Cytotoxic T Lymphocytes
CD28 Signaling in T Helper Cells
Th1 Pathway
Th1 and Th2 Activation Pathway
Pathogenesis of Multiple Sclerosis
Th2 Pathway
Communication between Innate and Adaptive Immune Cells
Hematopoiesis from Pluripotent Stem Cells
Nur77 Signaling in T Lymphocytes
Role of NFAT in Regulation of the Immune Response

-Log10 p-value
1.74E+01
1.68E+01
1.66E+01
1.60E+01
1.59E+01
1.50E+01
1.39E+01
1.38E+01
1.38E+01
1.37E+01
1.26E+01
1.18E+01
1.09E+01
1.07E+01
1.03E+01
1.83E+01
1.61E+01
1.58E+01
1.46E+01
1.45E+01
1.40E+01
1.39E+01
1.33E+01
1.19E+01
1.18E+01
1.14E+01
1.13E+01
1.09E+01
1.04E+01
1.01E+01
1.01E+01
9.85E+00
9.53E+00
9.48E+00
9.41E+00
8.94E+00
8.92E+00
8.87E+00
7.97E+00
7.60E+00
7.03E+00
6.58E+00
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GSE28735

GSE62452

T Cell Exhaustion Signaling Pathway
CCR5 Signaling in Macrophages
B Cell Development
Interferon Signaling
Communication between Innate and Adaptive Immune Cells
Antigen Presentation Pathway
Pathogenesis of Multiple Sclerosis
Pattern Recognition Receptors in Recognition of Bacteria/ Viruses
Protein Ubiquitination Pathway
Retinoic acid Mediated Apoptosis Signaling
Activation of IRF by Cytosolic Pattern Recognition Receptors
Autoimmune Thyroid Disease Signaling
T Cell Exhaustion Signaling Pathway
Allograft Rejection Signaling
UVA-Induced MAPK Signaling
PD-1, PD-L1 cancer immunotherapy pathway
Natural Killer Cell Signaling
Th1 and Th2 Activation Pathway
Pathogenesis of Multiple Sclerosis
IL-17A Signaling in Gastric Cells
Granulocyte Adhesion and Diapedesis
Agranulocyte Adhesion and Diapedesis
Activation of IRF by Cytosolic Pattern Recognition Receptors
Role of MAPK Signaling in the Pathogenesis of Influenza
IL-17 Signaling
CMP-N-acetylneuraminate Biosynthesis I (Eukaryotes)
Tryptophan Degradation
UVA-Induced MAPK Signaling
NAD biosynthesis II (from tryptophan)
Telomere Extension by Telomerase
Tryptophan Degradation III (Eukaryotic)
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Role of JAK1, JAK2, and TYK2 in Interferon Signaling

5.71E+00
5.63E+00
5.51E+00
1.39E+01
9.35E+00
6.84E+00
6.75E+00
6.25E+00
5.93E+00
5.70E+00
5.58E+00
4.88E+00
4.83E+00
4.79E+00
4.46E+00
4.25E+00
3.97E+00
3.97E+00
6.41E+00
3.08E+00
2.45E+00
2.36E+00
2.28E+00
2.10E+00
2.07E+00
2.07E+00
1.92E+00
1.91E+00
1.63E+00
1.60E+00
1.43E+00
1.39E+00
1.39E+00
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Figure 4.10

Figure 4. 10: Analysis of correlations between genes present in the IPA T-cell Exhaustion
Pathway and CXCR3A or CXCR3A ligands.
Analysis of individual correlations between CXCR3A (red bars), CXCR3A ligands (black bars)
and the genes that comprise the IPA T-cell Exhaustion Pathway. Here, a general trend towards a
stronger association of CXCR3A ligands with the immunosuppressive genes of the pathway can be
appreciated. In contrast, CXCR3A tends to have comparatively stronger correlations with the
general T-cell related genes present in the pathway.
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Chapter 4C.3 Gene Set Enrichment Analysis of CXCR3A and its Ligands
Additionally, a mathematically orthogonal approach in the form of GSEA was
employed to analyze the transcriptomic associations of CXCR3A and its ligands in TCGA
data. As in pathway analysis, GSEA demonstrated enrichment of immune-related gene
signatures for both CXCR3A and CXCR3A ligands (Figure 4.11). Interestingly, B-cell and
NK cell genesets, both positive and negative, were strongly associated with high CXCR3A
expression and were not enriched in CXCR3A ligand high patients (Figure 4.12). Further
analysis demonstrated that immunosuppressive general immune-related (Figure 4.13),
lymphocyte-related (Figure 4.14), and T-cell-related gene sets (Figure 4.15) were more
prevalent in high CXCL9, 10, and 11-expressing patients.

Moreover, these

immunosuppressive gene sets were ranked, in general, much higher among gene sets
associated with CXCR3A ligands compared to those associated with CXCR3. These
findings support the findings of IPA, suggesting that CXCR3A ligands are associated with
immunosuppression in PDAC.
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Figure 4.11
A.

B

Figure 4. 11: Gene Set Enrichment Analysis of TCGA Patients Stratified by CXCR3A and
CXCR3A Ligands
Patients stratified by CXCR3A and CXCL9,10 and 11 expressions, as in survival analysis, were
analyzed for enrichment of gene ontology terms in an unbiased manner. Enriched gene sets for
both stratification schemes center around immunological sets. A) The fraction of immunological
and non-immunological gene sets enriched in TCGA patients B) Distribution of enriched
immunological genes sets across lymphoid, myeloid cell types, and general immune-related gene
sets.
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Figure 4.12

Figure 4. 12: Distribution of Total Enriched Lymphocyte Gene Sets Across the Lymphocyte
Subsets.
Note that CXCR3 shows relatively prominent gene sets for B-cells as well as NK Cells, which are
diminished in the enriched gene sets for CXCR3A ligands.
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Figure 4.13
A.

B.

Figure 4. 13: Analysis of Immunologic Associations of Enriched General Immunological
Gene Sets.
A) Distribution of enriched, general immune gene sets for CXCR3A and CXCL9, 10, and 11 across
pro (positive) and anti-immune response (negative) related pathways. Note that positive-related
gene sets constitute a much larger proportion of the gene sets for both CXCR3A and its ligands.
However, the fraction of positive gene sets is higher for CXCR3. B) Bar plot depicting mean
percentile ranks of positive and negative immune response gene sets, among all enriched GO gene
sets, for CXCR3A and CXCL9,10, 11. Note that CXCR3A related genes are more closely
associated with pro-immune response genesets, while the opposite is true for CXCL9,10 and 11.
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Figure 4.14
A.

B.

Figure 4. 14: Analysis of Immunologic Associations of Enriched Lymphocyte Gene Sets.
A) Distribution of enriched, lymphocyte gene sets for CXCR3A and CXCL9, 10, and 11 across pro
(positive) and anti-immune response (negative)-related pathways. Note that positive-related gene
sets constitute a much larger proportion of the gene sets for both CXCR3A and its ligands.
However, the fraction of positive gene sets is higher for CXCR3. B) Bar plot depicting mean
percentile ranks of positive and negative immune response gene sets, among all enriched GO gene
sets, for CXCR3A and CXCL9,10, 11. Note that CXCR3A related genes are more closely
associated with pro-immune response genesets, while the opposite is true for CXCL9,10 and 11.
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Figure 4.15
A.

B.

Figure 4. 15: Analysis of Immunologic Associations of Enriched T-cell Gene Sets.
A) Distribution of enriched, T-cell gene sets for CXCR3A and CXCL9, 10, and 11 across pro
(positive) and anti-immune response (negative)-related pathways. Note that positive-related gene
sets constitute a much larger proportion of the gene sets for both CXCR3A and its ligands.
However, the fraction of negative gene sets for CXCL9,10 and 11 is twice of that for CXCR3A. B)
Bar plot depicting mean percentile ranks of positive and negative immune response gene sets,
among all enriched GO gene sets, for CXCR3A and CXCL9,10, 11. Note that while CXCR3A
ligands have balanced association strength between positive and negative sets, CXCR3A associates
more closely with pro-immune response genesets.
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Chapter 4C.4 CIBERSORT Analysis of TCGA Patients Stratified by CXCR3A and
its Ligands
We further investigated the role of CXCR3 and its ligands in altering the tumor
immune microenvironment. To do this, we used TCGA data, the LM22 gene set, and
CIBERSORT (an RNA expression deconvolution tool that returns relative quantifications
of immune cell subsets based on empirically-derived, cell-specific, gene signatures).
Within the TCGA dataset, Mθ and M2 macrophages, and CD4+ memory T-cells appeared
to be the most abundant immune cells within the tumor (Figure 4.16). As with the survival
analysis, we stratified patients based on the median expression of CXCR3A and the sum
of CXCR3A ligands and analyzed differences in the immune cell signatures between high
and low expression groups. In all analyses, CD8+ T-cell signatures were elevated in the
high expression group. CXCR3A ligands were associated with a greater number of
significantly changed immune cell gene signatures compared to CXCR3A and specifically
were associated with greatly increased M1 cell gene signature as well as the loss of NKcell gene signatures (Figure 4.17) importantly these changes were largely consistent across
all microarray datasets but not to the same degree of significance (Figure 4.18). For
stratification based on CXCR3A in the entire TCGA dataset, we noted increased CD8+ Tcell and naïve B-Cell signatures and decreased plasma cell gene signatures in high
CXCR3A-expressing patients as compared to the low expressing-group (Figure 4.19).
When samples were stratified based on sample cellularity and CXCR3A expression, as in
survival analysis, the differences in these immune cell subsets were isolated to the patients
with high CXCR3A and low cellularity; that is to say that the comparison of these three
categories remained significant (or became more significant) and in the same direction in
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the low cellularity comparison, but failed to achieve significance in the high cellularity set
of comparisons (Figure 4.19).
Chapter 4C.5 Immunofluorescence Staining of PDAC Resection Samples for CXCR3,
CD8, CD20, and CD138
CIBERSORT analysis demonstrated positive associations of CXCR3 expression
with CD8+ T-cell, and naïve B-cell gene signatures and negative associations with plasma
cell gene signatures. We next used IF for CXCR3, CD8, CD20, and CD138 to test if
CXCR3 protein expression in tissue would correlate with actual changes in the populations
of these immune cells within tumors. Analysis of staining patterns for the four markers in
normal human cerebral cortex and lymph node reveals highly specific staining in which
cerebral cortex (an immune-privileged site) shows minimal or no staining whereas lymph
nodes demonstrate robust staining of compartmentally distinct immune cell populations.
CD20 staining was prevalent throughout the lymph node with more concentrated staining
in germinal centers. CD8 and CD138 were both largely excluded from germinal centers,
and cells expressing these molecules were restricted to cortical spaces intervening between
germinal centers. Figure 4.20 portrays representative images from the staining of negative
controls, positive controls, PDAC-associated lymphoid aggregates, and PDAC tissue.
Importantly in lymph nodes as well as in the PDAC tissues, there was very little co-staining
of cells for CD8, CD20, and CD138, indicating that the staining was identifying three
unique populations of cells as is expected based on classical immunophenotypes of T-cells,
B-cells, and plasma cells.
In analyzing primary PDAC resection samples (n=23), we cataloged the immune
phenotype of each stained cell that was counted. Surprisingly, we saw that the majority of
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cells that were stained and counted were of the immunophenotype of CXCR3+ and CD8+,
with the percentage of this population making up between 50 and 100% of the stained cells
identified in a sample (Figure 4.21). The next most common cellular phenotype was that
of CD138+ single-positive cells, which made up approximately 10% of the cells in the
average sample. Rarer populations of CXCR3+ and CD8+ single-positive populations were
also observed, which made up on average 2 and 5% of the stained cells in a sample (Figure
4.21). Further analysis of CXCR3 expression on murine derived T-cells showed that
CXCR3 is expressed by both CD4+ and CD8+ cells; however, this expression is contingent
upon T-cell activation in both cases. CIBERSORT analyses demonstrated an overall lack
of activated CD4+ T-cells in the PDAC TME, and thus, our finding that the majority of
CXCR3+ cells were also positive for CD8+ is consistent with this observation.
Finally, we performed an analysis similar to that conducted with CIBERSORT
data in which samples were stratified by CXCR3, and the immune cell content in CXCR3high was compared to that in CXCR3-low samples. As an important note, CD20+ cells
were rare within areas containing malignant cells or associated stroma. In contrast, the
vast majority of tumor-associated B-cells were located within lymphoid aggregates, as
indicated by the profound CD20 staining present in these aggregates (Figure 4.20). For
this region, we quantified the total number and lymphoid aggregate area within each
sample rather than quantifying CD20 staining directly. In this analysis, CD8 and CXCR3
were highly correlated both at the field and sample level. And when stratified by median
CXCR3 expression, there was a clear increase in the mean number of CD8+ cells per HPF
(5 vs. 3 cells/HPF, p<0.0001). Similarly, CXCR3-high samples had a significantly greater
number and area of lymphoid aggregates compared to CXCR3-low samples (Figure 4.22,
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p=0.029). Finally, CXCR3-high samples had fewer CD138+ cells than did CXCR3-low
samples, though this difference was not statistically significant (Figure 4.22). Overall,
these data are consistent with those elucidated by CIBERSORT analysis and provide
increased insight due to the fact that these analyses were focused on protein level data and
make every attempt to quantify actual immune cells present in the TME environment.
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Figure 4.16

Figure 4. 16: Heatmap Depicting CIBERSORT Relative Quantification of Immune Cells in
TCGA Data.

Note that Mθ macrophages, M2 macrophages, resting CD4+ memory cells, and CD8+ Tcells appear to be the most prevalent immune cells in the PDAC microenvironment.
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Figure 4.17

Figure 4. 17: Analysis of CIBERSORT Immune Cell Quantification of TCGA Samples
Stratified by CXCL9, 10, and 11.
TCGA patients were stratified by the median value of the linear combination of CXCL9, 10, and
11. Associations with immune cell gene signatures were tested using Mann Whitney U tests.
CXCR3A ligands were positively associated with CD8+ T-cells (Top Left), and M1 macrophages
(Bottom Right). These ligands were also associated with decreased Mθ (Top Right) and NK cell
signatures (Bottom Left). Associations with M1 and NK cells were completely specific to
CXCR3A Ligands.
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Figure 4.18

Figure 4. 18: CIBERSORT Immune Cell Quantification of Microarray Data and Analysis
of Immune Signatures in Patients Stratified by CXCR3 and CXCL9,10 and 11.
Heatmaps that depict the quantification of immune cell gene signatures of CXCR3 and CXCL9,
10, and 11 high- relative to low-expressors. For CXCR3, trends in CD8+ T-cells are consistent
with TCGA in 5/5 microarrays for naïve B-cells in 3/5 microarrays, and plasma cells 2/5
microarrays. For CXCR3A ligands, trends for M1 Macrophages are consistent in 5/5 microarrays,
NK cells in 4/5 microarrays, Mθ in 4/5 microarrays, and CD8+ T-cells in only 1/5 microarrays.
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Figure 4.19
A.

B.

C.

Figure 4. 19: Analysis of CIBERSORT Quantification of Immune Cell Populations with
Respect to CXCR3A and Cellularity.
A) CIBERSORT quantification of immune cell gene signatures in all TCGA PDAC patients
stratified about the median of CXCR3A expression. High CXCR3A expression in the total entire
TCGA cohort is significantly associated with increased CD8+ T-cell and naïve B-cell signatures
and decreased plasma cell signatures. B) Analysis of associations of CXCR3A with immune cell
populations in low cellularity samples shows significant changes in the same direction as were
identified in the entire TCGA cohort. C) Analysis of associations of CXCR3A with immune cell
populations in high cellularity samples shows complete loss of all significant associations with
CXCR3 expression.
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Figure 4.20

Figure 4. 20: Immunofluorescence Staining of Cerebral Cortex, Lymph Node, PDACassociated Lymphoid Aggregates, and PDAC Desmoplasia and Parenchyma with CXCR3,
CD8, CD20, and CD138.
Images show negative staining in cerebral cortex and robust staining for all markers in lymph node.
Interestingly, lymphoid aggregates are, for all intents and purposes, the only CD20+ area associated
with PDAC tissue. Finally, PDAC stroma and parenchyma show interspersed staining with
CXCR3, CD8, and CD138.
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Figure 4.21
A.

B.

Figure 4. 21: Analysis of Immune Cell Populations in PDAC Resection Samples Based on IF
Staining
A) Boxplots depicting the relative distribution of stained cell immunophenotypes in PDAC tissue.
CD8+, CXCR3+ cells were the most prominent immunophenotypes observed in the samples
accounting for 80% of the total stained cells. CD138 single positive cells were also common,
making up approximately 10% of the observed cells. Populations of CD8+ CXCR3- cells and
CXCR3+ CD8- cells were rare but present in the samples. B) Correlation analysis of CXCR3+ cells
and CD8+ cells in each field analyzed for the experiment.
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Figure 4.22
A.

B.

C.

Figure 4. 22: Analysis of IF-based Immune Cell Quantification with Respect to CXCR3
Expression.
A) Analysis of the median number of CD8+ cells per field in CXCR3 high and low samples. MannWhitney U test was used to calculate p-values. CXCR3-high patients have a significantly higher
number of CD8+ T-cells per field. B) Analysis of the median number of CD138+ cells per field in
CXCR3 high and low samples. Mann-Whitney U test was used to calculate p-values. CXCR3high patients have an insignificant reduction in the number of CD138+ cells per field. C) Analysis
of the total area of lymphoid aggregate in samples stratified by CXCR3 expression. Mann-Whitney
U test was used to calculate p-values. CXCR3-high samples have a greater lymphoid aggregate
area than CXCR3-low samples.
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Chapter 4D: Discussion/Conclusions
Survival analyses of PDAC patients stratified by CXCR3A ligands and CXCR3A
in the TCGA dataset had opposite results for ligands and the receptor. High CXCR3A
ligand expression was associated with poor prognosis, while high CXCR3A expression
was associated with improved survival. For CXCR3A, this difference in survival was not
significant in unselected patients, but in low-cellularity patients, the survival difference
was more pronounced. These results correspond to the predominantly stromal expression
of CXCR3 and suggest that immune cells expressing CXCR3 in the microenvironment
may confer a survival benefit. In contrast, in high cellularity patients, in which a larger
contribution of CXCR3 expression is expected to be derived from epithelium, the survival
trend is reversed, however not significantly. Importantly, the results of pathway analysis
and GSEA support this hypothesis. Enriched pathways for CXCR3A were centered around
T-cell function and signaling, thereby supporting the concept that expression of CXCR3A
and its ligands has implications for tumor immunity.

Moreover, analysis of the

transcriptomic associations of CXCR3A compared to its ligands elucidate a potential
underlying rationale for the disparity in outcomes between patients stratified by CXCR3A
expression and patients stratified by CXCR3A ligand expression. Despite the overall
similarity in the pathway enrichment results for CXCR3A and its ligands, there are a few
key differences; only for CXCR3A ligands was there an enrichment in pathways associated
with immunosuppression, namely PD-1/PD-L1 and T-cell exhaustion pathways. These
findings were consistent in GSEA analysis of TCGA data in which CXCL9, 10, and 11 had
a greater proportion of enriched immunosuppressive pathways compared to CXCR3A and
these pathways ranked higher in terms of their association with combined CXCL9, 10, and
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11 expression as compared to immune-promoting pathways and in relation to the
association of immunosuppressive pathways with CXCR3A.
As in pathway analysis, CIBERSORT data from TCGA patients stratified by
CXCR3A and B as well as CXCL9, 10, and 11 showed increases in CD8 T-cell and loss
of Mθ gene signatures in high expression samples relative to low expression samples. In
addition to these changes, high vs. low CXCR3A ligand expression also had numerous
changes, including a loss of resting NK cell signatures and increased M1 signatures in the
high expression group. Notably, these changes were specific to the comparison of high vs.
low CXCR3A ligands and thus may potentially explain the poor overall survival seen in
the high CXCR3A ligand expression group. Indeed, a loss of NK cell signatures is
consistent with the results of GSEA.

Further, the expression of CXCL10 by M1

macrophages was recently shown to be associated with the differentiation of B-cells to
plasma cells and result in an immunosuppressive microenvironment in hepatocellular
carcinoma. Analysis of CIBERSORT signatures based on CXCR3A stratification in high
and low cellularity samples yielded interesting insight. Increased CD8+ T-cell and naïve
B-cell signatures and loss of plasma cell signatures were observed to be significant for high
CXCR3A vs. low CXCR3A in the total TCGA PDAC population and remained significant
only for the same comparison in low cellularity samples. Importantly, these changes were
also shown to be of prognostic significance in a large variety of human cancers as assessed
by both CIBERSORT and via independent methods of immune cell quantification. Finally,
a recent study of immune infiltrates in hepatocellular carcinoma showed that plasma cell
infiltrates were associated with suppressed anti-tumor immune response and more rapid
tumor growth in mice.
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IF of markers of CD8+ T-cells, B-cells, and plasma cells yielded interesting insights
into the potential functions of CXCR3 in the TME. First, we noted a high proportion of
cells that co-stained for CD8 and CXCR3. This finding was surprising and initially thought
to be an artifact caused by unexpected binding of anti-mouse secondary to both CXCR3
and CD8, resulting in an abnormally high percentage of double-positive cells. However,
CD20 is also a murine-derived antibody, and thus, we would expect to see a similar pattern
of staining with CD20+ CXCR3+ double-positive cells if this were the case. Furthermore,
CIBERSORT data indicated that there was an overall lack of activated CD4+ cells present
in the PDAC TME. As a result, we would expect to see the majority of CXCR3 expression
on CD8+ cells. Moreover, these findings are supported by several similar studies in the
literature, which both reported a high percentage of CD8+ T-cells in comparison to CD4+
T-cells [150, 316] —suggesting that these findings are reproducible outside of our specific
staining procedure. Overall, these findings suggest that CXCR3+ CD8+ cells may be a
major contributor to the anti-tumor immune response in PDAC, despite the fact that
CXCR3 is classically expressed on CD4+ cells and that the CD8+ CXCR3+ population of
cells is comparatively minor in other settings. Second, the findings of IF staining show an
identical trend in immune cell populations in comparison to CXCR3 high and low samples
as those indicated by CIBERSORT analysis.

Moreover, IF findings extend upon

CIBERSORT data by first providing some information at the level of immune cells and
second, indicating that the associations of CXCR3 and CD8 are likely directly linked,
whereas the associations with plasma cells and B-cells are likely indirect and associated
with pleiotropic changes associated with CXCR3 expression in the TME.
Two studies on CXCR3 in PDAC precede our own. A single report from Lunardi
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and colleagues found in vitro that CXCL10 expression was induced by the co-culture of
PDAC cells with pancreatic stellate cells and that in this culture system, CXCL10 was
largely derived from PSC cells. Our analysis of RNA-Seq data from 123 microdissected
PDAC samples confirms a stromal origin of CXCL10 in samples derived from human
tumors [208]. Lunardi et al. further used data from a single array on 45 patients with eight
normal controls to show that when 19 of the tumor samples were compared to 15 normal
samples, CXCL10 was overexpressed by 2.18-fold and that high CXCL10 expression was
associated with poor prognosis [208]. The results from our study in a much larger number
of patients support these findings to a large degree, with the addition that CXCL9 is also
highly overexpressed in the majority of PDAC samples. Finally, this study reported the
correlations of the expression of several immune cell marker genes with CXCL10 and
CXCR3 expression in 34 or 32 of 48 tumor samples depending upon the gene. The authors
noted that FOXP3, CTLA4, and CD39 were highly correlated with CXCL10 and CXCR3
expression [208]. While these highly positive correlations were present in our own
analyses, they played minor roles in the more robust pathway and CIBERSORT analyses.
Additionally, their expression does not realistically represent a quantification T regulatory
cells in RNA-Seq or microarray data as it does in other techniques where co-expression of
these molecules on a single cell can be ascertained. Moreover, the lack of consistency in
the description of this dataset and usage of samples for analyses cast substantial doubt
regarding the validity of these findings.
The second paper by Quemener et al. reported that PF4V1 expression was higher
than that of PF4 in PDAC samples based on the comparison of qRT-PCR data of PF4V1
and PF4 expression in the 6 (of 33 total samples) with the highest PF4V1 expression [291].
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The results we obtained from multiple large-scale gene expression datasets differed
substantially from this report but were consistent across the microarray and RNA-Seq
platforms used, providing strong evidence that the expression of PF4 is greater than that of
PF4V1 in PDAC.

Our results suggest that the functional consequences of PF4V1

expression in PDAC may be limited in a broad pool of patients due to its low expression
in the vast majority of samples. This limitation may be further enhanced by the relatively
high expressions of PF4, which binds CXCR3B with greater affinity than PF4V1, and
CXCL9, 10, and 11, all of which bind CXCR3A with greater affinity than PF4V1.
Overall, these analyses strongly suggested that CXCL9 and 10 are among the most
highly and consistently overexpressed cytokines in PDAC and that the expression of these
cytokines is associated with poor outcomes in PDAC patients, potentially resultant of
modulation of the immune microenvironment and exhaustion of T-cells. Furthermore,
CXCR3, the receptor for these two ligands, while not overexpressed in PDAC at the mRNA
level, is expressed robustly at mRNA and protein levels. Interestingly CXCR3 expression
is associated with improved outcomes, and while there is some commonality in the
pathways correlated with CXCR3 and CXCR3 ligand expression, there are associations
specific to each which provide insight into the underlying basis for opposite associations
with survival outcomes.
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Chapter 5: Analysis of Putative Roles of CXCR3B Axis in
PDAC Metastasis
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Chapter 5A: Introduction
In the preceding chapter, a comparative cytokine expression array conducted in the
aggressive KPC and indolent KC models of PDAC demonstrated overexpression of
CXCL10 and CXCL4 in the KPC model relative to WT littermates and KC. The remainder
of the previous chapter focused on CXCR3A and its ligands in the modulation of the
immune response as guided by analyses of large publicly available transcriptomic datasets.
Expression of CXCL4 in the aggressive murine model suggested that CXCL4 signaling
may also be associated with more aggressive disease, at least in PDAC. This is in sharp
contrast to numerous reports in the literature that support a generally tumor-suppressive
effect of CXCR3B/CXCL4 signaling (Chapter 3). Despite the abundance of literature
contradicting our findings, there are substantial gaps regarding the functions of CXCR3.
Most notably, the studies of CXCR3 in metastasis have focused on the effects of the
signaling axis on invasion and migration and angiogenesis or later events after the initial
colonization of the metastatic site. For CXCR3B, these gaps are considerably larger, as
most studies have focused on CXCR3 in general or CXCR3A. Moreover, when CXCR3B
was studied outside of this context, it was found to be associated with the promotion of
stemness in breast cancer cells and increased metastasis in a tail vein injection model,
suggesting that CXCR3B may a have a metastasis-promoting role [230, 240]. Moreover,
these findings suggest that studies of metastasis conducted with murine cell lines cannot
categorically be considered to model the functions of CXCR3A, as CXCR3 in mice appears
to mediate the functions of both human splice variants depending on the context. Similarly,
observations from studies using human cell lines which do not specifically delineate the
contribution of the CXCR3 splice variants either through use of specific ligands (such as
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CXCL9, CXCL11 or CXCL4) or modulation of expression of one of the splice variants
cannot, with confidence, be concluded to occur downstream of CXCR3A or B.
Regardless of the gaps in the current understanding of CXCR3B function, the
metastasis-related literature clearly supports that PF4 and/or CXCR3B have anti-metastatic
activities in both the primary tumor as well as in established metastatic lesions indicating
that at best there is a balance between pro- and anti-metastatic features. Notably, the context
in which the PF4/CXCR3B axis is expressed and active can shift this balance. Not
surprisingly, platelets are the major source of PF4 under physiologic conditions. Moreover,
metastasizing cancer cells have been shown to interact directly with platelets in
metastasizing cancer cells in murine models [317-320]. Importantly, depletion of platelets
in mouse models decreased the ability of cancer cells to colonize the lungs in tail-vein
injections carried out over a short time period [318-320]. Underlying these changes in the
metastatic ability of cancer cells, are changes in the ability of cancer cells to survive in low
attachment conditions [318-320] as well as the recruitment of myeloid-derived immune
cells to the ultimate site of metastasis [319, 320]. Based on these findings as well as the
results from our cytokine array, we hypothesized that CXCL4 signaling through CXCR3B
promotes the intravascular phase of PDAC metastasis. This chapter reports data gathered
from the analysis of transcriptomic data from matched circulating tumor cells (CTCs),
primary tumor samples, and hematological cells and TCGA to determine underlying
molecular associations present in metastasizing cancer cells and CXCL4 expression
respectively. These bioinformatic approaches are coupled with in vitro studies focused on
parsing the role of platelets and PF4 and CXCR3B in low attachment survival, resistance
to fluid shear stress, and cholesterol biosynthesis as well as in vivo tail-vein injection
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models of PDAC metastasis.
Chapter 5B: Methods and Materials
Chapter 5B.1 Analysis of Matched PDAC CTC, primary tumor and granulocyte
samples
Data from human PDAC microarray dataset, GSE18670 [202], were obtained
through NCBI Gene expression omnibus. This dataset consists of six patients with four
different sample types taken from each patient. These samples include adjacent normal
tissue, primary tumor tissue, circulating CD45-positive or CD34-positive cells representing
an immune cell population, and circulating CD45-negative and CD34-negative cells
representing CTCs. The staining procedure was validated by spiking blood samples with
PANC-1 PDAC cells followed by cell sorting and staining for pre-Cytokeratin 8; results
show a highly purified CK8-positive cell population following removal of CD45-positive
and CD34-positive cells. Microarray data was RMA normalized, as described in previous
chapters. Normalized data for primary tumor and CTC samples was analyzed using GSEA
with differential gene expression being determined by t-tests.
Subsequently, differential gene expression between immune cell fractions, CTC
cells, and circulating immune cells was analyzed by ANOVA followed by individual
pairwise comparisons using a paired t-test. Genes that were significantly overexpressed in
CTCs relative to both primary tumor and circulating granulocytes were passed to IPA for
analysis of associations with specific pathways.
Chapter 5B.2 Cytokine Array and Kaplan-Meier Survival Analysis
The murine differential cytokine array was conducted as described in Chapters 2
and 4. Briefly histologically matched KC, KPC tumors, and pancreata from corresponding
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age-matched WT littermates were isolated (n=6), and RNA was isolated and pooled,
followed by qRT-PCR cytokine array according to manufacturer instructions. Data were
analyzed on the Qiagen webserver allowing inference of differentially expressed cytokines
between WT pancreata and the KC and KPC tumor models. Subsequently, relative
expression levels in KC and KPC tumors were compared to each other to allow the
determination of differential upregulation of cytokines in the two models.
Kaplan-Meier survival analysis was performed in the selected TCGA data
described in Chapter 4. For this analysis, patients were stratified independently by
CXCR3B, PF4, and PF4V1 expression. Kaplan-Meier analysis was performed for each
stratification scheme, and Wilcoxon and log-rank p-values were calculated for each
comparison (α =0.05). Importantly, several levels of stratification were performed in
succession. First, samples were stratified by median target gene expression. If this
comparison was not significant, they were again stratified by the upper quartile of
expression and compared to the bottom 75%, 50%, and 25%. In the case of PF4V1, none
of these comparisons were significant, and patients were again stratified by PF4V1
expression; this time, the bottom quartile of expressors were compared to the upper 75%,
and 50%. No significant comparison for PF4V1 was found.
Chapter 5B.3 Tail Vein-Injection Model of Metastasis
Two different tail vein-injection experiments were carried out in the studies
reported here. In the first, syngeneic, GFP-positive FC1245 cells, derived from a C57BL/6
KPC model of PDAC, were treated in vitro with the CXCR3 inhibitor AMG487 (100uM)
or vehicle control for 12 hours prior to injection. Three hours prior to injection, 6 to 8week-old recipient C57BL/6 mice received an intraperitoneal injection of 100 ul of 2 mM
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AMG487 or corresponding vehicle control. Mice that had received AMG487 injections
were injected with 300,000 FC1245 cells that had also been treated with AMG487 (n=10),
and mice who received vehicle control were injected with 300,000 vehicle control-treated
FC1245 cells (n=10). At the time of injection, roughly 100 ul of whole blood was collected
from each mouse via jugular vein puncture. Collected blood was spun down washed once,
and red blood cells were lysed. Cells were fixed in 4% paraformaldehyde (PFA). Mice
were sacrificed at 12 hours after which blood, via cardiac puncture, and lungs, via en bloc
resection, were collected. Twelve-hour blood was processed as 0-hour blood. Lung tissue
was split with half of the lung being fixed in 10% buffered formalin followed by sectioning
for IHC staining of GFP, while the remaining tissue was processed into small pieces and
digested to produce a single cell suspension of cells retained in the lung. The suspension
of lung cells was washed, passed through a single cell filter, and fixed in 4% PFA. All flow
cytometry samples were refrigerated until analysis (conducted on the same day as mouse
sacrifice). Quantification of tumor cells was carried out, and one sample was excluded from
the data set based on a Dixon Q value of 0.1. Included samples from the treatment and
control groups were compared using a 1-way Mann-Whitney U test. Fixed lung tissue was
embedded in paraffin and sectioned to 5-micron thickness and stained for GFP (1:200).
The second model was procedurally identical to the first with four exceptions: 1) MiaPaCa2 cells with and without mini-MUC4 expression was utilized as the cell line, 2) MiaPaCa2 cells were stained with CFSE just prior to injection as the mechanism of tracking, 3) nude
mice n=10 for each group were used to accommodate the use of a human cell line, and 4)
IHC specimens were stained with anti-human MUC4 antibody (8G7 1:200).
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Chapter 5B.4 Low Attachment Survival Assay
T3M4 and were stripped non-enzymatically from tissue culture plates, counted and
seeded in HEMA-3 coated 24-well plates (150,000 cells per well) in DMEM with 10%
fetal bovine serum (FBS), 1.5% methylcellulose. Immediately following plating, cells
were treated with vehicle control, AMG487, activated platelets, or both activated platelets
and AMG487. Cells were incubated with treatment for 8 hours, followed by dilution of
media and plating of half of the diluted culture volume in standard 6-well plates with two
additional mL of DMEM with 10% fetal bovine serum. Twelve hours after the removal
from low attachment plates, the medium was aspirated and replaced with an additional 2
mL of DMEM with 10% FBS. Cells were cultured for an additional 60 hours and before
the cells were fixed in methanol and stained with crystal violet. Stained plates were
scanned, and stained area was quantified using Image J. Quantification of the stained area
was normalized to that of control and analyzed using ANOVA followed by Student’s ttest. An identical assay was used to determine the effects of MUC4 expression on low
attachment survival with and without platelet treatment with one exception: surviving cells
were quantified using MTT assay rather than colony formation assay.
Chapter 5B.5 Endothelial Adhesion Assay
Two days prior to conducting the assay, 30,000 HMEC endothelial cells were
trypsinized and plated in the black-side, clear-bottom, 96-well plates and grown to 100%
confluence at the time of assay. Two days prior to the assay, 500,000 thousand T3M4 cells
were plated in 6-well plates. T3M4 were treated for 24 hours with vehicle control, 100 uM
AMG487, 1000 ng/mL of recombinant PF4, or PF4 and AMG487. After 24 hours of
treatment, T3M4 were stripped from tissue culture plates non-enzymatically labeled with
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CSFE and counted. Cancer cells (50,000) were seeded atop a confluent endothelial
monolayer and incubated for 1 hour. After 1 hour, a baseline reading of the plate was
taken, and the medium and unbound cells were removed. The plate was washed three times
and reread to quantify the number of bound cells. Post-wash reading fluorescence was
normalized to pre-wash reading values and analyzed via ANOVA and Student’s t-tests.
Chapter 5B.6 Western Blotting
Five hundred thousand CD18 cells were plated in 6-well plates and treated with the
indicated treatments for the given time period. Cells were harvested in 200 µL of RIPA
buffer. Protein lysates were quantified, and 40 µg of protein was prepared for large mucin
gels, and 20 µg was prepared for mini gels. Gels were run and transferred to PVDF
membranes. Membranes were blocked in 5% milk for 1 hour, incubated with primary
antibody (1:1000 for 8G7, CA125, EGFR and MUC1, 1:2000 for beta-actin) overnight at
4ºC.

Membranes were washed three times.

Goat anti-mouse and goat anti-rabbit

secondary antibodies (1:4000 dilution) were incubated on blots for 1 hour at room
temperature, followed by an additional three washes. Blots were developed in ECL on
autoradiography film.
Chapter 5B.7 TCGA and Ingenuity Pathway Analysis
The expression of PF4 and CXCR3B were correlated with the human transcriptome
in the TCGA PDAC dataset and microarray datasets as they were initially described in
chapter 2. Genes correlating with CXCR3B or PF4 with a p-value of 0.0001 or less were
divided into positive and negative associations and passed to IPA for analysis. The top
pathways were included for further analysis.
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Chapter 5B.8 Cholesterol Assay
CD18, SW1990, or Hela (transfected with empty vector, CXCR3A, or CXCR3B
overexpression constructs) were plated in clear-bottom, black-wall, 96-well plates at 3000
cells per well and serum starved for 24 hours. Cells were treated for 12 hours with 500
ng/mL of PF4 or vehicle control. After twelve hours of treatment, cells were stained with
filipin III according to manufacturer instructions (Abcam ab133116), and staining was
quantified using a plate reader reading with excitation at 375 and emission at 410 nm of
light.
Chapter 5B.9 Fluid Shear Stress Resistance Assay
Two million CD18 or Hela cells (transfected with empty vector, or CXCR3B
overexpression constructs) were seeded in 10 cm dishes. Cells were treated with 500
µg/mL of PF4 or vehicle control for 12 hours. Cells were non-enzymatically detached
from plates, counted, and resuspended to 8 mL of 1x106 cells per mL concentration. Two
hundred uL of cell suspension were collected prior to exposure to shear stress, and 100 µL
was immediately put on ice while the other 100 µL was kept at room temperature to serve
as a low attachment control. The remaining cell suspension was forced through a 27 ga,
3.17 cm long syringe needle for a total of 10 times at a rate of 300 mL per hour. Following
shear stress exposure, cells were either stained for CXCR3 or Flag tag (in overexpression
constructs) and quantified via flow cytometry or plated for MTT [321].
Chapter 5C: Results
Chapter 5C.1 Analysis of Matched PDAC CTC, primary tumor and granulocyte
samples
Despite the limited number of samples in this dataset analysis of differentially
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expressed genes between paired primary PDAC tumor and CTCs using GSEA showed
enrichment in platelet related pathways. Of the top ten pathways, four were related to
platelet gene expression (Figure 5.1). This represents some of the first evidence from
human samples that platelets interact with cancer cells during the process of hematogenous
metastasis. While this observation confirmed a key component of our hypothesis regarding
the functions of PF4 in metastasis, it obscured some of the signaling within these cancer
cells. To minimize the confounding effect of platelet gene signatures, we analyzed genes
that were differentially expressed between CTCs and primary tumors, as well as CTCs and
circulating immune cell samples. Genes that were significantly upregulated in CTCs in
comparison to both primary tumor and immune cells were passed to IPA. The top pathways
returned from this analysis were surprising; each of the top pathways was related to Gprotein-coupled receptors, and specifically Gαs-mediated signaling, thereby further
supporting a function of CXCR3B/PF4 in the intravascular phase of metastasis. (Figure
5.2).
Chapter 5C.2 Cytokine Array and Kaplan-Meier Survival Analysis
In Chapter 4, we reported a differential cytokine array in KPC and KC PDAC
models. Here PF4 was among the most highly overexpressed cytokines in the KPC model
relative to the KC model. Consistently, Kaplan-Meier survival analysis in patients stratified
by very high expression of PF4 (greater than the 25th percentile compared to the lower
75%) showed that high CXCL4 expression was associated with worse prognosis in TCGA
PDAC patients (Figure 5.3). Interestingly, patients stratified by median CXCR3B
expression had improved overall survival indicating a similar paradox, as was seen with
the analysis of CXCR3A and its ligands (Figure 5.3). Furthermore, the analysis of
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CXCR3B and CXCL4 in relation to patient stage at diagnosis revealed a slight association
of CXCL4 with M1 metastatic stage (Figure 5.4).
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Figure 5.1

Figure 5. 1: Gene Set Enrichment Analysis of Differentially Expressed Genes Between
Circulating PDAC cells and Primary Tumor
GSEA revealed that genes overexpressed in circulating PDAC cells compared to primary tumors
relate to platelet function indicating physical interaction of platelets with CTCs. Four of the top 10
genes sets in this analysis related to platelet function.
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Figure 5.2

Figure 5. 2: Pathway Analysis of Genes Uniquely Upregulated in Circulating PDAC Cells
Compared to Leukocyte and Primary Tumor Samples.
Pathway analysis of genes overexpressed in CTCs compared to both leukocyte and primary tumor
samples indicate that GPCR related genes and Gαs-mediated signaling are strongly associated with
CTCs, further supporting a role of CXCR3B and PF4 in metastasis.
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Figure 5.3
A.

B.

C.

Figure 5. 3: Kaplan-Meier Survival Analysis of TCGA PDAC Patients Stratified by PF4,
PFV1, and CXCR3B.
A) Survival analysis of TCGA patients stratified by expression of PF4 (75th percentile and higher
vs. 50th percentile and lower). Results indicate that high PF4 expression is associated with
aggressive disease consistent with data from the cytokine array in murine tissue. B) Survival
analysis of PF4V1 in TCGA data stratified as in Figure 5.3A; PF4V1 has no association with OS
in the TCGA data. C) Survival analysis of TCGA patients stratified by median CXCR3B
expression. CXCR3B is associated with improved OS in TCGA data.
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Figure 5.4
A.

B.

C.

Figure 5. 4: Analysis of the Association of PF4 with TNM Stage in TCGA PDAC Patients
A) Expression of PF4 in PDAC samples grouped by T stage at diagnosis. B) Expression of PF4
in samples grouped by N stage at diagnosis. C) PF4 expression in samples grouped by M stage at
diagnosis. No association was significant; however, PF4 had a trend toward higher expression in
patients with metastases at diagnosis.
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Chapter 5C.3 Tail Vein-Injection Models of Metastasis With and Without Inhibition
of CXCR3
We sought to establish a role for PF4/CXCR3 in an experimental model of
metastasis. To do this, we used a small molecule inhibitor of CXCR3 to suppress CXCR3
signaling in a syngeneic model of PDAC metastasis.

Blood collected from mice

immediately after injection of cancer did not show any difference in the number of GFPlabeled cancer cells, indicating that equal numbers of cells were injected in both AMG487
and vehicle control groups. In contrast, at 12 hours, collected blood demonstrated a trend
towards a decreased number of cells in the blood of AMG487-treated cells. Finally, and
most importantly, in the lungs at 12 hours, there was a statistically significant decrease in
the number of cancer cells present in the lungs in the AMG487 treatment group compared
to vehicle control (Figure 5.5). These flow cytometry studies were confirmed upon IHC
staining of lung tissue for GFP.
Chapter 5C.4

Role of CXCR3 in the Effect of Platelets on Cancer Cell Survival in

Low Attachment Conditions, Endothelial Adhesion, and Mucin Expression
To dissect the differences in metastasis observed in the tail vein-injection model,
several in vitro analogues of processes relevant to metastasis were investigated. In low
attachment survival studies, platelets increased the survival of T3M4 cells by
approximately 50% within 8 hours of low attachment culture (p<0.05).

Critically,

inhibition of CXCR3 with AMG487 suppressed the ability of platelets to increase the
ability of cancer cells to survive low attachment conditions (p<0.05) (Figure 5.6).
Additionally, treatment of T3M4 cells with recombinant PF4 increased the ability of these
cells to adhere to an endothelial monolayer; this effect was also inhibited by treatment with
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AMG487 (Figure 5.7). Further investigation of the molecular mechanisms associated with
these changes, examined the ability of PF4 to regulate the mucin expression. In CD18
cells, treatment with PF4 increased the expression of MUC1, MUC4, and MUC16 within
hours of treatment initiation (Figure 5.8A). Additionally, the human PDAC samples
MUC4 and CXCR3 were observed to be co-expressed in cancer cells (Figure 5.8B).
Further analysis of the mechanism of mucin regulation showed that PF4-mediated
increases in MUC4 expression were suppressed to the greatest extent by concomitant
treatment with microtubule inhibitor vinblastine (Figure 5.8C).

Interestingly, the

expression of mini-MUC4 in MiaPaCa-2 did not increase the ability of cancer cells to
survive in low attachment conditions; however, it was required to potentiate the effect of
platelets on low attachment survival (Figure 5.9). This finding suggests that MUC4 is not
critical downstream of PF4 activation of CXCR3B and subsequently increases low
attachment survival but was perhaps upstream of it.
Chapter 5C.5 Role of MUC4 in a PDAC Tail Vein-Injection Model of Metastasis
The role of PF4/CXCR3B signaling in regulating mucin expression suggested that
there was a potential role in the metastatic process of PDAC. To test this in vivo, we used
MiaPaCa2 cells expressing vector control or mini-MUC4 in tail vein injections (Figure
5.10). In blood samples collected immediately after injection, there were roughly equal
amounts of cancer cells found in the blood. At 12 hours, there were significantly increased
numbers of mini-MUC4-expressing cancer cells in the blood. In the lungs, independent
overexpression of mini-MUC4 in this setting drastically increased the number of labeled
cancer cells present in the lung 12 hours after injection. These results were confirmed
using IHC for human MUC 4 in the lungs of mice.
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Figure 5.5
A.

C.

B.

D.

Figure 5. 5: Effect of CXCR3 inhibition on the Retention of PDAC cells in a Tail VeinInjection Model of Metastasis.
A) Flow cytometric analysis of GFP-labeled FC1245 PDAC cells in the blood immediately after
injection demonstrates no significant differences in the percentage of cells observed, indicating that
an equal number of cells were injected. B) Analysis of GFP-labeled cancer cells in the blood 12
hours after injection shows a trend towards fewer cells in the blood in the AMG487-treated group.
C&D) Flow cytometric and IHC analysis of GFP-labeled cancer cells in the lungs demonstrates a
significant decrease in the number of cells retained in the AMG487 group.
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Figure 5.6

Figure 5. 6: Effect of Platelets with and without CXCR3 Inhibitor AMG487 on Low
Attachment Survival of PDAC Sells
Treatment of T3M4 PDAC cell line with platelets augments the ability of the cells to survive in
low attachment conditions at the 8-hour time point. Treatment of T3M4 with platelets and CXCR3
inhibitor AMG487 suppresses the ability of platelets to augment cancer cell survival, suggesting
that CXCR3 and PF4 play critical roles in this interaction.
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Figure 5.7.

Figure 5. 7: Effect of PF4 Treatment on PDAC Cell Endothelial Adhesion.
Treatment of T3M4 cells with PF4 for 24 hours prior to seeding them on top of a confluent
endothelial monolayer increased the adhesion of the cancer cells to the top of the endothelial cells.
This effect was inhibited by AMG487, thereby demonstrating the dependence on CXCR3. These
findings suggest that PF4/CXCR3B may be involved in the initiation of extravasation.
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Figure 5.8
A.

B.

C.

Figure 5. 8: Effect of PF4 Treatment on Mucin Expression in PDAC Cells.
A) Treatment of PDAC cell line CD18 with 500 ng/mL PF4 caused rapid upregulation of MUC4,
16, and to a lesser extent, MUC1. B) IF analysis of human PDAC tissue shows co-expression of
MUC4 and CXCR3 indicating that PF4 can potentially act on this cell population. C) Treatment
of CD18 cells with or without PF4 and Control (Con) Actinomycin D (D), Cycloheximide (CHX),
MG132 (132), and Vinblastine (Vin) demonstrates that PF4 mediated upregulation of MUC4 is
phenocopied most effectively by treatment with Vinblastine, suggesting that post-translational
regulation is a key mechanism.
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Figure 5.9

Figure 5. 9: Analysis of the Effect of MUC4 Expression on Low Attachment Survival in the
Presence or Absence of Platelets
MiaPaCa-2 cells expressing either vector control (VC) or mini-MUC4 (MM4) were seeded in low
attachment dishes with and without platelets. MM4 expressing cells by themselves did not
survive low attachment conditions better than VC cells (data not shown). However, MM4
expression combined with platelets increased the relative survival of cells and reversed the effect
of platelets observed in the VC cells.
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Figure 5.10
A.

B.

Figure 5. 10: Effect of MUC4 Expression on Cell Retention in the Lung Following Tail Vein
Injection.
A) Western blot validation of MiaPaCa-2 Cells with and without MUC4 overexpression. B)
Boxplot showing the detection of CSFE-labeled MiaPaCa2 cells in the lungs 12 hours after
injection of cells. MM4 greatly enhances the ability of MiaPaCa-2 cells to be retained in the
lung, suggesting that MUC4 upregulation may be an important mechanism by which it augments
metastasis. Note that only data for the lungs is shown; however, there was no difference in the
number of cells in the blood immediately following injection.
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Chapter 5C.6 The Role of PF4/CXCR3B signaling in Cholesterol Biosynthesis.
To further and more broadly investigate the function of PF4 and CXCR3B in
PDAC, we analyzed the correlations of CXCR3B and PF4 with all other genes in the
human transcriptome in the PDAC TCGA dataset. All genes that correlated with target
genes with a p-value of less than 0.0001 were further analyzed using IPA. Pathway
analysis revealed strong enrichment of cholesterol biosynthetic pathways among the top
hits for PF4 (Figure 5.11). The pathways enriched for CXCR3B were very similar to those
enriched for CXCR3A, which may be the result of the strong correlation between the splice
variants (Figure 5.11). Analysis of cholesterol biosynthesis genes in microarray datasets
confirmed these findings with many of the gene sets demonstrating positive associations
between PF4 and these genes in most datasets (Figure 5.12). To test this in vitro, CD18,
and SW1990 cells were treated with recombinant PF4 in serum-free conditions, and the
cellular cholesterol content was measured (Figure 5.13). Here PF4 increased the cellular
cholesterol content by a modest 5%, possibly due to the small percentage of cells that
express CXCR3B. In Hela cells, which do not natively express CXCR3, transfected with
CXCR3A, CXCR3B, or vector control expression vectors, PF4 treatment increased cellular
cholesterol content by over 20% whereas transfection with CXCR3A suppressed cellular
cholesterol content independent of treatment with ligands (Figure 5.13).

Functional

investigation focused on the ability of cancer cells to resist fluid shear stress based on the
ability of cholesterol to modulate cellular membrane dynamics. When CD18 cells were
treated with PF4 and exposed to shear stress, flow cytometry revealed a PF4-dependent
enrichment in CXCR3+ cells compared to cells not exposed to shear stress. Similar studies
in Hela cells transfected with CXCR3B and treated with PF4 showed the dependence of
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CXCR3+ cell enrichment on CXCR3B expression as well as PF4 treatment (Figure 5.14).
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Figure 5.11
A.

B.

Figure 5. 11: Pathway Analysis of Genes Highly Correlated with PF4 or CXCR3B
A) PF4 expression was correlated with each gene represented in the TCGA PDAC dataset. Genes
with strong associations (p<0.0001) were furthered analyzed using IPA. IPA identified that genes
correlated with PF4 had functional relation to cholesterol and steroid biosynthesis. B)Analysis of
CXCR3B, as in ‘A’, demonstrated enrichment of genes associated with T-cell functions, which
may be a function of the strong correlation between CXCR3A and B.
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Figure 5.12

Figure 5. 12: Analysis of Correlations Between PF4 and Genes Directly Involved in Cholesterol Biosynthesis

Rho is plotted along the Y-axis; red boxes denote genes positively correlated with PF4 in all datasets tested. Asterisks denote
significant correlation (p<0.05) .
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Figure 5.13
A.

B.

Figure 5. 13: Effect of PF4 Treatment on Cellular Cholesterol Content.
A) CD18 and SW1990 were treated with PF4 (500 ng/mL) for 12 hours in serum-free conditions.
Following treatment, cellular cholesterol was measured. PF4 treatment resulted in a modest but
significant increase in cellular cholesterol. B) Hela cells were transfected with empty vector,
CXCR3A or CXCR3B overexpression constructs, 36 hours after transfection, cells were treated
with PF4 as in ‘A’. CXCR3B transfected cells treated with PF4 had a 20% increase in cellular
cholesterol content.
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Figure 5.14
A.

B.

Figure 5. 14: Fluid Shear Stress Enriches the CXCR3+ Population of Cancer Cells in a PF4
Dependent Manner.

A. CD18 Cell treated with PF4 or vehicle for 12 hours prior to exposure to fluid shear
stress. Fluid shear stress increased the CXCR3+ population of CD18 cells; in the presence
of PF4, the enrichment is 3-fold greater than in the absence. B). Hela cells were transfected
with an empty vector or CXCR3B overexpression construct. These cells were treated with
and PF4 or vehicle control and subsequently exposed to fluid shear stress. Fluid shear
stress did not enrich vector control cells expressing flag-tag with or without PF4, nor did it
enrich Hela cells transfected with CXCR3B-transfected cells in the absence of PF4.
However, in the presence of PF4, CXCR3B-transfected cells were enriched when exposed
to fluid shear stress.
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Chapter 5D: Conclusions
This chapter presents data regarding the function of CXCR3B/PF4 during the
intravascular phase of PDAC metastasis. We hypothesized that platelet-derived PF4 would
be a critical source of the cytokine during this phase of metastasis. Consistent with this
hypothesis, microarray data of paired primary tumor and CTCs derived from PDAC
patients showed that the top enriched gene sets in CTC samples were strongly related to
platelets and platelet function. Furthermore, when the signature of platelets was removed
to the extent possible by selecting only genes that were significantly upregulated in CTCs
compared to primary tumors and circulating immune cells, the top pathways returned
showed a prominent role for Gαs signaling, which again supports our hypothesis. As
reported in previous chapters, PF4 was specifically overexpressed in KPC mice (the more
aggressive model).

These findings were confirmed by Kaplan-Meier analysis,

demonstrating significantly worse survival in patients with very high PF4 expression.
Cumulatively, these findings indeed suggested that PF4 may be associated with a more
aggressive phenotype in PDAC.
To test if PF4 promotes metastasis in PDAC experimentally, we employed a tail
vein-injection model of PDAC metastasis in immunocompetent mice. Here inhibition of
CXCR3 with AMG487 was able to suppress the number of cells present in the lungs after
12 hours. This short time frame is critical; it is long enough for cells to find their final
destination without being so long as to allow cell proliferation or formation of secondary
metastatic sites or to require angiogenesis.

While each of these aspects represents

important functions of CXCR3 and PF4, the additional influence of these processes would
obscure data specifically regarding the intravascular phase of metastasis. This serves as a
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key distinction between the present studies and those reported in the literature, which have
allowed much longer periods following cell injections. Importantly, it is clear that when
active within the primary tumor or at the metastatic site, signaling downstream of PF4
suppresses tumor growth and metastatic dissemination. However, the extent to which the
PF4/CXCR3 axis is active in these specific sites is not clear. In contrast, metastasizing
cancer cells in circulation interact with and activate large numbers of platelets such that
this becomes a major contributor to the differential gene expression between primary
tumors and CTCs. Because of this, it is at least clear that there is a tremendous impetus for
CXCR3 activation through PF4 during the intravascular phase of metastasis. It is arguable
that this spatial difference in the activation of PF4 may play a more prominent role in the
effect of PF4 and CXCR3 on metastasis than the comparatively minimal level of activation
present in the primary tumor and established metastatic site. Previous studies of CXCR3
in similar contexts, however, force extremely high expression of PF4 either in the primary
tumor or in the metastatic site. Thus, the potential effects of CXCR3B and PF4 in these
sites may be exaggerated, resulting in findings that suggest PF4 suppresses metastasis
overall.
Several potential mechanisms by which PF4 and CXCR3B signaling may promote
the ability of cancer cells to surmount the challenges of the intravascular phase were
investigated. We noted significant differences in the abilities of PF4-treated cancer cells
to survive in low attachment conditions, adhere to an endothelial monolayer, and resist
shear stress-induced cell death.

With respect to low attachment survival, this was

demonstrated to be dependent, in part, on CXCR3 as inhibition of CXCR3 suppressed the
effect of platelets on low attachment survival. Interestingly we were unable to show that
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recombinant PF4 or platelet supernatant in the absence of cellular membranes were capable
of producing any difference in terms of the ability to improve survival of cancer cells in
low attachment conditions (data not shown). Importantly, this has been observed
previously [317]. Despite this fact, both our studies and the study by Labelle et al. [317]
were able to demonstrate roles for specific platelet-secreted factors. Together, these
findings suggest that the role of platelets in the survival of cancer cells in low attachment
conditions is complex and requires multiple platelet-derived signals, including PF4.
Likewise, we were unable to show that heat inactivation of activated platelets was able to
attenuate the effect of platelets on cancer cell low attachment survival. This finding is
remarkably consistent both with the complex mechanism by which platelets are suspected
to promote low attachment survival but also with the physical property of PF4 of being
heat stable. Finally, we did not find evidence that PF4-mediated upregulation of MUC4
contributed to this phenotype as MUC4 expression in MiaPaCa-2 cells did not result in
increased low attachment survival. In contrast, the expression of mucin in these cells was
required for platelets to mediate an increase in cancer cell survival. This finding is in
accord with previous literature demonstrating that mucins are critical mediators of the
interaction of cancer cells with platelets and an underlying reason for the observed decrease
in metastatic frequency in patients taking heparin [322]. A promising alternative hypothesis
for the molecular mechanism mediating increased low attachment survival in cancer cells
is that PF4 activates p21, which suppresses cell cycle and also the initiation of apoptotic
pathways [323] including anoikis.
Increased ability of cancer cells to adhere to an endothelial monolayer was also
observed following treatment with recombinant PF4, thereby potentially indicating that
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CXCR3 signaling augments the ability of cancer cells to initiate the process of
extravasation at a metastatic site. While not directly tested by the studies presented here,
previous research from the Batra lab has shown that mucin and specifically mucin
glycosylation is critical for the ability of PDAC cells to adhere to endothelium [324]. Thus,
it is plausible that PF4 acts through the upregulation of mucins to increase the ability of
cancer cells to adhere to endothelium and initiate the process of exiting the circulation.
Additionally, we found that activation of CXCR3B augments the cellular
cholesterol contents of cancer cells. This observation was additionally supported by the
fact that PF4 and many cholesterol biosynthetic genes are positively correlated in PDAC
transcriptomic data sets. Importantly, the studies presented here show that the PF4 also
increases the resistance of CXCR3B-overexpressing cells to shear stress-mediated cell
death in a PF4-dependent manner and that shear stress enriches the population of CXCR3+
PDAC cells in the presence of PF4. Together, these findings indicate that activation of
CXCR3B is important for increasing the ability of cancer cells to survive the increased
shear stress experienced in circulation. This conclusion, however, must be viewed in light
of a substantial caveat. In the assay that was used, shear stress levels produced are quite
high, likely on par with those produced by turbulent blood flow within the heart. The extent
to which cancer cells would be exposed to this level of shear stress is likely small during
the actual process of metastasis, and the effects of lower levels of shear stress on cancer
cells are currently not well understood. Furthermore, the level of shear stress experienced
by a cancer cell at each point during its journey through the vasculature remains unknown
and very difficult to calculate/determine experimentally.

For these reasons, the

physiological relevance of our findings remains to be determined [321].
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The findings presented here represent a stark departure from those already reported
in the literature regarding PF4 and CXCR3B. However, there are several key differences
between these studies and those presented here.

Most notably, we focused on the

intravascular phase of metastasis by looking strictly at time periods over which this process
is believed to occur (generally 24 hours after entering circulation). Because of this, our
studies are not affected by processes that govern metastasis outside of this phase. Thus,
the suppression of tumor growth and angiogenesis, either in the primary tumor or at the
metastatic site, do not affect our studies. In contrast, the previously reported studies observe
a time period that lasts weeks or up to a month; this time frame allows for both suppression
of tumor growth as well as angiostasis to factor in considerably to the results [249, 250].
Moreover, previous studies have relied on overexpression of the PF4 or intratumoral
injection of PF4. Such experimental setups have tremendous potential to augment PF4mediated signaling that is out of context. When this experimental design is coupled with
long experimental duration, any confounding influences or physiologically irrelevant
influences of forced exposure to high PF4 are magnified and potentially mask true
physiologically relevant effects. The design of the studies presented here avoids such
confounding influence by inhibiting CXCR3B activation; thus, the effects of PF4 at each
point in the experiment reflect what is physiologic in mice in the control group, and the
AMG487 treatment groups represent the loss of that physiologic signaling. Overall, it is
likely that these differences combined with potential differences in the effects of
PF4/CXCR3B signaling in different cancers and cancer cells account for a large portion of
the discrepancies between the data reported here and that reported in the literature.
Finally, there are several gaps present in each of these mechanisms by which
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CXCR3B and PF4 putatively augment the ability of PDAC cells to successfully navigate
the intravascular phase of metastasis. Therefore, additional studies are needed to further
decipher the molecular mechanism involved in the observed phenomenon. With respect to
low attachment survival, the underlying mechanism remains mysterious. p21 appears to
be a promising candidate, but this is derived from signaling studies in endothelial cells and
has not been tested in cancer. Initial experimentation should focus on the ability of PF4
and CXCR3B to upregulate p21 expression in PDAC cells. Subsequently, the dependence
of platelet-mediated low attachment survival on p21 can be tested through genetic
inhibition of p21. With respect to endothelial adhesion, the knockdown of mucins and or
overexpression of mucin in non-expressing cell lines can be used to determine if this
abrogates the ability of PF4 treatment to increase endothelial adhesion. Finally, with
respect to cholesterol and fluid shear stress resistance, it is likely that future studies from
the Batra lab will require extensive collaboration in order to identify and replicate
physiologic levels of shear stress as these tasks require a great deal of physics, biophysics,
and engineering expertise. Additional studies regarding this function of PF4/CXCR3B
signaling should focus on connecting increased cellular cholesterol content and resistance
to fluid shear stress. In this setting, utilization of statins to demonstrate independently that
loss of cellular cholesterol diminishes resistance to fluid shear stress (including that
induced by PF4) is a critical next step.
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Chapter 6: Summary, Discussion, Conclusions, and Future
Directions
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This dissertation presents the results of a computational cytokine screen of 149
cytokines in the publicly available PDAC microarray and RNA-seq datasets followed by
an in-depth analysis of one of the signaling axes, CXCR3 and its ligands, identified by that
screen in these same datasets, our own population of PDAC samples and in select cases
murine and cell line models of PDAC (Figure 6.1). This analysis investigated the
associations of both splice variants of CXCR3 and all ligands of this receptor with patient
outcomes in TCGA. Analysis of key molecular associations elucidated dominant functions
of the CXCR3 axis in PDAC. When combined with a thorough search of the literature
regarding CXCR3 and its ligands in the setting of solid malignancies, this analysis reveals
that the functions of CXCR3 and its ligands in PDAC broadly fit within a framework
established by previously published reports of CXCR3 in other cancers. At a more detailed
level, however, there appear to be clear and critical distinctions between the functions of
CXCR3 in PDAC and those in other cancers, which are likely related to differences in the
underlying biology of different malignancies.
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Figure 6.1

Figure 6. 1: Schematic Outline of the Work Presented in this Dissertation.
Identification of CXCR3 ligands in the cytokine screen (Chapter 2) prompted a more in-depth
analysis of this signaling axis. Because of key differences in the expression and functions of
CXCR3 splice variants, the data regarding each variant was presented in 2 parts. In the first, the
transcriptomic associations of CXCR3A were examined and validated in human samples in
conjunction with survival analysis in patients stratified by the components of the CXCR3A
signaling axis. These analyses revealed prominent associations of CXCR3A and its ligands with
markers of anti-tumor immune response and immunosuppression. These changes were associated
with corresponding changes in patient survival (Chapter 4). The second part focused on the role
of CXCR3B and CXCL4 in pancreatic cancer (Chapter 5). Here, the use of transcriptomic
associations demonstrated alterations in cholesterol biosynthesis associated with CXCL4
expression, while in vitro and in vivo experimentation demonstrated the ability of PF4 to augment
the metastatic potential of PDAC cells. Notably, these changes were also associated with altered
patient outcomes.
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CXCR3A ligands CXCL9 and CXCL10 were identified as being highly
overexpressed in numerous microarray datasets. Notably, CXCR3 is expressed in the vast
majority of patient samples within each of these datasets, indicating that CXCR3A and its
ligand CXCL9 and 10 form a functional signaling axis in the PDAC microenvironment.
The fact that the ligands are derived from tumor stroma in most cases indicates that
expression of CXCR3 and its ligands in primary PDAC tumors has clear spatial patterns
that are consistent with those of CXCL12/CXCR4 signaling, which has been shown to
promote immune suppression through the recruitment of tumor-infiltrating lymphocytes to
stromal rich and cancer cell poor areas [57]. Independently, this spatial distribution of
lymphocytes, especially T-cells, within the tumor has been associated with the
effectiveness of anti-tumor immune response [150]. Consistent with these findings,
CXCR3 associates strongly with T-cell related signatures via several independent
computational methodologies suggesting that CXCR3 and its ligands may have similar
roles as the already established CXCR4/CXCL12 axis with the exception the CXCL9 and
10 are actually overexpressed in the PDAC microenvironment. Closer examination of the
gene signatures identified in these analyses further suggest that CXCL9, 10, and 11 may
promote immunosuppression through more than recruitment of lymphocytes to cancer cellpoor areas; the combination of CXCL9, 10, and 11 was strongly correlated with
immunosuppressive pathways including those associated with PD-1 and PD-L1
checkpoints, and T-cells exhaustion suggesting that the immunosuppressive functions of
CXCR3A ligands may be two-fold. Consistently, CXCR3A ligands were associated with
worse overall survival in TCGA patients, while CXCR3A itself was associated with
improved overall survival. The confluence of these findings suggests that CXCR3A
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functions as a marker, or proxy measure, of immune response whereas high CXCR3
activity (as suggested by the prominent expression of ligands), is associated with
attenuation of effector functions in immune cells.
Broadly speaking, the immunological functions of CXCR3 and its ligands have
been well characterized in numerous settings, including several malignancies. In the
context of malignancy, most studies show that CXCR3 and its ligands are associated with
a more robust anti-tumor immune response. Despite this general trend, several reports have
suggested that the axis can function in an immunosuppressive capacity; thus, the
immunological functions of CXCR3 may be highly context-dependent. In the case of the
PDAC, the immunosuppressive functions of CXCL9 and 10 may be derived from the
intense desmoplastic reaction, the resulting hypoxia associated with desmoplasia, low
mutational burden, or other factors that have yet to be identified. Further analysis of
specific associations of this signaling axis in multiple related and unrelated cancers are
required to begin to have traction on what specifically dictates the immune functions of
CXCR3 in human malignancy.
Additional studies regarding CXCR3A and its ligands are required to further
enhance our understanding of the axis in PDAC. Most notably, in vitro and in vivo studies
regarding the direct or indirect ability of CXCR3 activation to promote T-cell exhaustion
are of particular interest as this association has not been reported previously. Additionally,
there is a possibility that CXCR3 may be used as a therapeutic target in PDAC. However,
the role of CXCR3 and its ligands in recruiting lymphocytes to the tumor must first be
determined. Specifically, experiments must test if the loss of CXCR3 function results in a
substantial decrease in the number and/or effector function of T-cells in the
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microenvironment or if there are collateral pathways which T-cells utilize to guide their
migration, and as a result, inhibition of CXCR3 does not affect lymphocyte recruitment but
rather the ability of CXCR3 specifically to contribute to the immunosuppressive nature of
PDAC.
In contrast to CXCL9 and CXCL10, our cytokine screen did not demonstrate that
PF4 was overexpressed to any appreciable extent in PDAC. However, in order to gain a
broader understanding of the entire CXCR3 axis in PDAC, we investigated all CXCR3
ligands in the setting of PDAC. Overexpression of PF4 was associated with worse overall
survival in PDAC patient samples and the more aggressive KPC murine model of PDAC
specifically. These findings suggested that while not overexpressed in PDAC, there may
be some role for CXCR3B and PF4 signaling in PDAC. This was confirmed via a
multitude of methods, including the analysis of gene expression in CTCs from human
PDAC patients, which demonstrated a strong association with platelet-related gene
signatures in these cells. Such findings indicate a physical interaction between platelets,
the major physiologic source of PF4, and metastasizing cancer cells. Further analysis of
theses CTCs with correction for platelet gene signatures showed that key signaling
molecules in CTCs themselves centered on Gαs-mediated signaling, thereby highlighting
the canonical signaling mechanism downstream of CXCR3B and PF4. Notably, the
inhibition of CXCR3 in tail vein injection models suppressed the number of cancer cells in
the lungs 12 hours after injection. Mechanistically, platelets and or PF4 were found to
augment the ability of cancer cells to survive in low attachment conditions, adhere to
endothelium, and resist shear stress in a CXCR3 dependent manner. Such findings
corroborate the in silico and in vivo analyses that support a pro-metastatic role of PF4 and
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CXCR3 in PDAC.
Results from our studies represent a sharp departure from what has been reported
in the literature regarding CXCR3 and PF4. In most cancers, PF4 is reported to suppress
metastasis in tail vein and subcutaneous models. There are, however, several differences
between these studies and our own. Most importantly are the time frames over which the
experiments are conducted and the methods by which PF4 signaling is modulated. As
previously explained, the studies we conducted utilize time points that allow sufficient time
for cells to arrive at the metastatic site and potentially begin the process of colonization but
do not allow time for proliferation, angiogenesis, or secondary metastatic spread. Studies
in the literature [249, 250] use much longer time points (weeks or a month), which not only
allows these processes but requires them for the detection of metastases. Combined with
the fact that previous studies have used long term intratumoral injection of high PF4
concentrations or overexpression of PF4, it is likely that these studies greatly exaggerate
the functions of PF4 in the primary tumor or metastatic site, especially considering that
most epithelial samples in our data did not express PF4. We contend that there is phasespecific activation of CXCR3B during the metastatic process that far exceeds CXCR3B
activation in the primary tumor established metastatic site and that within this phase,
CXCR3B has a pro-metastatic function.
Here too, additional studies are required to further understand the role of CXCR3B
in PDAC metastasis. While data that has been gathered suggests the underlying cellular
processes that give rise to the loss of metastatic potential with inhibition of CXCR3, the
underlying molecular mechanisms governing low attachment survival, endothelial
adhesion, and resistance to shear stress are not yet fully characterized or directly related to
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CXCR3/PF4 signaling. Similarly, we have little evidence directly demonstrating that any
of these processes give rise to the observed effects of CXCR3 inhibition on the number of
cells in the lungs following tail vein injection, and if they are involved to what extent each
process contributes to the phenotype. Understanding the molecular mechanisms through
which platelets/ PF4 and CXCR3 govern low attachment survival, endothelial adhesion,
and shear stress resistance will be critical for designing experiments which modulate these
molecular pathways and cellular processes independently of CXCR3 and PF4 and
determine the effect of this modulation of the metastatic potential of cells in our injection
model. Finally, and perhaps most importantly, the studies here investigate a single aspect
of the metastatic cascade. Moving forward, it is critical that the contributions of PF4 and
CXCR3 to each phase of the metastatic process, as well as to metastasis as a whole, be
determined. Only through such studies will it be possible to fully understand the balance
of the various pro- and anti-metastatic effects of PF4/CXCR3B. However, these studies
will be arduous and time-consuming. Ultimately, the balance of these effects will likely
determine the extent to which CXCR3B signaling can be targeted in PDAC as a therapy.
Despite this potential, it should be noted that the window for targeting CXCR3B in PDAC
is likely very small, as it must inhibit the signaling on cells that are metastasizing or are
about to do so. This becomes especially evident when one considers that the functions of
PF4 and CXCR3B during other phases of tumor progression are almost uniformly
metastasis suppressing. For this reason, CXCR3B is only likely to be a good therapeutic
target in early-stage disease at times when metastasis is disproportionately more likely,
such as in the process of surgery and immediately following [325].
Overall, in this dissertation, we provide evidence that CXCR3 and its ligands play
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diverse roles in PDAC biology. CXCR3A and its ligands CXCL9, 10, and 11 are
associated with tumor immune response, and whereas CXCR3A appears to be a marker of
immune response present within the PDAC tumor, activation of CXCR3A through high
expression of its ligands appears to promote the suppression of this immune response.
While the major effects of CXCR3A appeared to be centered around the immune response,
we investigated the potential contribution of CXCR3B to cancer cells undergoing
hematogenous dissemination. Here, observations from human CTCs, mouse tail veininjection models of metastasis, and in vitro studies support a multifaceted pro-metastatic
role of PF4 and CXCR3B signaling.
The importance of these findings clinically remains to be determined as it appears
that the functions of both CXCR3 splice variants represent a balance between numerous
pleiotropic effects. Determining where this overall balance lies in PDAC is a substantial
challenge for on-going CXCR3 research but will ultimately determine what components
of CXCR3 signaling in PDAC are therapeutic targets. Irrespective of therapeutic potential,
it is clear that CXCR3 sits at a crossroads of multiple aspects of PDAC biology and is likely
critical for understanding the overarching processes governing anti-tumor immune
response and metastatic dissemination.
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